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ABSTRACT 
Sensorineural hearing loss (SNHL) is a common sensory defect that has an enormous impact 
on the affected individual as well as on all of society. Approximately 13% of EU citizens, 
over 60 million individuals, suffer from hearing loss. The human cochlea is buried deeply in 
the temporal bone, and its access is limited by membranous partitions. This fact makes the 
diagnosis of inner ear disorders using imaging techniques, such as MRI, challenging. The 
traditional treatment strategy for SNHL has not been successful. Cochlear implant (CI) has 
certain indications and problems. A cure for SNHL would thus depend on novel concepts, 
such as CI in combination with gene delivery or stem cell therapy. 
 
Herein, contrast agent or nanoparticles are evaluated using 4.7 T MRI in vivo. The contrast 
agent gadolinium, administered either by intravenous injection or an intratympanic route, was 
studied to demonstrate the limits of MR imaging resolution of the fine inner ear structures in 
the mouse and to explore intracochlear barriers permeability. The MRI manifestation of 
superparamagnetic iron oxide nanoparticles hierarchically coated with oleic acid and 
Pluronic®F127 copolymers (POA@SPIONs) was investigated in the rat inner ear. 
Internalization and of nuclear entry capacity for hyperbranched polylysine nanoparticles 
(HPNPs) were tested in vitro and in vivo. Math1 was selected as the model gene and was 
cloned into the pCDNA6.2/C-EmGFP vector, which is designed for non-viral vector mediated 
gene expression in mammalian cells. Neuron directed-differentiation of bone marrow 
mesenchymal stem cells (MSCs) via Math1 gene engineering was investigated. 
Internalization and targetability of TrkB ligand-functionalized multifunctional liposome 
nanoparticles were analyzed in primary cochlear cell culture, cochlear explants, and rats.  
 
Based on this series of five studies, contrast agent MRI is capable of discerning the inner ear 
structures of the mouse and intracochlear barrier function. The normal blood-endolymph 
barrier is tighter than the blood-perilymph barrier. POA@SPIONs are a promising T2 
negative contrast agent that is detectable within the rat inner ear using MRI. The normal 
blood-perilymph, blood-endolymph, and perilymph-endolymph barriers restrict passage of 
POA@SPIONs. HPNPs were efficiently internalized by the cochlear cells in primary cell 
culture, in organotypic culture, and in vivo. Both cytoplasm and nucleus showed the 
distribution of HPNPs. This finding suggests that HPNPs have a potential use in gene delivery 
to the cochlea. Plasmid pcDNA6.2/C-EmGFP-Math1 is suitable for non-viral gene delivery of 
Math1. Unique intracellular trafficking for Math1 was demonstrated using this novel plasmid. 
Neuron-like cell differentiation of MSCs transfected with the Math1 plasmid was observed. 
HPNP-mediated gene transfection efficiency was higher than liposome nanoparticles in 
dividing cells, and both induced poor gene transfection efficiency in primary cochlea cells. 
Likely targetability of TrkB ligand-functionalized liposome nanoparticles was observed in rat
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cochlea, but not in primary cochlear cell culture and cochlear explants.   
 
Taken together, the results reported here demonstrate that contrast agent MRI can evaluate 
inner ear biological barrier function. The novel POA@SPIONs are a promising T2 negative 
contrast agent, which may be further surface-modified by either peptides or antibodies to 
increase their use as a diagnostic agent and as traceable therapeutic nanoparticles in SNHL 
molecular imaging. The nuclear localization of the Math1 protein is important for their 
function. Neuron-like MSC differentiation mediated by Math1 provides information for future 
studies of the spiral ganglion neuron-orientated stem cell differentiation. The nuclear entry 
and efficient endosomal escape of HPNPs result in high gene transfection efficiency. TrkB 
ligand-functionalized liposome nanoparticles can potentially be used for the targeted delivery 
of genes or drugs to spiral ganglion cells. Transfection efficacy and targetability may be 
improved by using multifunctional nanoparticles, functionalized with peptides or antibodies. 
Nanoparticle-mediated biological treatment of SNHL is a very promising strategy.    
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ABBREVIATIONS 
 
2D                          Two-dimensional  
3D                          Three-dimensional  
Am                         Ampulla  
bHLH                     Basic helix-loop-helix  
CA                           Cochlear aqueduct 
CI                           Cochlear implant  
DAPI                      4', 6-diamidino-2-phenylindole  
DLS                        Dynamic light scattering 
DMEM                    Dulbecco’s Modified Eagle’s Medium  
DOPE                   1, 2-dioleoyl-sn-glycero-3 phosphoethanolamine  
ESCs                     Embryonic stem cells 
FBS                       Fetal bovine serum 
GFP                       Green fluorescent protein  
Gd-DOTA             Gadolinium-tetra-azacyclododecane-tetra-acetic acid 
HPNPs                  Hyperbranched polylysine nanoparticles 
IC                          Intracochlear 
Ids                         Inhibitor of DNA binding/differentiation proteins  
   iPSs                       induced pluripotent stem cells 
   IT                          Intratympanic 
IV                          Iintravenous  
LW                       Lateral wall 
MFNPs                  Multifunctional nanoparticles  
Mn                         Manganese 
Mod                         Modiolus 
MPR                        Multiplanar reconstruction 
MR                        Magnetic resonance 
MRI                         Magnetic resonance imaging 
MSCs                    Mesenchymal stem cells  
NLS                        Nuclear localization signal  
NPC                      Nuclear pore complex 
NSCs                     Neural stem cells    
OHC                      Outer hair cell 
OSL                       Osseous spiral lamina 
PBS                        Phosphate-buffered saline 
PC                          Polyurethane catheter 
PCR                        Polymerase chain reaction 
pDNA                       Plasmid DNA 
 
7
                                                                                                                                                             
 
PEI                        Polyethylenimine 
POA@SPIONs     SPIONs coated with Pluronic® F127 copolymers and oleic acid  
RWM                    Round window membrane                    
SC                         Silicon catheter 
SGC                      Spiral ganglion cell 
shRNA                  Short hairpin RNA  
siRNA                   Small interfereing RNA  
SM                        Scala media 
ST                         Scala tympani 
SV                         Scala vestibuli 
SNHL                   Sensorineural hearing loss 
SPIONs                Super paramagnetic iron nanoparticles  
Vest                      Vestibulum  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
LIST OF ORIGINAL PUBLICATIONS  
 
The thesis is based on the following original publications, which are referred to in the text 
using their roman numerals: 
 
I.    Jing Zou, Ya Zhang1, Weikai Zhang1, Sanjeev Ranjan1, Rohit Sood, Andrey Mikhailov,   
       Paavo Kinnunen, Ilmari Pyykkö. Internalization of liposome nanoparticles functionaliz- 
       ed with TrkB ligand in rat cochlear cell populations. Eur J Nanomedicine; 2009; 2(2): 
       7-13. 
         
II.   Jing Zou, Weikai Zhang, Dennis Poe, Ya Zhang, Usama Abo Ramadan, Ilmari Pyykkö.   
       Differential passage of gadolinium through the mouse inner ear barriers evaluated with 
       4.7 T MRI. Hear Res. 2010; 259(1-2):36-43. 
         
III.  Jing Zou, Weikai Zhang, Dennis Poe, Jian Qin, Andrea Fornara, Ya Zhang, Usama 
       Abo Ramadan, Mamoun Muhammed, Ilmari Pyykkö. MRI manifestation of novel 
       superparamagnetic iron oxide nanoparticles in the rat inner ear. Nanomedicine (Lond). 
       2010; 5(5):739-54 
         
IV.  Weikai Zhang, Ya Zhang, Marian Löbler, Klaus-Peter Schmitz, Aqeel Ahmad, Ilmari 
        Pyykkö, Jing Zou. Nuclear entry of hyperbranched polylysine nanoparticles into 
        cochlear cells. Int J Nanomedicine. 2011; 6:536-46. 
          
V.   Weikai Zhang, Ya Zhang, Rohit Sood, Sanjeev Ranjan, Elena Surovtseva, Aqeel Ahm-   
       ad, Paavo kinnunen, Ilmari Pyykkö, Jing Zou. Visualization of intracellular trafficking 
       of Math1 protein in different cell types with a newly-constructed nonviral gene delivery 
       plasmid. J Gene Med. 2011; 13(2):134-44. 
         
 
 
1 Equal contributor. 
 
The original publications are reproduced in this thesis with the permission of the copyright 
holders. 
 
 
 
 
9
                                                                                                                                                             
 
1. INTRODUCTION  
Hearing loss is a major public health problem that ranks 9th among the most severe diseases 
in the EU. The traditional treatment strategies for SNHL have not been very successful. 
Cochlea hair cells are mechanosensory receptors that can convert sound signals into electrical 
impulses. Hair cell loss from overstimulation, ototoxic drugs, bacterial and viral infections, 
aging and other causes is irreversible and leads to permanent hearing impairment. CI is 
currently the only therapeutic intervention for patients with severe or profound SNHL. 
However, CI has its indications and at the same time progressive degeneration of the cochlear 
neurons (spiral ganglion cells) takes place and may eventually result in complete hearing loss 
(Rejali et al., 2007; Roehm , Hansen, 2005; Shepherd et al., 2004). A cure for SNHL would 
thus depend on novel concepts, such as CI in combination with successful gene/drug delivery 
or stem cell therapy (de Felipe et al., 2011; Ciorba et al., 2009; Okano et al., 2006).   
 
Magnetic resonance imaging (MRI) is a powerful tool for visualizing the anatomy and certain 
aspects of the physiology of different organs in vivo. MRI of the delicated inner ear structure 
has been realized using higher field strength magnets and contrast agents. The inner ear is 
housed in dense bone and is subdivided into different fluid-filled compartments; thus, it is 
possible to evaluate the biological barrier function using MRI. The current challenge in inner 
ear MRI today is distinguishing the inner ear fluids (endolymph and perilymph) using contrast 
agents and, eventually, identifying the pathological changes.  
 
Gene therapy offers new treatment possibilities for a large number of common acquired and 
inherited human inner ear diseases for which conventional therapy is not effective (Maiorana 
and Staecker, 2005;Van de Water et al., 1999). Identification of effective methods to 
stimulate either new functional hair cells or spiral ganglion cells regeneration in the cochlear 
would be of therapeutic value for treating hearing deficits. The bHLH transcription factor 
Math1 is both necessary and sufficient for hair cell development in the mammalian cochlea 
(Bermingham et al., 1999; Zheng and Gao, 2000). Math1 has been reported as being the 
necessary molecule to initiate stem cell differentiation toward both hair cells and neurons 
(Bermingham et al., 1999; Flora et al., 2007). One potential strategy for hair cell regeneration 
is to induce the phenotypic transdifferentiation of nonsensory cells that remain in the inner ear 
(de Felipe et al., 2011; Shibata and Raphael, 2010; Batts SA and Raphael Y, 2007; White er 
al., 2006). To achieve this goal, gene therapy requires technologies capable of gene transfer 
into targeted cells within the cochlea in a large quantity. A key factor of successful gene 
therapy is development of gene delivery systems for efficient gene delivery into target cells. 
Thus far, two types of gene delivery systems, viral and non-viral vectors, have been employed 
as vehicles for gene transfer. Viral vectors are still not regarded as safe for inner ear gene 
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delivery. Nonviral gene transfer techniques represent a simple and, more importantly, safer 
alternative to viral vectors. Nonviral vectors can circumvent some of the problems associated 
with viral vectors such as oncogenic effects and unexpected immune response (Nabel et al., 
1993; Smith et al., 1993b; Yang et al., 1994). Nanoparticles are one of the most promising 
gene carriers among the nonviral gene delivery systems (Borkholder DA., 2008). Thus far, 
there have been no reports of the use of nanoparticles as vectors for Math1 gene transfer in the 
treatment of hearing deficiencies.   
 
Stem cell-based therapy is a rapidly growing area of research and has potential applications in 
the treatment of SNHL. Although many major hurdles still exist, stem cell-based therapy has 
the potential to become the gold standard for the restoration of hearing loss (Pauley et al., 
2008). MSCs have been reported to differentiate into inner ear hair cells (Jeon et al., 2007) 
and neurons (Jiang et al., 2002). Thus, MSCs are attractive candidates for autologous 
transplantation in replacement of damaged inner ear hair cells and neurons. 
 
The purpose of the present study was to evaluate the effects of different contrast agents on 
reporting function of the inner ear barrier using MRI; to investigate the nuclear entry of 
nanoparticles into cochlear cells for potential gene delivery; to demonstrate the efficacy of 
nanoparticle-mediated delivery of the model gene Math1; and to explore the spiral ganglion 
cell targetability of TrkB ligand-functionalized liposome nanoparticles. 
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2. REVIEW OF THE LITERATURE  
2.1 Anatomy of the inner ear  
The ear is made up of three main parts: the outer ear, the middle ear, and the inner ear. The 
ear drum separates the outer and middle ear. Behind the ear drum is the middle ear, which is 
normally filled with air. Three tiny bones inside the middle ear are named for their shapes: the 
malleus, incus, and stapes. The three bones connect to form a chain. The first bone, the 
malleus, is connected to the ear drum. The last bone, the stapes, is connected to another 
membrane called the oval window. The oval window is the beginning of the inner ear or 
cochlea. When sound hits the ear drum, the tiny bones are set in motion, and the last bone 
pushes on the oval window, activating the cochlea. The hair cells transform sound waves into 
electrical impulses that travel along the auditory nerve to the brain. The brain processes these 
impulses and translates the electrical signal into meaningful message.   
 
The mammalian cochlea is a small spiral snail-shaped organ that measures 9 mm in diameter 
at the base and 5 mm in height in humans (Popper A, 1996). Its anatomy consists 
predominantly of fluid-filled chambers that contain endolymph and perilymph. The two larger 
chambers, the scala tympani and scala vestibuli, contain perilymph, a fluid with high Na+ 
content and a similar ionic composition to extracellular fluid. The central chamber or scala 
media, which houses the auditory receptor hair cells, is separated from the scala tympani and 
scala vestibuli by the basilar membrane and Reissner’s membrane, respectively, and contains 
the K+-rich fluid endolymph (Makimoto et al., 1978; Ryan et al., 1979). The isolating 
structure for the endolymph is watertight in order to maintain the electrolyte homeostasis, 
which is essential for the normal function of the organ of Corti, the site of sensory 
neuroepithelium (Hibino et al., 2006; Leonova et al., 1997). Loss of the integrity of these 
membranes, increase in the permeability of the stria vascularis, or reduce in absorptive 
functions of the endolymphatic sac may produce a number of disorders, such as 
endolymphatic hydrops, which can produce pathological changes in the sensory endorgans 
(Poe et al., 2009).   
 
2.2 Sensorineural hearing loss  
2.2.1 The causes of sensorineural hearing loss 
SNHL is a common disease, which includes two types of hearing loss: either damage to the 
hair cells or the auditory nerve and auditory nerve pathways. Typically, it is difficult to know 
whether the problem is either the hair cell, neural, or both. Thus, we often use the general 
term, sensorineural hearing loss. SNHL usually typically begins in the high frequencies. As 
broad damage occurs, the hearing loss will spread towards the lower frequencies.    
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SNHL may be caused by different mechanisms. The most common pathological change of 
SNHL arises from either damage to, or loss of, cochlear hair cells or their associated neurons. 
Cochlear hair cells are mechanosensory receptors, which can convert sound signals into 
electrical impulses that are transmitted along the auditory nerves to the central nervous system. 
Their loss, resulting from overstimulation, ototoxic drugs, bacterial and viral infections, aging 
and other causes, is irreversible and leads to permanent hearing impairment in the mammalian 
ear (Shibata and Raphael, 2010). SNHL may be divided into genetic and acquired sensorineu- 
ral hearing loss. Commonly, genetic mutations, which are related to the normal develop- ment 
or function of the inner ear tissues, may lead to hearing loss. Currently, at least 70 genes that 
cause hearing loss have been identified (www.hereditaryhearingloss.home-page). Noise-
induced hearing loss is a common cause for acquired hearing loss, which refers to any type of 
hearing loss that is caused or aggravated by environmental factors.  
 
2.2.2 Treatment of sensorineural hearing loss 
At present, the traditional treatment strategy for SNHL is often unsuccessful. In the EU, 
approximately 44 million individuals are significantly handicapped by SNHL and require 
some treatment (http://www.hear-it.org/multimedia/hear_it_Report_October_2006.pdf). For 
mild to moderate forms, hearing aids alleviate the communication problems. In severe forms 
of hearing loss and deafness, the auditory function can only be restored by a cochlear implant 
which functionally replaces lost inner ear sensory cells by directly stimulating the auditory 
nerve. Cochlear implants were first developed in France in 1957 by Djourno and Eyries 
(Djourno, 1957), who described a method to stimulate the cochlear nerve using electric 
currents. This technique makes use of the topographical arrangement of the cochlea, with 
high-frequency sounds coded near the base, and low-frequency sounds at the apex of the 
cochlea. Currently, cochlear implantation has gained widespread acceptance in the profoundly 
(＞90 dB) and severely (between 70 and 90 dB) deaf patients (Marsot-Dupuch and Meyer, 
2001).   
 
However, the cochlear implant does little either to repair or regenerate hair cells and neurons 
(Patel et al., 2004). Hair cells and associated neurons can not be regenerated in mammals once 
they are lost. Obviously, a cochlear implant can only be successful when enough functioning 
spiral ganglion cells (SGCs) are present. More important, a cochlear implant has some 
indications and at the same time it has the possibility to further degenerate the SGCs, and may 
eventually result in complete hearing loss (Rejali et al., 2007). Moreover, the cost of a 
cochlear implant procedure is still too high for most of patients.     
 
As hair cell loss is the major outcome from most acquired and inherited forms of SNHL, their 
regeneration and repair through application of cellular and molecular therapies represents a 
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major focus in current hearing research (Patel et al., 2004). Simultaneously, expectations for 
the development of new therapeutic tools have increased, as research has been conducted on 
inner ear gene and stem cell therapy. Development of SNHL treatments at the cellular and 
molecular levels is a promising new research area. In the future, improvements in 
nanotechnologies, and inner ear regeneration, may yield new devices, such as cochlear 
implants combined with either local drug/gene therapy or stem cell therapy (Ciorba et al., 
2009). 
 
2.3 MRI   
Magnetic resonance imaging (MRI) is primarily a noninvasive medical imaging technique. 
The advent of MRI has provided scientists and clinicians with a powerful tool for visualizing 
the detailed internal structure and certain aspects of physiology for different organs in vivo. 
MRI is a relatively new technology. The first MR image was published in 1973 (Lauterbur, 
1973), and the first studies performed on humans were reported in 1977 (Damadian et al., 
1977; Hinshaw et al., 1977). With the development of novel magnetic nanoparticles, MRI has 
led to various biomedical applications in “theragnostics” (therapeutic and diagnostic) 
applications such as hyperthermia (Wyatt et al., 2009), stem cell tracking (Thu et al., 2009), 
gene expression (Klose et al., 2010), cancer detection (Giesel et al., 2009), and inflammation 
(Yang et al., 2010). 
 
2.3.1 Magnetic resonance basics 
MRI is a method for human in vivo imaging that uses an external magnetic field to align the 
nuclear magnetization of water protons, which are responsible for the MRI signals (Schroeder, 
2008). When a body is placed in a magnetic field, the proton magnetic moments will orient in 
the direction of the magnetic field and precess at a resonance frequency. Relaxation is 
measured in two directions, longitudinal and transverse. Longitudinal, or spin-lattice 
relaxation, is defined by the time constant T1 and occurs in the direction of the main magnetic 
field. Signals related to T1 relaxation are obtained after excitation by an external magnetic 
field, as the proton’s dipole moment vector begins to realign, or relax back to its ground state 
of alignment with the main magnetic field. The spin-spin, or transverse relaxation time, or T2, 
is the exponential loss of coherence among the spins oriented at an angle to the static 
magnetic field due to interactions of the spins. The T2* is the loss of phase coherence of the 
spins in the external magnetic field and is a combination of magnetic field inhomogeneities 
and T2.  
 
2.3.2 MRI contrast agents 
MRI contrast agents are used to improve the visibility of internal body structures in magnetic  
 
14 
resonance imaging. They alter the nuclear magnetic resonance relaxation times of the water 
protons in solution or tissue known as T1, T2 and T2*. With the help of contrast agents, MRI 
shows the water distribution in the organ in correlation with the anatomy of the organ 
(Logothetis, 2008). Thus, MR contrast agents are not directly imaged; rather, they indirectly 
affect the surrounding water protons that then influence the MRI signal.  
 
Gadolinium (Gd) chelates and manganese (Mn) chloride are paramagnetic positive contrast 
agents used in experimental and clinical studies. These agents tend to shorten T1 relaxation 
time more than the T2 and T2* of tissues, generating a signal brightening on MR images. Mn 
chloride was the first paramagnetic contrast agent used in MRI, and it has been shown in vivo 
that cells can take up Mn chloride through calcium channels in the cell membrane 
(Mendonca-Dias et al., 1983). The major drawback using Mn as a MRI contrast agent is its 
narrow therapeutic window and significant cardiotoxicity (Arbab et al., 2006). Gd chelates are 
commonly used clinically to enhance pathological MRI signals in the brain, heart, and liver as 
well as tumors, among other tissues. However, the Gd ion is highly toxic in its free form, thus, 
a number of biocompatible chelating agents have been developed to render the metal ion 
nontoxic in its chelated form. One class of Gd complexes is macrocyclic chelates. 
Gadolinium-tetra-azacyclododecane-tetra-acetic acid (Gd-DOTA) is one such chelate that is 
highly water soluble and thermodynamically stable. Another class of such agents is acyclic 
chelates, such as gadolinium diethylenetriamine pentaacetic acid dimeglumine salt (Gd-
DTPA), which was approved for clinical use in adult patients in 1988 and has since become 
the most commonly used MRI contrast agent. Intravenously administered Gd-DTPA and Gd-
DOTA has relatively low morbidity and minimal side effects. However, patients with poor 
renal function are considered to have an increased risk for nephrogenic systemic fibrosis 
when they are exposed to gadolinium-containing contrast agents (Grobner, 2006; High et al., 
2007).  
 
Superparamagnetic iron oxide nanoparticles (SPIONs) is one type of superparamagnetic 
negative contrast agents, which shorten the T2 and T2* much more than the T1, generating a 
signal darkening on MR images. SPIONs are small superparamagnetic iron-oxide 
nanoparticles with a crystalline magnetite structure coated either with dextran or more 
advanced biomaterials. They are a promising group of imaging probes and have been 
extensively studied in recent years (Mahmoudi et al., 2011).  
2.3.3 Application of MRI in diagnosis and treatment 
2.3.3.1 Application of MRI in diagnosis  
 
MRI is a new and important tool in the diagnosis of hearing loss (Davidson, 2001). Magnetic 
resonance imaging of the delicate structure of the inner ear has been addressed using higher 
field strength magnets. High-resolution MRI on inner ear ultrastructure anatomy may provide 
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important information for inner ear disease that is otherwise unobtainable. In previous studies, 
great progress has been made in the evaluation of pediatric SNHL using MRI as a diagnostic 
tool (Klingebiel et al., 2001; McClay et al., 2008; Simons et al., 2006).  
 
Thus far, the diagnosis of SNHL due to cochlear barrier dysfunction is largely based on 
patient history and physical examination. A more precise determination of the impairment 
aetiology and pathology is difficult to achieve in a noninvasive manner. No imaging modality 
is routinely used to confirm diagnosis of such inner ear disease. The inner ear is housed in 
dense bone and subdivided into different fluid-filled compartments, which makes it possible 
to evaluate the barrier function using MRI. The challenge in inner ear MRI today is to 
distinguish the inner ear fluids (endolymph and perilymph) using contrast agents and, 
eventually, identify the pathological changes. A Gd-enhanced T1-weight signal was first 
detected in labyrinthitis associated with SNHL-induced barrier dysfunction in human after 
intravenous gadolinium administration (Casselman et al., 1994). However, the low resolution 
of MRI limited its application. Introduction of high-resolution MRI in mammalian inner ear 
using a 4.7 T system enabled in vivo visualization of cochlea details. MR imaging of guinea 
pigs has revealed possible perilymph origins, communications between perilymph-containing 
spaces, and pathological changes in endolymphatic hydrops and perilymphatic fistulae 
(Counter et al., 2003; Zou et al., 2003a; Zou et al., 2005a; Zou et al., 2003b). High-resolution 
imaging of guinea pig cochleae using T1 Gd enhancement demonstrated normal and impaired 
functions of the inner ear barriers (Counter et al., 2000). Great advances in cochlea MRI were 
realized with the recent introduction of intratympanic and high dose intravenous 
administration of Gd in animal models and in humans (Pyykko et al., 2010; Zou et al., 2009).  
 
Although mice are widely used in hearing research, such studies have not included inner ears 
of mouse models. Contrast agent-enhanced MRI has been applied to visualize the mouse 
central auditory system activity (Watanabe et al., 2008; Yu et al., 2005). High resolution MR 
imaging of the mouse inner ear in vivo could provide new insights into the mechanisms of 
various inner ear disorders. Of particular interest is the genetic origin hearing loss, such as the 
connexin 26 mutation, connexion 30 mutation, Caludin 14 knockout, Foxi1 knockout, COCH 
mutation, as well as age related hearing loss (Ben-Yosef et al., 2003; Cohen-Salmon et al., 
2007; Cohen-Salmon et al., 2002; Kudo et al., 2003; Robertson et al., 2008; Teubner et al., 
2003; Zheng et al., 1999).     
 
The disadvantages of Gd include its short relaxation and adverse effects. The longitudinal 
relaxation of gadolinium chelates decreases rapidly at high field strengths, reducing the 
sensitivity of these contrast agents in high fields (Sosnovik et al., 2008). A high concentration 
of gadolinium was reported to be ototoxic in a preliminary study (Kakigi et al., 2008). 
Nanoparticles loaded with contrast agents have aroused enormous interest in recent years and 
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promise to be useful in novel or improved biomedical applications (Mahmoudi et al., 2011; 
McCarthy et al., 2007). Such nanoparticles could be traced using high resolution MRI, while 
serving as a delivery vehicle for clinical therapeutic agents. One promising group of contrast 
agents is derived from SPIONs. SPION is an effective MRI T2 contrast agent that has been 
used in high resolution MRI to trace apoptosis and gene transcription in animal models of 
cerebral ischemia (Liu et al., 2007b; Liu et al., 2008b; Liu et al., 2009; Liu et al., 2007a; 
Smith et al., 2007). Currently, multifunctional nanoparticles (MFNPs) are in development and 
are under investigation as a means for controlled, targeted drug delivery to selected cochlear 
cell populations for SNHL treatment (www.nanoear.org/, 2009). Labeling of these 
nanoparticles with imaging contrast materials is under investigation for visualization of their 
distribution in the cochlea in vivo (Li et al., 2004; www.nanoear.org/, 2009). SPIONs are 
potent signal suppressors in T2-weighted MRI sequences that create a negative or dark 
contrast against the intensely bright signal from proton rich fluids without SPIONs.  
 
2.3.3.2 SPIONs-labelled stem cell tracking 
Stem cell therapies hold promise for hearing loss treatment of (Li et al., 2004; Pauley et al., 
2008). A major challenge in development of applied clinical stem cell therapy is a lack of 
efficient cell tracking methods. Even though excellent histological techniques remain the gold 
standard, no good in vivo techniques are currently available to assess transplanted cells for 
survival, migration, differentiation, and regenerative impact. 
 
Cellular magnetic resonance imaging (CMRI) can be used to track long-term non-invasive 
temporal-spatial migration within desired organ of transplanted cells labeled with MR 
contrast agents (Dousset et al., 2006; Ferreira et al., 2008; Petry et al., 2007; Yang et al., 
2009). MRI is the most readily accessible tracking method. Under proper conditions, it is safe, 
reliable, an available in most hospitals. MRI has successfully detected and tracked stem cell 
migration in brain disease models (Thu et al., 2009; Yang et al., 2009). MRI could be 
designed to track differentiation, physiological, and pathological state as well as in vivo 
movement of a transplanted stem cell through the body. Given their high sensitivity for cell 
detection and their excellent biocompatibility, SPIONs are currently recognized as the best 
contrast agent candidates for non-invasive in vivo tracking of labeled cells using MRI 
(Dousset et al., 2006; Mahmoudi et al., 2011; Petry et al., 2007). Many examples of in vitro 
labeling for various cells have been described, including the following: embryonic stem cells 
(Rudelius et al., 2003), neural stem cells (Bulte et al., 2001; Jendelova et al., 2004; Rudelius 
et al., 2003), bone marrow stem cells (Jendelova et al., 2004). After labeling with SPIONs in 
vitro, the maximum of physiological properties of the stem cells must be preserved, some of 
which some are obligatory, including the following: viability, migration capability, phenotype 
differentiation, controlled proliferation, and ability to retain the contrast agent for following 
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the cell, among others. It has been reported that when labelled with SPIONs, cells are 
unaffected in their viability and proliferating capacities, and labeled human neuronal stem 
cells differentiate normally into neurons (Bulte et al., 2001). In previous experiment, SPIONs-
labeled cells have been followed for up to 8 weeks, which indicates a long lasting label 
(Jendelova et al., 2004). Labeled olfactory ensheathing cells migrated extensively in normal 
spinal cord were readily detectable in vivo by MR imaging for at least 2 months after 
transplantation (Lee et al., 2004). 
 
Labeling cells with SPIONs has several potential advantages: their MRI signal has high 
spatial resolution, and they are nontoxic to cells, as the iron oxide nanoparticles are 
biodegradable and can be metabolized by cells. Experiments have shown no cytotoxicity upon 
increasing the concentration of SPIONs in the cell culture media increased up to 250 μg Fe/ml 
(Lawrence et al., 2000). Magnetic labeling of cells may provide researchers with a tool to 
elucidate the role or contribution of a specific cell population during either normal and 
abnormal development or pathological processes. In vitro labeling of cells with SPIONs 
allows for the detection of single labeled cells within target tissues using CMRI (Arbab et al., 
2006). In vitro experiments have shown that SPION-labeled cells move towards an external 
magnetic field and magnetically labeled cells can be delivered and retained at a site of interest 
by applying an external magnetic field (Arbab et al., 2004). The magnetic targeting of either 
genetically altered cells or cells serving as gene delivery vehicles may be feasible in the future. 
A likely method for such targeting includes infusion SPION-labeled cells during either 
angiography or invasive procedures and use of image guidance by placing an external magnet 
over a predetermined region to maximize cells delivery and retention in target tissue (Arbab et 
al., 2006).    
 
However, cellular MRI also has its limitations. It is still not sensitive enough to discriminate 
between a labeled stem cell signal and products of ferritin deposition (Mani et al., 2008). 
Moreover, MRI technology requires improvement, as each labelled-cell division reduces the 
concentration of SPIONs within progeny cells. This progressive cell marker dilution via cell 
division limits the capacity of this method for long-term stem cells tracking. A threshold 
concentration must be maintained for MRI to image cells. This threshold limits the length of 
time that MRI can be used to track stem cells in vivo (Li et al., 2010). Next-generation 
magnetic nanoparticles are expected to be truly multifunctional, incorporating therapeutic 
functionalitiy and further enhancing an already diverse repertoire of abilities (McCarthy et al., 
2007). This rapidly growing area of experimental research has the potential to translate from 
bench to bedside. 
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2.4 Gene therapy  
At present, gene therapy is a promising therapeutic modality for inner diseases (Sun et al., 
2011). The concept of gene therapy maybe defined as a technique or approach to introduce a 
foreign gene or gene-regulatory into the target cells, which results in either a cure for the 
disease or slowing its progress (Verma et al., 2005. Mulligan, 1993). Gene therapy offers new 
treatment possibilities for a large number of common acquired and inherited human diseases 
where conventional clinical procedures are less effective (Gardlik et al., 2005). The study of 
gene therapy for the inner ear started in the mid-1990s (Fujiyoshi et al., 1994). It may become 
a treatment option for SNHL in the near future. A number of genes and specific mutations 
related to hearing loss that are linked to specific locations in the genome have already been 
identified, and this number is growing as the field rapidly advances (Ryan et al., 2009b). This 
information provides a basis for therapy centered on genetic approaches. Numerous new 
discoveries and tremendous advances have been made in inner ear gene therapy. Therapeutic 
genes encoding proteins for inner ear gene therapy can be divided into two major groups: 
inner ear protectors and transdifferentiation activators.  
 
Hair cells and SGCs are common pathological sites for inner ear diseases and the major 
targets for inner ear gene therapy (Brough, 2007). Identification of effective methods that 
stimulate new functional inner ear hair cell and SGC regeneration would have therapeutic 
value in treating SNHL. One potential strategy for regenerating hair cells with normal 
morphological and functional properties is to induce phenotypic transdifferentiation of 
nonsensory cells that remain in the inner ear (Izumikawa et al., 2005; Shou et al., 2003). To 
achieve this goal, gene therapy requires technologies capable of gene transfer to the target 
cochlear cells. Hair cells and supporting cells have common cellular precursors during 
mammalian embryogenesis (Fekete, 1996; Fekete, 2000; Torres et al., 1998). Differentiated 
supporting cells are able to change their phenotype and become new hair cells in inner ear 
(Corwin et al., 1988; Ernfors et al., 1995; Ernfors et al., 1996; Farinas et al., 1994; Liu et al., 
2008a; Noushi et al., 2005; Ryals et al., 1988; Staecker et al., 1996; Sun et al., 2011; Wise et 
al., 2010; Woods et al., 2004). Therefore, supporting cells are an attractive target for 
interventions designed to produce new hair cells.  
 
SGCs sense the electrical impulses generated by inner hair cells and send them to the brain. 
Cochlear implants effectively replace the mechanosensory transduction function of lost hair 
cells and furnish the user with substantial hearing benefit by exerting direct electrical 
stimulation on SGCs. Although there are controversial clinical reports on the contribution of 
SGCs to cochlear implant efficacy, at least 10% spiral ganglion cell survival is necessary for 
current cochlear implants to succeed in helping patients communicate (Khan et al., 2005; 
Linthicum et al., 1991). Thus, either preventing degeneration or promoting regeneration of 
deafferented SGCs in the inner ear would also have therapeutic value in treatment of hearing 
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disorders. Neurotrophic factors are a large group of biologically active proteins, most are able 
to protect inner ear hair cells and spiral ganglion neurons from damage caused by various 
pathogenic factors and promote recovery from cochlear injury (Ernfors et al., 1995; Ernfors et 
al., 1996; Farinas et al., 1994; Sun et al., 2011). Targeted delivery of neurotrophic factor 
genes to SGCs using functionalized nanoparticles is an efficient method of fulfilling this goal. 
A large number of documents have demonstrated successful transfection and expression of 
neurotrophic factors in the inner ear, mediated by both viral and nonviral vectors in vitro and 
in vivo (Liu et al., 2008; Noushi et al., 2005; Staecker et al., 1996; Wise et al., 2010). 
Therefore, neurotrophic factor genes have become the preferred genes for inner ear gene 
therapy. 
 
2.4.1 Math1 gene and inhibitor of DNA binding/differentiation proteins 
2.4.1.1 Math1 gene 
The discovery of developmental genes that encode hair cell and neuron differentiation 
facilitates the design of interventions that promote generation of new hair cells and SGCs. 
Thus far, one of the most crucial genes for inner ear hair cell differentiation control is the 
mouse basic helix-loop-helix (bHLH) transcription factor, Math1, a mammalian homolog of 
Drosophila atonal. The bHLH transcription factor, Math1 (or Atoh1), is both necessary and 
sufficient for hair cell development in the mammalian cochlea (Bermingham et al., 1999; 
Zheng et al., 2000b). Previous studies have demonstrated that a dynamic pattern of Math1 
expression plays a key role in regulating the number and position of mechanosensory hair 
cells. Adenovirus-mediated Math1 gene transfection in the inner ear may be the most exciting 
progress made in inner ear gene therapy; it effectively activated the regeneration of cochlear 
hair cells in mature mammalian ears (Bermingham et al., 1999). Targeted deletion of the 
Math1 gene leads to hair cell differentiation failure (Bermingham et al., 1999). In vitro 
Math1overexpression induced generation of new hair cells (Woods et al., 2004; Zheng et al., 
2000b). Overexpression of Math1 in vivo leads to new hair cell-like cells in the organ of corti 
(Izumikawa et al., 2008; Kawamoto et al., 2003). These results were were observed using the 
human Math1 homologue (hath1) in vitro (Shou et al., 2003). Previous studies have shown 
encouraging progress in Math1-based gene therapy that improves auditory dysfunction. 
Math1-based gene therapy has been proposed for producing functional supernumerary hair 
cells in mice (Gubbels et al., 2008) and restoring hearing in guinea pigs deafened by ototoxic 
drugs (Izumikawa et al., 2005). Therefore, Math1 is a good candidate gene for gene-based 
treatment of SNHL. 
 
Math1 also plays an important role in regulating development of the mammalian nervous 
system (Flora et al., 2007). Math1 is a positive regulator for the differentiation of cerebellar 
granule neurons (Ben-Arie et al., 1997; Helms et al., 1998), dorsal commissural interneurons 
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(Helms et al., 1998), and hindbrain neurons (Benezra et al., 1990; Jones et al., 2006; Kreider 
et al., 1992; Norton et al., 1998; Rose et al., 2009; Yokota et al., 1999). Thus, the Math1 gene 
may potentially be used for future studies on spiral ganglion neuron-oriented differentiation. 
Endogenous stem cells in the inner ear have been identified in a previous study (Li et al., 
2003a), but they can spontaneously generate neither hair cells nor spiral ganglion neurons. 
Modification of inner ear endogenous stem cells with Math1 using a gene delivery technique 
can potentially be applied in future therapies to treat deafness. 
 
2.4.1.2 Inhibitor of DNA binding/differentiation proteins 
Inhibitor of DNA binding/differentiation proteins (Ids) are one family of bHLH transcription 
factor regulators (Benezra et al., 1990; Jen et al, 1992; Kreider et al., 1992; Sun XH, 1994; 
Yokota et al., 1999). Math1 is critical for hair cell development and patterns in the organ of 
Corti. A previous study suggested that Ids play an important role in inhibiting the expression 
of Math1 and the differentiation of hair cells in developing cochlea (Jones et al., 2006).  
 
Heterodimer formation of Math1-ubiquitous bHLH with ubiquitously expressed bHLH, 
referred to as E-proteins is essential to induce gene transcription (Benezra et al., 1990; Norton 
et al., 1998). Ids negatively regulate Math1 function by inhibiting activity of basic bHLH 
transcription factors. Ids heterodimerize with bHLH transcription factors to inhibit the 
formation of functional heterodimers (Jones et al., 2006). Although Ids also contain the HLH-
dimerization domain that is required for dimerization with other bHLH proteins, they lack the 
basic DNA-binding domain. Thus, the dimers formed by Ids and bHLHs cannot bind DNA 
and are inactive. As a result, Ids actively inhibit cellular differentiation (Benezra et al., 1990).  
 
Therefore, Ids are good candidates for regulating Math1 in the cochlea. The target gene can be 
silenced by short hairpin RNA (shRNA) via mRNA down-regulation, which is similar to 
small interfering RNA (siRNA). Id shRNA can inhibit the activity of Ids and enhance the 
Math1 function. Gene-based hair cell regeneration can involve a combination nanoparticle-
mediated delivery of the Math1 gene and Id shRNA.  
 
2.4.2 Gene delivery system 
A key factor in the success of gene therapy is development of safe and effective gene delivery 
systems with which to ferry genetic material into target cells and tissue (Verma and Weitzman, 
2005; Niidome et al., 2002; Li S and Huang L, 2000). The simplest way for gene delivery is 
the direct injection of naked DNA that encodes the therapeutic protein into the target tissue 
(Li and Huang, 2000). However, given this method’s low efficiency, it is necessary to develop 
novel strategies and methods to improve the gene delivery efficiency. A vector can be 
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described as a system that fulfills several functions, including gene delivery into the target 
cells and their nuclei, protection of the gene from degradation, and ensuring gene 
transcription in the cell (Gardlik et al., 2005). Administration of gene therapy vectors requires 
that they are not only targeted and safe, but also protected from degradation, sequestration, 
and immune attack, among other events. The ideal DNA vehicle should also be suitable for 
clinical application. Morever, it must be inexpensive, easy to produce, and purify in large 
amounts at high concentrations (Gardlik et al., 2005; Neumann et al., 1982; Titomirov et al., 
1991).   
 
Two types of gene delivery systems have been employed as gene transfer vehicles, viral 
vectors and non-viral vectors. The commonly used viruses include, but are not limited to, 
adenovirus, adeno-associated virus, and retrovirus. The commonly used nonviral vectors are 
cationic liposomes, cationic polymers, and other inorganic nanoparticles, which typically 
contain positive charges at their surfaces. Although viral vectors are able to mediate gene 
transfer with high efficiency, non-viral vectors, which have more advantages over viral 
vectors, seem to be more promising (Elfinger et al., 2008; Al-Dosari MS and Gao X., 2009). 
However, neither of the two types of gene delivery system is an ideal too up to now. 
 
2.4.2.1 Electroporation 
Plasmid DNA (pDNA) delivery can be enhanced by physical methods that aid passage of the 
plasmid through the cell membrane. Electroporation is an effective and simple non-viral 
delivery method that can be applied to different cell types in vitro and in vivo. The process of 
electroporation involves exposure of the cell membrane to high-intensity electrical pulses, 
which can cause transient and localized destabilization of the barrier. During this perturbation, 
the cell membrane becomes highly permeable to exogenous pDNA present in the surrounding 
medium. The first in vitro and in vivo attempts to utilize electroporation in gene transfer were 
demonstrated in 1982 and 1991 (Neumann et al., 1982; Titomirov et al., 1991), respectively. 
Electrotransfer can be used to deliver a wide range of potentially therapeutic agents, including 
drugs, proteins, and oligonucleotides, both RNA and DNA. This technique also has the 
advantage that, unlike viral vectors, it can be used to target specific tissues with systemic 
delivery. When the parameters are optimized, this method can generate transfection efficiency 
equal to that achieved by viral vectors (Andre et al., 2004). 
 
The use of electric pulses to deliver therapeutic molecules to tissues and organs in vivo is a 
rapidly growing field of research. One encouraging applications of electroporation was 
reported ten years ago by Zheng and Gao, who, using the in vitro electroporation, 
demonstrated that overexpression of Math1 induced robust production of additional hair cells 
after transfection with the Math1 plasmid (Zheng et al., 2000b). In another recent report, 
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Gubbels demonstrated that functional auditory hair cells were produced in mammalian 
cochlea via in utero Math1 gene transfer using in vivo electroporation (Gubbels et al., 2008; 
Liu et al., 2005). Despite the recent progress, one limitation of in vivo electroporation-
mediated gene transfer to solid tissues is electrodes accessibility to the internal organs, which 
can induce substantial tissue damage associated with the procedure. Another limitation of 
electrotransfer is that gene transport into the cell during the time of electropermeability is 
relatively nonspecific. Thus, plasmid DNA delivery via electroporation is still far from the 
perfect gene carrier for potential therapeutic applications. 
 
2.4.2.2 Viral vector  
Viral techniques use various classes of virus as tools for gene delivery. The underlying 
concept behind viral vectors is harnessing the innate ability of viruses to deliver genetic 
material into an infected cell. Viruses introduce their DNA into the cells with high efficiency. 
Therefore, it is possible to take advantage of this activity by introducing a foreign gene into 
the virus and then, taking advantage of viral properties, deliver this gene with high efficiency 
into the target cells. Several viral vectors, including adenovirus (Kawamoto et al., 2003; 
Huang et al., 2009), adeno-associated virus (Liu et al., 2005), lentivirus (Bedrosian et al., 
2006), herpes simplex type I virus, and vaccinia virus (Derby et al., 1999; Praetorius et al., 
2002), are highly efficient in gene delivery and providing sustained expression of the 
transgene.  
 
In previous studies, Most Math1 gene delivery vectors used for hair cell regeneration were 
adenoviruses. Great achievements and progress related to viral gene delivery systems have 
been made in inner ear gene therapy (Huang et al., 2009; Izumikawa et al., 2008; Izumikawa 
et al., 2005; Kawamoto et al., 2003; Liu et al., 2005; Shou et al., 2003; Staecker et al., 2001; 
Raphael et al., 1996). Although the use of adenovirus vector has been associated with higher 
transfection efficiency, there are toxicity and safety problems associated with these vectors, 
such as immunogenicity and insertional mutagenesis (Braun, 2008; Soininen et al., 2010; 
Verma et al., 2005). Such side effects can result in serious problems or even death (Raper et 
al., 2003; Thomas et al., 2003). Therefore, the adenovirus vector is not yet regarded as a safe 
system for inner ear gene delivery. Furthermore, the adenovirus vector has several intrinsic 
drawbacks, including difficulty in large scale production yields, limited opportunity for 
repeated administrations due to an acute inflammatory response, limitations on the size of the 
carried therapeutic genes, and inefficient in vivo targeting to specific cells.  
 
2.4.2.3 Nonviral vector 
The nonviral vector gene delivery, which uses either synthetic or natural compounds to 
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deliver DNA into a cell, represent a simple and, more importantly, safer alternative to viral 
vectors (Mintzer and Simanek, 2009). The materials used in nonviral vectors are generally 
less toxic and immunogenic than the viral counterparts. The basic unit in a nonviral vector 
system consists of a backbone with nonviral materials and plasmid DNA, which contains a 
therapeutic and/or reporter gene. 
 
Nonviral vectors can circumvent some of the problems occurring with viral vectors. Nonviral 
vectors have no or low toxicity and immunogenicity, and they typically do not pose a threat to 
safety. Moreover, nonviral vectors also have advantages in their ease of manipulation and 
large-scale production as well as potential for cell specificity and high flexibility in the size of 
the delivered gene (Anderson, 1998; Ferber, 2001; Niidome et al., 2002; Schmidt-Wolf et al., 
2003; Chattopadhyay et al., 2005). The major disadvantage for all nonviral vectors is low 
transfection efficiency and transient expression in the host cells. It is likely that future gene 
therapy protocols will use innovations to improve on the nonviral vector system efficiency, 
often building upon observations from viral vector transduction. 
 
Among the nonviral vectors, nanoparticle carriers are regarded as the most promising gene 
carriers (De la Fuente et al., 2008; Farjo et al., 2006; Wang et al., 2006; Ziady et al., 2003).  
Nanoparticle carriers are are organic or inorganic materials with diameters ranging from 1-
1000 nm. It is noteworthy that cationic liposomes and polymers make up the two major and 
most promising classes of nonviral gene delivery vectors within the category of nanoparticle 
carriers (Tros de Ilarduya et al., 2010; Godbey et al., 2001). The complexes that they form 
with DNA are defined as “lipoplexes” or “polyplexes”, respectively. They have been 
extensively investigated and hold great promise as a safe and non-immunogenic approach to 
gene therapy. Liposomes complexed with LacZ and GFP reporter genes have successfully 
transfected the tissues of mice and guinea pig cochleae in vivo (Jero et al., 2001; Staecker et 
al., 2001; Wareing et al., 1999). A previous study showed commercial linear 
polyethylenimine (PEI) is able to transfect the cochlea in vivo via cochleostomy and osmotic 
pump infusion method (Tan et al., 2008). As a strategy for gene therapy, the use of 
nanoparticle carriers for delivery of therapeutic materials to the inner ear has great potential. 
Potential candidate nanoparticles, lipid nanocapsules, were observed to distribute in the rat 
(Zou et al., 2008) and guinea pig (Scheper et al., 2009) cochlear cells in in vivo test. 
 
2.4.2.3.1 Liposome and polymers 
Use of cationic lipids and cationic polymers for gene transfer was introduced by Felgner and 
Wu, respectively (Felgner et al., 1987; Wu et al., 1987). Their use has moved rapidly from 
cell culture transfection to clinical gene therapy applications. The first in vivo experiments 
using cationic lipids were conducted in mice in 1989 (Brigham et al., 1989) and a clinical trial 
was initiated in 1993 (Nabel et al., 1993). Cationic lipid/DNA complexes (lipoplexes) and 
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cationic polymer/DNA complexes (polyplexes) used in gene therapy are based on the 
hypothesis that the complexes adsorb more effectively to the mammalian cell anionic plasma 
membrane via electrostatic interactions (Gershon et al., 1993; Ruponen et al., 1999; Tros de 
Ilarduya et al., 2010). Compared with other non-viral delivery systems lipoplexes and 
polyplexes tend to mediate a higher level of transfection in numerous cell lines. However, the 
application of liposomes and polymers for inner ear gene delivery is still in its infancy. 
 
Liposomes are made from the same material as a cell membrane and typically contain at least 
two components: a cationic lipid and a neutral lipid or a “helper lipid”. Cationic lipids are 
amphiphilic molecules containing a positively charged polar headgroup linked, via an anchor, 
to a hydrophobic domain that generally comprises two alkyl chains. 1, 2-dioleoyl-sn-glycero-
3 phosphoethanolamine (DOPE) and cholesterol are often used as neutral lipids. When 
membrane phospholipids are disrupted, they can reassemble themselves into spheres, smaller 
than a normal cell, either as bilayers or monolayers. The bilayer structures are liposomes, and 
the monolayer structures are micelles. Lipoplexes are formed by spontaneous liposomal self-
assembly and complexed with DNA. Cationic polymers include polyethylenimine (PEI), 
cationic dendrimers, natural DNA-binding proteins, and synthetic polypeptides carbohydrate-
based polymers, such as chitosan, among others. As most of these are synthetic compounds, 
the molecular weight can be modified, and ligands can be attached to them. Poly (l-lysine) 
(PLL) and PEI are among the most widely studied polymers for gene delivery. Cationic 
polymers differ from cationic lipids in that they do not contain a hydrophobic moiety and are 
completely soluble in water. The most striking difference between cationic lipids and cationic 
polymers is the ability of the latter to more efficiently condense DNA into a relatively small 
size, compared with cationic liposomes (Gershon et al., 1993; Ruponen et al., 1999). This can 
be crucial for gene transfer, as small particle size may be favorable in improving transfection 
efficacy, particularly in vivo. 
 
Despite numerous applications, elucidation of the cellular pathways mechanisms for cationic 
lipid- and polymer-mediated transfection has been relatively slow. Rational design of highly 
efficient liposomes and polymers requires understanding all the interactions between the 
vector and DNA as well as the cellular pathways and mechanisms involved in DNA cellular 
entry and nuclear import. Several biological barriers must be overcome to achieve efficient 
nonviral gene delivery (Bally et al., 1999; Khalil et al., 2006; Pathak et al., 2009). These 
barriers include binding to the cell surface, traversing the plasma membrane, escaping 
lysosomal degradation, and overcoming the nuclear envelope. Endocytosis and nuclear entry 
are two main steps that hinder successful gene therapy, as they play very important roles in 
gene delivery (Boussif et al., 1995). These pathways have been studied intensely, and 
endosome escape and nuclear entry have been improved rapidly in recently years (Friend et 
al., 1996; Kakimoto et al., 2009; Kim et al., 2011; Zabner et al., 1995).   
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The endosomal escape ability to release DNA into the cytoplasm is a key step in intracellular 
delivery of DNA by nonviral vectors (Cotten et al., 1992; Friend et al., 1996; Simoes et al., 
1999). There is convincing evidence that endocytosis is the major pathway for lipoplex and 
polyplex entry into the cells before productive gene expression (Friend et al., 1996; Rejman et 
al., 2006; Simoes et al., 1999; Labat-Moleur et al., 1996). If the plasmid can not be released 
into the cytoplasm by breaking the endosomal membrane, then it will be transported to the 
lysosomes, where all DNA is destroyed before achieving its function. Cationic polymers are 
devoid of a hydrophobic domain, and therefore cannot fuse/destabilize the endosome by 
direct interaction with the endosomal membrane, as is the case for cationic lipids. The first 
generation of cationic polymers, such as polylysine or polyarginine, was inefficient in 
endosomal escape and transfection efficiency. In an effort to increase the efficiency of the 
endosomal escape efficiency, the second generation of cationic polymers were developed with 
intrinsic endosomolytic activity, including polyamidoamine dendrimers (PAMAM) (Boussif 
et al., 1995; Kichler et al., 2001; Tang et al., 1996) and polyethylenimines (PEI) (Boussif et 
al., 1995; Kichler et al., 2001). PEI and PAMAM can buffer the endosomal interior to some 
extent, thereby inducing osmotic swelling and rupture. The “proton sponge” hypothesis has 
found widespread acceptance in past years (Godbey et al., 2000; Boussif et al., 1995). It was 
also reported that liposomal and polymer transfection efficiency can be increased by targeting 
DNA release from the endosome with endosomal escape peptides (Moore et al., 2008). These 
peptides can accommodate multiple functions within short sequences. Peptides offer the 
capacity for DNA condensation, metabolism blocking, endosomal escape, nuclear localization, 
and receptor targeting (James et al., 2000; Martin et al., 2007; Tachibana et al., 2002). 
Furthermore, they are readily synthesized, economically, by numerous commercial custom 
peptide suppliers.  
 
Transport of the gene construct into the nucleus is also a key stage for gene delivery 
efficiency. The mechanism transporting the transfecting DNA into the nucleus is still a matter 
of debate. Many studies have confirmed that, in cells with cytoplasmic plasmid delivery 
mediated by nonviral vectors, only those with evidence of nuclear plasmid localization 
showed efficient transgene expression (James et al., 2000; Tachibana et al., 2002). 
Microinjection of plasmid DNA into the nucleus produced much higher gene expression than 
when the same plasmid was microinjected into the cytosol (Carlisle et al., 2001; Dean et al., 
2005; Pollard et al., 1998). This suggests that the nuclear envelope is a significant barrier 
against transfection. DNA transport into the nucleus is still not well understood. Molecules of 
<10 nm can passively diffuse through nuclear pores. This is much smaller than DNA, even 
when DNA is condensed in lipoplexes or polyplexes. In that case, how is the DNA delivered 
to the nucleus? The most widely accepted mechanism is that cell division is an important 
factor in transgene nuclear translocation. During the cell division stage, the nuclear membrane 
is temporarily disassembled, which allows DNA to diffuse into the nucleus. This is the case 
for in vitro transfection with dividing cells, whereas, in vivo transfection typically targets 
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differentiated nondividing cells. Most cochlear cell populations, especially SGCs and hair 
cells that are targeted for gene therapy, do not actively undergo cell division during the gene 
transfer process. Therefore, the infrequent DNA nuclear localization greatly limits the 
application of liposomes and polymers as carriers for gene therapy. 
   
Nuclear plasmid delivery induced by nanoparticle carriers may be an option for improving 
transgene expression in nondividing or growth-arrested cells (Carlisle et al., 2001; Dean et al., 
2005; Godbey et al., 1999a; Pollard et al., 1998). Pollard et al microinjected PEI–DNA 
polyplexes into cell’s cytoplasm and showed that transfection efficiency was higher compared 
with either microinjected naked DNA or lipoplexes. This result was interpreted primarily in 
terms of the ability of PEI to facilitate DNA translocation into the nucleus. It could not be 
excluded, however, that PEI may aid in nuclear import of DNA via other indirect mechanisms, 
including enhanced DNA protection and cytoplasmic mobility. Nuclear import of proteins 
require a nuclear localization signal (NLS), which contains basic amino acids and can be 
recognized by cytosolic factors to mediate active transport through the nuclear pore complex 
(Jans et al., 1996; Sebestyen et al., 1998). The same approach can be used to enhance gene 
delivery to the nucleus, especially for transfection of nondividing cells. It was reported that 
the nuclear delivery of DNA was increased by coupling of 100 NLS peptides/kilobase pair of 
DNA (Sebestyen et al., 1998). Development of multifunctional nanoparticles or 
nanocomplexes for gene delivery promises formulations that mimic the structure and function 
of viral particles. These formulations offer the best prospects for development of improved 
efficient vector systems while maintaining the safety characteristics of nonviral formulations 
(Hart, 2010). Multifunctional nanoparticles functionalized with different peptides that are 
introduced to overcome different cellular barriers can increase cellular uptake via receptor-
mediated endocytosis, endosomal release, and nuclear delivery. 
 
2.4.3 Cellular targeting  
Although the development of gene delivery vectors that are capable of efficient delivery is a 
key factor in the success of gene therapy, targeting the therapeutic carrier to the cells that 
require treatment is equally vital. This is especially important in the complex inner ear tissues, 
which contain many cell types that must function in a coordinated manner for hearing. Gene 
therapy delivered to either the wrong cell type or at the wrong time could be ineffective or 
even harmful (Ryan and Dazert, 2009a; Friedmann, 1994). Cell-specific gene promoters offer 
an opportunity to direct gene therapy to a desired cell type. The ideal gene promoter for an 
inner ear cell type would only be expressed in that cell type. Certain promoters and enhancers 
that direct gene expressions in cochlear cells have already been identified (Ryan et al., 2009b). 
Incorporation of targeting ligands to nanoparticles is a promising tool for nonviral gene 
delivery to a specific tissue or cell type (Elfinger et al., 2008). 
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Arguably, the most obvious target for gene therapy of the inner ear is the outer hair cells 
(OHCs). Many of the genes responsible for inherited hearing loss are expressed in the OHCs,  
and their mutation primarily affects this cell type. Therefore, OHC-specific promoters are of 
special interest for inner ear gene therapy. One candidate for OHC targeting is prestin, which 
is a member of the anion solute carrier family 26 (SCL26), with important roles in normal 
physiology and human pathophysiology (Colvin et al., 1996; Dallos et al., 2002; Oliver et al., 
2001; Pasqualetto et al., 2008; Pirvola et al., 1995; Zheng et al., 2000a). Prestin is a 
transmembrane protein that is highly and exclusively expressed in the lateral plasma 
membrane of OHCs (Zheng et al., 2000a).  It is a unique molecular motor protein that senses 
membrane potential change and mediates OHC length changes (Dallos et al., 2002; Oliver et 
al., 2001). Another candidate for OHC targeting is the FGF receptor, FGFR3, splice variant 
IIIc. FGFs and their receptors (FGFRs) are critically important for normal development of the 
organ of Corti and may also protect hair cells from ototoxic damage (Colvin et al., 1996; 
Pirvola et al., 1995). The FGFRs consist of three extracellular immunoglobulin-type domains, 
a single-span transmembrane domain and an intracellular split tyrosine kinase domain. The 
FGF receptor, FGFR3, splice variant IIIc, is exclusively expressed in cochlear outer hair cells 
(Fobian, 2007; O'Leary et al., 2003; Pickles et al., 1998; Schimmang et al., 2003). Therefore, 
prestin and FGFR3, splice variant IIIc, are useful targets for the nanoparticles delivery in 
cochlear OHCs. Prestin binding peptides or synthetic FGF ligands can be synthesized and 
conjugated either to the surface of nanoparticles or directly to plasmid for OHC-targeted 
delivery.   
 
The SGCs are the only neurons within the cochlea. Thus, a number of genes with expressions 
that are restricted to neurons could supply promoters for use in targeting applied in gene 
therapy vectors. This includes many neuron-specific developmental genes. Similarly, a 
variety of genes encoding neuron-specific proteins, such as the neurotrophin receptor 
tropomyosin related kinase (Trk) receptor tyrosine kinase, especially TrkB, are expressed 
only expressed in spiral ganglion cells of the inner (Schimmang et al., 2003). TrkB binding 
peptides have been developed using either phage display or molecular modeling to mimic the 
biological functions of brain derived neurotrophic factor (BDNF) and nerve growth factor 
NGF (Fobian, 2007; O'Leary et al., 2003). Targeted delivery of agents to spiral ganglion cells 
using TrkB binding peptide-functionalized nanoparticles is an efficient way to either preserve 
or regenerate deafferented SGCs.  
 
2.5 Stem cell-based therapy  
Degeneration of inner ear hair cells and associated neurons results in hearing impairment. 
There are currently no treatments designed to halt or reverse the progression of hearing loss. 
These disabilities are incurable, as loss of the hair cells and neuronal cells is currently 
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irreversible. Stem cell-based therapy is a rapidly growing area of research and has potential 
applications in treating inner ear disorders (Nakagawa and Ito, 2005). It is considered the 
ultimate remedy for hearing loss. Although many major hurdles still exist, stem cell-based 
therapy has the potential to become the gold standard for restoration of hearing loss (Forge et 
al., 1993; Li et al., 2003a; Malgrange et al., 2002; Oshima et al., 2007; Pauley et al., 2008; 
Rask-Andersen et al., 2005; Warchol et al., 1993; Zhai et al., 2005; Zhang et al., 2007). 
 
2.5.1 In situ differentiation of inner ear stem cells 
In 1988, Corwin and Ryals reported that birds can regenerate hair cells and recover hearing 
after acoustic trauma (Corwin et al., 1988; Ryals et al., 1988). It was also reported that the 
adult mammalian vestibular system can regenerate modest hair cells upon damage (Forge et 
al., 1993; Warchol et al., 1993). These results suggest that unidentified latent or dormant stem 
cells are retained in the inner ear of adult animals. Li et al. first demonstrated the presence of 
stem cells in the adult mouse utricle (Li et al., 2003a). Since that time, stem cells have been 
characterized in the spiral ganglion (Rask-Andersen et al., 2005), the lesser epithelial ridge 
(Zhai et al., 2005), greater epithelial ridge (Zhang et al., 2007), and in the organ of corti and 
the stria vascularis (Oshima et al., 2007). Although stem cells are present in the mammalian 
cochlea (Malgrange et al., 2002; Oshima et al., 2007; Rask-Andersen et al., 2005; Zhai et al., 
2005), endogenous cochlear stem cell do not spontaneously generate hair cells or neurons 
after damage (Reyes et al., 2008; Richardson et al., 2008; Parker et al., 2007;  Matsuoka et al., 
2006; Hu et al., 2005; Doetzlhofer et al., 2004; Li et al., 2004; Li et al., 2003b; Tateya et al., 
2003; Gage, 2000; Zheng et al., 2000b; Thomson et al., 1998; Evans et al., 1981; Martin, 
1981). Previous work has shown that hair cells and neurons can be differentiated from 
endogenous cochlear stem cells in vitro (Doetzlhofer et al., 2004; Malgrange et al., 2002; 
Oshima et al., 2007; Rask-Andersen et al., 2005), particularly in response to treatment with 
growth factors. However, these approaches are not yet possible in the adult mammalian organ 
of Corti in vivo. To stimulate the proliferation and differentiation in these cochlear stem cells 
toward a desired cell type, we must discern which genes control the properties of self-renewal 
and pluripotency and what mechanism control stem cell quiescence in the mammalian cochlea. 
Math1 is both necessary and sufficient for hair cell development in the mammalian cochlea 
(Bermingham et al., 1999; Zheng et al., 2000b). A previous study showed that endogenous 
cochlear stem cell can be converted to hair cells when they were forced to express Math1 
(Zhai et al., 2005). 
 
2.5.2 Exogenous stem cell transplantation  
Exogenous stem cellular therapy is an intellectually attractive option for replacing damaged 
sensory epithelia and neurons. Embryonic stem cells (ESCs) and neural stem cells (NSCs) are 
 
29
                                                                                                                                                             
 
two important and potent graft materials, which have a direct phylogenetic root in the inner 
ear sensory epithelia. Xenografted ESCs, adult NSCs, and fetal dorsal root ganglion survived 
for certain period following implantation into the vestibulocochlear nerve or inner ears of 
adult rats and guinea pigs (Hu et al., 2005; Regala et al., 2005). ESCs, which are pluripotent 
cells derived from the inner cell mass of blastocysts, can grow indefinitely in an 
undifferentiated state and have the potential to differentiate into all mature cell types, except 
embryonic tissue (Evans et al., 1981; Martin, 1981; Thomson et al., 1998). Previous results 
indicate that NSCs have a multipotent capacity and can generate a wide range of cell types for 
transplantation in a variety of diseases (Clarke et al., 2000; Gage, 2000). Hair cells and 
neurons can be generated in vivo from embryonic stem cells and neural stem cells after 
transplantation (Li et al., 2003b; Parker et al., 2007; Reyes et al., 2008; Tateya et al., 2003). 
Embryonic NSCs transduced with the Math1 gene gave rise to both neurons and HCs, 
following their implantation into normal guinea pig cochleae (Han et al., 2010). ESCs and 
NSCs replacement therapy, although promising, must overcome potential problems, including 
immune rejection and post-transplantation immunosuppression (Matsuoka et al., 2006; 
Richardson et al., 2008). Compared with ESCs, tissue-specific NSCs have less self-renewal 
capacity and, although they differentiate into multiple lineages, they are not pluripotent. 
Long-term consequences of ESCs use in cell replacement therapy may include facilitation of 
tumorigenesis in host tissues (Aoi et al., 2008; Frankel, 2000; Hong et al., 2009; Lanza, 2007; 
Prockop, 2003). Moreover, ESCs replacement therapy is still highly controversial, and their 
use in research and therapeutics has been encumbered by ethical considerations (Frankel, 
2000; Lanza, 2007). Furthermore, they rely on post-mortem cell harvesting, and typically a 
low-yield sources of tissue, thus, requiring a large number of animals to produce sufficient 
cells for transplantation.  
 
2.5.3 Autologous transplantation 
Autologous transplantation is a widely accepted and approved technique in regenerative 
medicine, which can circumvent many problems associated with ESCs. It has the great 
advantage of avoiding the risk of immune rejection and ethical concerns regarding the use of 
human embryos. Mesenchymal stem cells and induced pluripotent stem (iPSs) have been 
recognized as two important promising sources for autologous inner ear hair cell and neuron 
replacement. Significant breakthrough research has found that activation of a set of stem cell 
genes can reprogram terminally differentiated cells to acquire properties similar to ESCs (Aoi 
et al., 2008; Hong et al., 2009; Nishimura et al., 2009; Park et al., 2008; Takahashi et al., 2006; 
Takahashi et al., 2007; Staecker et al., 2007; Yu et al., 2007). The reprogrammed cells are 
namely induced iPSs. These iPSs exhibit the morphology and growth properties of ESCs and 
express ESC marker genes. After transplantation of iPS cell-derived neural progenitors into 
mouse cochleae, approximately 50% of the iPS cell-derived cells settled in the cochlea and 
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differentiated into neural lineages (Nishimura et al., 2009). Further, a recent report showed 
that mechanosensitive sensory hair cell-like cells can be generated from iPSs (Oshima et al., 
2010). However, it is unclear whether iPSs will ever be safe for future use in patients. As 
retroviral transfection necessary to randomly insert “stem cell” genes to form iPSs, there is 
still a strong risk of tumor formation (Holden et al., 2008). In previous experiments, adult 
human fibroblasts and adult mouse fibroblasts were induced to become pluripotent stem cells. 
NIH 3T3 cells (a spontaneously immortalized fibroblast cell line) have the potential to 
differentiate into SGCs. Therefore, NIH 3T3 cells were selected herein to acquire data for 
future studies on the SGC-oriented differentiation. 
 
Mesenchymal stem cells (MSCs) are another promising source for autologous inner ear hair 
cell and neuron replacement (Korbling et al., 2003), and they have been reported to 
differentiate into multiple lineages and have long been evaluated in clinical practice. MSCs 
can be readily obtained in abundant quantities for used as an autologous graft material. 
Previous studies have documented in vitro differentiation of bone marrow-derived stem cells 
into neurons (Jiang et al., 2002). Using this strategy, Naito et al. demonstrated that autologous 
bone marrow-derived stem cells can survive in the inner ear for up to 4 weeks (Naito et al., 
2004). Grafted cells, some of which are expressed a neuronal or glial cell marker, were 
introduced into the scala tympani and modiolus via microinjection. Another in vitro study 
reports that bone MSCs are progenitors for inner ear hair cells (Jeon et al., 2007). By a 
combination of growth factor stimulation and expression of Math1, they show that MSCs 
derived from bone marrow can be induced to differentiate into hair cell-like cells with specific 
hair cell markers. Trans-differentiation of MSCs into a neuronal and hair cell-like phenotype 
suggested that MSCs are potential candidates for cell therapy in SNHL.  
 
2.5.4 Perspectives for future research 
Cellular therapy is an intellectually attractive option for replacing damaged inner ear hair cells 
and SGCs. The discovery of adult inner ear stem cells and the generation of hair cells and 
neurons from exogenous stem cells and iPSs have opened an exciting new avenue for 
developing of hearing restoration strategies. These findings provide a sound foundation for 
the development of therapies to treat SNHL. Despite these exciting findings, there are 
numerous challenges to face and obstacles to overcome before clinical translation. It is 
conceivable that stem cell-based therapy alone will not be the ultimate solution for the 
treatment of SNHL. Most likely, future manifestations of biological therapy for hearing loss 
will probably combine existing cochlear implant with cell-based therapy, or gene/drug 
therapy (Ciorba et al., 2009; Tang et al., 2006; Patel et al., 2004). 
 
 
31
                                                                                                                                                             
 
3. AIM OF THE STUDY  
 
The purpose of the study was to diagnose inner ear disease using nanoparticle-based MRI and 
to evaluate the efficacy of different nanoparticles in gene delivery to treat sensorineural 
hearing loss.   
 
The original publications covered the following issues: 
 
1. To study inner ear barrier function using different MRI contrast agents;    
       
2. To investigate the ability of nanoparticles to enter the nucleus of cochlear cells for     
    gene delivery; 
 
3. To demonstrate the efficacy of nanoparticle-mediated delivery of the model gene,   
     Math1; and  
 
4. To explore the targetability of TrkB ligand functionalized liposome nanoparticles to    
    spiral ganglion cells.  
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4. MATERIALS AND METHODS   
 
This chapter briefly describes the main methods used. For more detailed descriptions of the 
methods, please refer to original publications I-V. 
4.1 Plasmid preparation 
4.1.1 Math1 Plasmid construction 
The Math1 coding fragment was amplified from pCLIG-Math1 plasmid (provided by R. 
Kageyama Kyoto University, Kyoto, Japan) by PCR using 5'-GCG ATG TCC CGC CTG 
CTG CA-3’ as the forward primer and 5' -AAA ACT GGC CTC ATC AGA GTC-3’ as the 
reverse primer. For generation of an EmGFP C-terminally tagged Math1 expression clone, we 
used the Gateway recombination system (Invitrogen, USA). The entry clone, pENTR/D-
TOPO containing the Math1 open reading frame, was obtained using the pENTRTM 
Directional TOPO Cloning Kit (Invitrogen, USA). Once the entry clone was obtained, a LR 
recombination reaction was performed for transfer of Math1 open reading sequence into a 
Vivid Colors pcDNA 6.2/C-EmGFP-DEST vector to create an EmGFP C-terminally tagged 
Math1 expression clone. The EmGFP sequence from pcDNA 6.2/CEmGFP- DEST was 
ligated to the 3’ end of the Math1 coding sequence with a short linking peptide (thirteen 
amino acids). The pcDNA6.2/C- EmGFP-Math1plasmid was first analyzed by PCR (M13 
forward primer and M13 reverse primer provided by Invitrogen) to confirm the presence and 
the size of the insert. The plasmid was sequenced to further verify the integrity of the Math1 
gene and its orientation in the vector. 
 
4.1.2 Id2.3 shRNA plasmid preparation 
We purchased the plasmid pGeneClipTM hMGFP, which encodes a shRNA to transiently 
silence the inhibitor of differentiation and DNA binding-2 (Id2) and expresses the reporter 
gene EGFP (SuperArray, Bioscience Corp, Frederick, MD, USA). The plasmid was 
propagated in OneShot TOP10 Competent Cells (Invitrogen, Carlsbad, CA, USA) and then 
extracted using the PureLinkTM Plasmid DNA Megaprep kit (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. The purity and concentration of Id2.3 shRNA 
Plasmid were determined by spectrophotometer (NanoDrop® ND-1000, USA).  
 
4.2 Cell cultures and treatment 
NIH 3T3 cells (ATCC, USA) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Sigma, Product Number: D5671) supplemented with 4 mM L-glutamine, 10% fetal bovine 
serum (FBS), and 1% penicillin-streptomycin (Invitrogen, USA). The cells were cultured at 
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37°C in a CO2 incubator. Parts of NIH 3T3 cells were transfected with pCLIG_Math1 plasmid, 
pcDNA6.2/C-EmGFP-Math1 plasmid, and pcDNA6.2/C-EmGFP-BDNF plasmid using 
Lipofectamine 2000 for 24h. Parts of NIH 3T3 cells were transfected with pcDNA6.2/C-
EmGFP-Math1 plasmid using liposome nanoparticles and HPNPs for 24h, respectively. 
Lipofectamine-mediated transfection was performed according to the manufacturer’s 
instructions.  
 
Primary cochlear cells were obtained from newborn rats. 1-5-day-old newborn rats were 
sacrificed by decapitation after deep anesthetization and sterilization with 70% ethanol. The 
cochleae were isolated and cut into small pieces and then dissociated with a PBS-based 
solution containing elastase (1 mg/ml, Sigma Aldrich, USA), collagenase type I (1 mg/ml, 
Sigma Aldrich, USA), and trypsin (0.5 mg/ml, Sigma Aldrich, USA) for 30 min at 37°C. The 
digestion was terminated by adding 1 ml DMEM-F12 (Sigma Aldrich, USA) containing 10% 
fetal bovine serum (Sigma Aldrich, USA). After centrifugation for 5 min at 250 x g, the cell 
pellets were resuspended in 1 ml defined medium [DMEM-F12 with B27 supplement, 1 mM 
n-acetyl-L-cysteine, penicillin–streptomycin, and 20 ng/ml EGF (Sigma Aldrich, USA)] and 
plated into a 4-well Lab-Tek®II Chamber Slide (Nalge Nunc International, Naperville, USA) 
containing 1.0 ml defined medium/well. The cells were cultured at 37°C in a CO2 incubator 
overnight. Parts of the cochlear cells were treated with HPNPs which were freshly prepared 
with cell culture medium at different concentrations (from 3 x 10-9 to 6.25 x 10-6 mol/L) for 
24h. Parts of cochlear cells were transfected with the pGeneClipTM hMGFP plasmid using 
HPNPs at N/P (w/w) ratio of 5:1 and Lipofectamine 2000 (Invitrogen, USA) for 24h, 
respectively.  Parts of cochlear cells were transfected with the pcDNA6.2/C-EmGFP-Math1 
plasmid using liposome nanoparticles and Lipofectamine 2000 for 24h, respectively. Parts of 
the cochlear cells were treated with A371-functionalized liposome nanoparticles (final 
concentrations: 10 μM, 1.0 μM, and 0.1 μM) and non-functionalized liposome nanoparticles 
(final concentrations: 10 μM, 1.0 μM, 0.1 μM, and 0.01 μM) without plasmid DNA 
encapsulation for 2 hours and 24 hours. 
 
Bone marrow mesenchymal stem cells (Biosite, USA) were cultured in Qualified RMSC 
medium (Biosite, USA) supplemented with 10% FBS and 1% penicillin-streptomycin 
(Invitrogen, USA). The cells were cultured at 37°C in a CO2 incubator overnight. MSCs were 
transfected with the pcDNA6.2/C-EmGFP-Math1 plasmid using Lipofectamine 2000. 
Fluorescence activated cell sorting was performed to sort for EmGFP positive cells. After 48 h, 
EmGFP positive cells were plated in a tissue culture dish and treated with 10 ng/ml BDNF 
and 10 ng/ml glial cell line-derived neurotrophic factor (GDNF) (Invitrogen). After 2 weeks, 
the cells were counter-stained with neurofilament-200. 
  
After incubation or transfection, all the cells were washed with PBS and fixed with 4% 
paraformaldehyde for 30 min. The nuclei were stained with 4', 6-Diamidino-2-phenylindole 
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(DAPI) (10ng/ml, Sigma-Aldrich, USA) for 10 min. Part of cells were counter-stained with 
50 μg/ml TRITC-labeled phalloidin (Sigma Aldrich, USA) for 40 min. Finally, all of the cells 
were mounted with Fluoromount for confocal microscopy.  
 
4.3 Cochlear organotypic culture 
Five 1-5-day-old new born rats were used to test HPNPs. The cochlear tissues were treated 
with HPNPs at concentrations of 2.5 x 10-6 mol/L and 1 x 10-5 mol/L for 24 hours. Five 1-5-
day-old new born rats were treated with liposome nanoparticles carrying plasmid 
pGeneClipTM hMGFP DNA at concentrations of 1 x 10-3 mol/L and 2 x 10-4 mol/L for 
different time points (15 min, 30 min, 120 min, and 120 min, 2 d, and 4 d). The new born rats 
were decapitated after deep anesthetization and sterilized with 70% ethanol. Similar to the 
primary cochlear cell culture, each cochlea was isolated, cut into 3-4 pieces, and plated into a 
4-well Lab-Tek®II Chamber Slide (Nalge Nunc International, Naperville, USA) containing 
1.0 ml defined medium/well. The cochlear tissues were cultured at 37ºC in a CO2 incubator 
overnight and then treated with nanoparticles. At the end of the incubation, all of the cochlear 
tissues were fixed with 4% paraformaldehyde for 30 min. After washing with PBS, the 
specimens were counter-stained with then DAPI (10 ng/ml) for 10 min. For the HPNPs 
treated specimens, part of them were counter-stained with TRITC-labeled phalloidin (50 
μg/ml) for 40 min and the rest of the specimens were used for Myosin VIIA staining. For the 
liposome nanoparticles treated specimens, part of them were used for Neurofilament staining. 
Finally, all of the specimens were mounted with Fluoromount for confocal microscopy.  
  
4.4 In vivo experiment 
In the in vivo study, eleven male Sprague-Dawley (3-10-month-old) rats weighing 400-750 g 
with normal Pryer’s reflex were supplied by the experimental animal unit, University of 
Tampere. Six rats were used to test HPNPs. A small piece of gelatin sponge pledget (around 8 
mm3 after saturation) saturated with 10-3 mol/L HPNPs were administered to rat the round 
window membrane for 24 hours. Five rats were used to test liposome nanoparticles. A small 
piece of gelatin sponge pledget (around 8 mm3 after saturation) saturated with 10-1 mol/L 
liposome nanoparticles were administered to rat the round window membrane for 24 hours. 
For intratympanic administration of nanoparticles, animals were under general anesthesia 
[Domitor (0.5 mg/kg medetomidine hydrochloride, ORION Pharma, Finland) and Ketalar (75 
mg/kg ketamine, PFIZER AB, Finland) given intraperitoneally]. After local analgesia with 
lidocaine, a retro-auricular incision was used to expose the left bulla. A hole was drilled on the 
bulla with a 2 mm diameter burr. After visualizing the stapedial artery, the round window 
membrane was identified above the artery. The gelatin sponge saturated with nanoparticles 
was placed on the round window membrane for 24 hours. The operation was performed under 
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sterile conditions. Atipamezole hydrochloride (2 mg/kg) was injected intraperitoneally (i.p.) 
immediately after the operation to accelerate recovery from anesthesia. Saline (2 ml) was 
administered through subcutaneous injection in the neck. L-Polamivet (0.4 ml/kg) was 
injected twice a day to relieve pain. Following i.p. injections of pentobarbital (60 mg/kg), 
cochleae were fixed using cardiac perfusion with 4% paraformaldehyde, and bullae were 
removed and further fixed for 60min. The cochleae were thoroughly washed with tap water 
for 30 seconds, opened by breaking the bony wall under a stereomicroscope, and then washed 
again with PBS for 2x5 min. The bullae were incubated with DAPI (10 μg/ml) for 10 min to 
stain the nuclei. After washing with PBS for 3x5 min, the round window membrane, lateral 
wall and modiolus together with the basilar membrane were harvested using a 
stereomicroscope, placed on glass slides, and mounted with Fluoromount for confocal 
microscopy. 
 
4.5 Confocal microscopy  
The specimens were observed under an Olympus IX70 microscope with ANDOR IQ installed. 
The excitation filters were 488 nm (blue excitation) and 568 nm (green excitation), and an Ar-
Kr laser was used as the excitation source. The corresponding emission filters were 525/50 
(FITC) and 607/45 (TRITC). DAPI was excited with a 340-380 nm filter and detected using a 
500 LP filter.  
 
4.6 Statistical analysis  
Statistical analyses were performed using the SPSS 11.5 software package. Significant 
differences were identified using one-way analysis of variance, a Bonferroni test was used for 
pairwise multiple comparison. A difference was considered to be statistically significant at 
P<0.05. 
 
4.7 Synthesis of different nanoparticles 
4.7.1 Synthesis of lipoplex nanoparticles 
4.7.1.1 Synthesis of lipoplexes with TrkB ligand 
The liposome nanoparticles were provided by UH.IB, Helsinki. TrkB ligand peptides (A371) 
were synthesized by FMOC technology (in Storkbio former inbiolabs, Tallin, Estonia), which 
have been developed using molecular modeling with the aim of mimicking the biological 
functions of brain derived neurotrophic factor (BDNF) and nerve growth factor (NGF).  The 
appropriate amounts of the lipid stock solutions in chloroform and the lipid peptide conjugate 
were mixed in a molar ratio of 0.5:0.44:0.02:0.01:0.03 (Sph: eggPC: DSPE-PEG-2000: lipid-
peptide conjugate: TRITC-DHPE) to obtain the desired composition. The solvent was 
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removed under a stream of nitrogen and the lipid residues was subsequently maintained under 
reduced pressure for at least 2 h to remove trace amounts of chloroform. The lipid film was 
hydrated with 5 mM Hepes, 0.1 mM EDTA, pH = 7.4 at 60 0C for 1h.  The lipid mixture at 
final concentration of 0.1 mM was subjected to focused ultrasound (Covaris, KBiosciences, 
UK). An average diameter of 182 and 89 nm for lipoplexes with and without targeting peptide 
(A371), respectively, was determined by dynamic light scattering (Zetasizer, Nano ZS, 
Malvern Instruments Ltd., UK). Liposome nanoparticles were mixed with plasmid DNA 
(pGeneClipTM hMGfp) at a lipid/DNA charge ratio (+/-) of 1.2:1 to obtain nanoscale 
particles, also termed as lipoplexes. The diameter of lipoplexes with and without targeting 
TrkB ligand peptide was 108 nm and 112 nm, respectively.   
 
4.7.1.2 Synthesis of lipoplexes with Math1 plasmid   
Liposome nanoparticles were prepared similar as described above. The liposome nanopar-
ticles were mixed with plasmid DNA (Math1) at a lipid/DNA molar charge ratio (+/-) of 1.2:1 
or 2:1 to obtain lipoplexes. The final concentration of lipids in both lipoplexes was 0.1 mM or 
1 mM. The following nanoparticles were obtained: LPX (DHAB /eggPC = 1:1), TRITC 
labeled LPX (DHAB/EggPC/ TRITC = 0.5:0.47:0.03), LPX-PEG (DHAB/ EggPC/ TRITC/ 
XDSPE-PEG-2000 = 0.5:0.47:0.03:0.01), LPX-DOPE (1.2:1) (DHAB/EggPC/-DOPE = 
0.5:0.4:0.1, lipid/DNA molar charge ratio (+/-) of 1.2:1), and LPX-DOPE (2:1) 
(DHAB/eggPC/DOPE = 0.5:0.4:0.1, lipid/DNA molar charge ratio (+/-) of 2:1). The physi-cal 
characterization of lipoplexes is included in the original publications (V).    
 
4.7.2 Synthesis of hyperbranched polylysine nanoparticles 
The HPNPs were provided by EPFL, Switzerland. Briefly, HPNPs were synthesized by 
thermal polymerization of L-lysine*HCl and labeled with fluorescent dye, FITC (HPNPs 
without FITC tagged were used for gene transfection). The thermal polymerization of L-
lysine*HCl was performed at 150 °C in the presence of an alkaline metal base (MOH) to 
neutralize the amine hydrochloride and to create the corresponding free amino acid base 
according to the procedure described by Scholl et al (Scholl et al., 2007). Samples were 
purified by dialysis and gel filtration with a Sephadex Column. The final product was 
recovered in 85% yield as an orange powder. Before usage in vitro or in vitro, the powder was 
dissolved in PBS, resulting in a molecular concentration of 10-3mol/l. The molecular weight, 
average hydrodynamic diameter, and polydispersity index (PDI) of hyperbranched polylysine 
nanoparticles were determined by dynamic light scattering (DLS, Zetasizer Nano ZS, 
Malvern Instruments Ltd., UK): Mn = 22 000 g/mol; hydrodydynamic diameter: 73 nm; PDI = 
1.9. The scanning electron microscopy showed the HPNPs spherical morphology and similar 
size to the DLS measurement. The physical-chemical characterization of polyplexes formed 
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by complexation of HPNPs and plasmid DNA is included in the original publication (IV).    
 
4.7.3 Synthesis of POA@SPIONs 
The SPIONs were provided by KTH, Stockholm. Briefly, a total of 0.903 g FeCl3 • 6H2O 
(3.34 mmol) and 3.046 g sodium oleate (10.02 mmol) were dissolved in a mixed solvent, 
including 25 mL ethanol, 20 mL deionized water and 45 mL hexane. The resulting solution 
was heated to 62°C and refluxed for 4 hours. Then the iron oleate complex containing organic 
phase was washed with deionized water three times. After the evaporation of hexane, 2.90 g 
waxy Fe oleate complex (3.23 mmol) and 0.47 g oleic acid (1.67 mmol) were dissolved in 20 
mL dioctyl ether at 70°C. The reaction mixture was heated to 290°C for 1.5 hours. A total of 
30 ml ethanol was added to the reaction mixture, and the nanoparticles were collected by 
centrifugation under 6000 rpm. The nanoparticles were purified by centrifugation. Finally, the 
SPIONs were dispersed in 40 ml tetrahydrofuran (THF) in the presence of 100 µl oleic acid. 
To achieve transfer from organic phase to water phase, a 2 ml solution of SPIONs in THF was 
mixed with 2 ml 10 mg/ml Pluronic® F127 aqueous solution at room temperature. After 30 
minutes of vigorous agitation, the organic solvent was evaporated overnight to obtain a stable 
aqueous suspension of SPIONs. The aqueous solution of SPIONs was then dialyzed to 
remove free-standing PF127 polymers. The particle suspension was filtered by 200 nm 
syringe filter and stored at 4°C. 
 
4.8 MRI measurements 
MRI was performed with a 4.7 T MR scanner with bore diameter of 155 mm (PharmaScan, 
Bruker BioSpin, Germany) using a dedicated rodent head coil with diameter of 38 mm (for rat 
and for mice >50 g) and 23 mm (for mice <25 g). The maximum gradient strength was 300 
mT/m with an 80-μs rise time. All animal experiments were approved by the Ethical 
Committee of the University of Tampere (permission: STH527 A ESLH-2006-07528/Ym23). 
Animal care and experimental procedures were conducted in accordance with the European 
legislation. All experimental procedures were performed under general anaesthesia. The body 
temperatures of the animals were maintained by circulating warm water and their respirations 
were recorded with Physio Tool-1.0.b.2 program (Bruker BioSpin, Germany). Animals were 
placed in the magnet with the ears positioned at the isocenter.  
  
4.8.1 MRI measurement of Gd-DOTA 
Twenty-three albino female FVB mice, weighing from 18 to 55 g were included in this study. 
For intravenous administration, the gadolinium-tetra-azacyclododecane-tetra-acetic acid (Gd-
DOTA, Guerbet, Aulnaysous-Bois, France, 500 mmol/L) was injected into the tail vein (IV) at 
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dosages of 1.5, 0.75, or 0.3 mmol/kg via canula during MR scanning (Table 1). For 
intratympanic (IT) delivery, a portion of gelfoam was soaked in Gd-DOTA diluted in 
physiological saline to concentrations of 500, 100, 50, or 25 mmol/L, and placed in the 
middle ear cavity against the round window through a myringotomy (Table 1). Excess 
solution was removed by absorption with a small piece of cotton. It is estimated that the 
gelfoam pieces measured 1 x 1 x 3.5 mm3 when wet and contained approximately 5 μl Gd-
DOTA, i.e. ranging from 0.014 to 0.0045 mmol/kg. Head coils of either 38 or 23 mm were 
used, depending on the size of the animal. 
 
T2-weighted two-dimensional (2D) images were acquired with the rapid acquisition with 
relaxation enhancement (RARE) sequence (TR/TEeff 25,000/40 ms, resolution 0.156 x 0.156 
mm2). T1-weighted 2D images were acquired with RARE sequence (TR/TEeff 500/10 ms, 
resolution 0.098 x 0.13 mm2). High resolution T1-weighted three-dimensional (3D) images 
were acquired with RARE sequence (TR/TEeff 500/43 ms, resolution 0.078 x 0.078 x 0.078 
mm3).  
 
For IT delivery, serial MR imaging was obtained from 1.5 to 4 h after Gd-DOTA 
administration. 2D and 3D T1-weighted images were acquired. For IV administration, a series 
of images were acquired with 10 min intervals to study serial dynamic uptake over a period of 
120 min following the Gd-DOTA injection in a group of animals using the 38 mm coil. It was 
noted that the 23 mm coil could potentially limit the animals’ ventilatory excursions. 
Consequently, most of the serial dynamic uptake observations made with the 23 mm coil were 
performed at longer time intervals, immediately, 90 min, and 180 min after Gd-DOTA 
injection and using 3D sequences, which reduce the time of acquisition. Animals imaged with 
the 23 mm coil were removed from the machine between scans (Table 1). 
 
4.8.2 MRI measurement of POA@SPIONs 
A total of 26 male Wister rats weighing from 218 to 470 g with normal Prey’s (hearing) reflex 
were included in this study. Overall, the study was designed with three arms of 
POA@SPIONs administration, including intracochlear (SPIONs-IC), intratympanic (SPIONs-
IT) and intravenous (SPIONs-IV) routes. The SPIONs-IC arm was subdivided into two 
groups based on whether a silicon catheter (SC) or polyurethane catheter (PC) was employed 
for the IC injection. Animals in the SPIONs-IT arm underwent MRI at varied time intervals 
following POA@SPIONs administration ranging from day 0 through day 7. T2-weighted 2D 
images were acquired with RARE 2D sequences (TR/TEeff 2500/40 ms, resolution 0.156 x 
0.156 mm2). T2-weighted 3D images were acquired with RARE 3D sequences (TR/TEeff 
500/43 ms, resolution 0.078 x 0.078 x 0.078 mm3). For IC delivery, 2D T2-weighted images 
were acquired at different time points post POA@SPIONs administration (1-6 h). 3D T2-
weighted imaging was performed in one animal. For IT delivery, 3D T2-weighted images 
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were acquired at different time points post POA@SPIONs administration in different animals 
(Table. 2). For IV administration, a series of images were acquired with 30 min intervals over 
a period of 210 min following the POA@SPIONs injection.  
 
In the SPIONs-IC arm, the left bulla was exposed through a postauricular approach. Working 
under an operating microscope, a hole was drilled through the bulla with a 2 mm diameter 
burr. The round window membrane was identified superior to the stapedial artery. The scala 
tympani in the basal turn was opened with a 0.5 mm cutting burr inferior to the stapedial 
artery. POA@SPIONs were slowly injected either through a SC group that was connected to a 
reservoir (tubing outer diameter: 0.64 mm; inner diameter: 0.3 mm; MedEl, Innsbruck, 
Austria) or through a custom made polyurethane catheter (outer diameter: 0.25 mm; inner 
diameter: 0.12 mm; AgnTho’s AB; PC group). The SC-reservoir drug-delivery system was 
designed to administer multifunctional nanoparticles into the human cochlea and was, 
therefore, included in the present study. However, the catheter was excessively large for 
insertion into the cochlea of a rat, which necessitated our design of an appropriately sized 
polyurethane catheter drug-delivery system. The catheter tip was inserted into the scala 
tympani just through the opening and was sealed circumferentially with Histoacryl glue 
(Aesculap AG, Tuttlingen, Germany). After the glue was dry, 10–20 μl (in SC group) or 5 μ μl 
(in PC group) POA@SPIONs were slowly instilled over 1 min into the scala tympani. The 
wound was sutured closed. MRI scanning commenced immediately after the POA@SPIONs 
administration. 
 
In the SPIONs-IT arm, POA@SPIONs was administered through a postauricular middle ear 
operation, as described above or through a transcanal approach with a myringotomy over the 
round window. In the postauricular approach, a small pledget of gelatine sponge 
(approximately 8 mm3) soaked in POA@SPIONs was placed against the round window 
membrane. A muscle plug was used to fill the opening made in the bulla and the wound was 
sutured closed. In the transcanal approach, an anterior myringotomy was initially made to 
relieve any air bubbles. A posterior myringotomy was then made and a similar sized gelatine 
sponge soaked in POA@SPIONs was placed into the round window niche and allowed to fill 
the posterior middle ear cavity. A control procedure was carried out through a similar 
approach on the contralateral side and the gelatine sponge was soaked only in physiological 
saline. 
 
In the SPIONs-IV arm, the lateral tail vein was dilated by soaking the tail in warm water 
followed by topical application of 70% alcohol. The vein was cannulated with a 30-gauge 
needle connected to catheter tubing and taped securely into position. Saline containing 5% 
heparin was initially instilled to maintain patency. Baseline pretreatment MRI scans were 
obtained as a control. POA@SPIONs were slowly injected intravenously. MRI scanning 
commenced immediately after the contrast agent administration. 
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Table 1 Animals were grouped according to administration approaches and dosages of the 
contrast agent. 
 
 
  
 
 
 
 
 
Groups/dosages n Coil size Histology/embedding 
IT           25 mmol/L 2 23 mm
               50 mmol/L 2 23 mm
              100 mmol/L 2 23 mm
              500 mmol/L 2 23 mm/38 mm
IV          0.3 mmol/kg 1 23 mm
              0.75 mmol/kg 3 23 mm/38 mm
              1.5 mmol/kg 9 23 mm/38 mm 2/paraffin
IT, intratympanic; IV, intravenous; n, number of the animal 
 
 
Table 2. Animals were grouped according to administration approaches and MRI time post-
POA@SPION delivery.  
 
Groups n Dosages† MRI time Ears for histology 
SPION-IC:   
SC 3 10-20 Day 0 (1–6 h) 3
PC 6 5 μl/rat Day 0 (1–6 h)
SPION-IT:   
Day 0 8 20 μl/rat Day 0 (2–3 h) 1
Day 1 2 20 μl/rat Day 1
Day 3 2 20 μl/rat Day 0 and 3
Day 7 2 20 μl/rat Day 0 and 7 1
SPION-IV 3 2.37 μl/kg Day 0
 
†Fe+ concentration: 1.0mg/ml (4.3mM) –1.3mg/ml (5.6mM). 
IC: Intracochlear; IT: Intratympanic; IV: Intravenous; PC: Custom-made polyurethane catheter (AgnTho’s 
AB, Sweden); SC: silicon catheter connected to a reservoir (MedEl, Innsbruck, Austria); SPION: 
Superparamagnetic iron oxide nanoparticle.  
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5. RESULTS  
 
5. 1. Passage of gadolinium through the mouse inner ear barriers 
The mouse inner ear structures delineated by MRI using intratympanic Gd- 
DOTA administration 
T1 and T2 signal characteristics were compared using a 2D imaging protocol in animals with 
the 23 mm diameter coil. The T2-weighted sequences showed that the inner ear fluids 
generated a bright signal, including the perilymph in the scala tympani, scala vestibuli, 
vestibulum, and semicircular canals as well as endolymph in the scala media. The modiolus 
signal was grey, while the osseous spiral lamina was dark (Fig.1A). The T2 signal was more 
intense in ears treated with Gd-DOTA. In comparison, T1-weighted images showed that 
endolymph in the scala media and ampullae of the semicircular canals were dark, while 
perilymph was bright. The modiolus was also bright, although less than the perilymph. The 
contralateral non-treated side showed a diffuse grey signal (Fig.1B). The scala tympani and 
vestibuli were also distinguishable from the scala media in Gd-DOTA contrasted, T1-
weighted images using the 38 mm coil. 
 
3D images using T1-weighted sequences revealed greater contrast and detail within the inner 
ear than 2D images. For example, the lateral wall in the basal turn of the cochlea contained a 
grey appearing region that likely represents the spiral ligament against the dark endolymph. A 
dark border appeared between ST and LW in the basal turn near the hook region (Fig.2A). 
Identification of the lateral wall via MR imaging, located lateral to the perilymph and 
endolymph, was confirmed by comparison to histological sections. The cochlear aqueduct, 
which originates in the scala tympani near the round window membrane, was visible (Fig.2). 
The vestibular perilymph was continuous with the perilymph in the scala vestibuli and 
semicircular canals; however, the superior semicircular canal was infrequently visible 
(Figs.2E).   
 
 
Figure 1. Mouse cochlear structures in coronal 2D MR images with IT administration of Gd-DOTA (23 
mm coil) (180 min time point). (A) T2-weighted image shows Gd-DOTA enhanced signal in the cochlea 
except for the OSL. SM appears slightly darker than the perilymphatic compartments. (B) T1-weighted 
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image shows much more intense Gd-DOTA enhanced signal in the perilymphatic compartments, ST and 
SV compared to the bright signal in the T2-weighted image A. SM is dark and clearly distinguishable from 
the perilymphatic compartments and LW. LW, lateral wall; Mod, modiolus; OSL, osseous spiral lamina; 
SM, the scala media; ST, the scala tympani; SV, the scala vestibuli; 1st, the basal turn; 2nd, the second turn. 
Scale bar = 1 mm. 
 
 
 
 
Figure 2. Mouse cochlear and vestibular structures in MPR multi view of T1-weighted images with IT 
administration of Gd-DOTA (23 mm coil) (180 min time point). Gelfoam soaked with 5 μl, 500 mmol/L 
Gd-DOTA was placed into the left ear. In the enlarged window A, LW and Mod are slightly highlighted by 
Gd-DOTA uptake in addition to more pronounced enhancement in ST and SV. The structure adjacent to ST 
is suspected to be CA with signal intensity similar to ST. LW demonstrated brighter signal than SM. A dark 
border appeared between ST and LW in the basal turn near the hook region. OSL is seen as a sharp dark 
line. In the enlarged window E, the vestibular perilymph, including the Vest, Am, and SCC, show obvious 
uptake of Gd-DOTA. The perilymph in the Vest merges with the perilymph in the basal turn of SV. CA is 
seen adjacent to the basal turn of the ST. Small window B is a relative perpendicular cut through the centre 
of plane A. Small window C is a relative axial cut through the centre of the cochlea in window A. Small 
window D is the minimised image of window A. Am, ampulla; SCC, semicircular canal; Vest, vestibulum. 
CA, cochlear aqueduct; LW, lateral wall; Mod, modiolus; MPR, multiplanar reconstruction; OSL, osseous 
spiral lamina; SM, the scala media; ST, the scala tympani; SV, the scala vestibuli; 1st, the basal turn; 2nd, 
the second turn.   
 
The images were acquired in mice receiving IT administration of Gd-DOTA at concentrations 
of 500, 100, 50, and 25mmol/L. The signal intensities in the perilymphatic compartments and 
Gd-DOTA concentrations were linearly correlated (R = 0.445, p < 0.05, ANOVA test). Gd-
DOTA uptake in the scala tympani was consistently higher than in the scala vestibule, while it 
was variable in the vestibulum. 
 
Dynamic uptake of Gd-DOTA in the mouse inner ear fluids upon intravenous 
administration 
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Inner ear images acquired after IV administration of Gd-DOTA were roughly similar to those 
obtained following IT delivery. Two-dimensional T1-weighted sequences were performed at 
10 min intervals in a 38 mm coil and showed a strong linear increase in signal intensity within 
the perilymph of the scala tympani between 10 and 70 min. The signal enhancement within 
the perilymphatic compartments reached an initial plateau 80 min after IV administration and 
continued to slightly increase to a maximum level by 100 min (Fig. 3A).     
 
Three-dimensional images were acquired with T1-weighted sequences using the 23 mm coil. 
At the time point 0, just after IV injection of Gd-DOTA, the perilymph space did not contain 
sufficient signal for quantitation. The signal subsequently increased in the perilymph of the 
scala tympani, scala vestibuli, and vestibulum and showed an increasing trend in intensity 
from the 90 min to the 180 min scans, but the differences were not statistically significant 
(Fig. 3B) (p > 0.05, Student’s t-test). These results were consistent with the 2D observations, 
wherein Gd-DOTA uptake reached a plateau at approximately 90 min. The higher signal 
intensities for the perilymph over the endolymph were statistically significant (Fig. 3B) (p < 
0.001, paired samples t-test). Certain finer details of inner ear structures were better defined 
following IV administration of Gd-DOTA compared with IT delivery. Uptake within the 
cochlear apex was slightly greater in the IV group. The cochlear aqueduct and all semicircular 
canals were better demonstrated in the IV group. However, the signals in the lateral wall and 
modiolus were slightly higher in the IT group than the IV group.  
 
 
 
Figure 3. Dynamic uptake of Gd-DOTA in the inner fluids after IV administration at the dosage of 1.5 
mmol/kg. (A) Signal intensities of ST plotted versus time imaged with 2D T1-weighted sequences using 
the 38 mm coil. The uptake reached a plateau after 80 min and stepped to the second one after 100 min. (B) 
There was slightly increased signal intensity from 90 to 180 min time points when measured with 3D T1-
weighted sequences using the 23 mm coil. The uptake in perilymphatic compartments was significantly 
greater than that in SM (**p < 0.01, paired samples t-test). N, number of the ears; SM, the scala media; ST, 
the scala tympani; SV, the scala vestibuli; Vest, vestibulum. 
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5. 2. MRI manifestation of novel POA@SPIONs in the rat inner ear 
 
MRI manifestation of POA@SPIONs in the inner ear after IC administration 
Without any contrast agent, the inner ear fluids, including perilymph and endolymph, gen-
erated an intense signal on T2-weighted MRI. Therefore, the cochlear and vestibular compart-
ments were highlighted on the volume rendering from a T2-weighted 3D scan. In the IC–PC 
subgroup, 3D rendered images acquired 180 min after IC delivery showed that the areas with 
high signal in the cochlea and vestibulum were greatly decreased in comparison with the 
untreated contralateral side. The disappearance of signal for the perilymph signal was 
attributed to the presence of POA@SPIONs within that compartment. Quantitation of 2D 
images demonstrated statistically significant decreases in the signal intensity (normalized by 
the nearby brain signal intensity; POA@SPIONs treatment side vs untreated side) for both the 
cochlea (p < 0.001, paired Student t-test) and ampulla (p < 0.05, paired Student t-test) 2 h 
post-IC injection (Fig. 4). The signal changes persisted over a 6 h observation time (Fig. 4B). 
In another measurement, the T2 relaxation time (mean ± SD) in the scala vestibuli perilymph 
after POA@SPIONs (25.608 ± 5.351 ms) treatment was lower than than the untreated side 
(130.5 ± 71.9 ms). In the IC–SC subgroup, which received a larger injected volume of 
nanoparticles to compensate for a leak at the round window, the signal decrease in rat the 
perilymph was greater than in the IC–PC subgroup, which was exposed to a smaller 
POA@SPION volume (5 μl).  
 
Limited passage of POA@SPIONs through the middle-inner ear barriers 
POA@SPIONs were delivered to the round window membrane, and T2-weighted MRI was 
performed at different time points, from 2 h to 7 days (Table 2). In the 2D MR images, no 
visible difference was observed between the left inner ears, which were exposed to the round 
window membrane POA@SPION administration, and the right side, which were exposed to 
physiological saline (Fig. 5). Quantitation showed no statistically significant difference at 2 h 
through 7 days post-round window membrane administration (p > 0.05, paired t-test). 
However, the data did show slight decreases in signal intensity for the left cochleae 1 and 3 
days after POA@SPIONs delivery and on the left ampullae day 1 through day 7. At 3.5 h 
post-nanoparticle administration, there was no difference in T2 relaxation time between the 
cochlea exposed to POA@SPIONs (123.510 ± 4.640 ms) and the untreated cochlea (124.005 
± 22.526 ms). Following this, 1 week later, a slight decrease in T2 relaxation time was 
observed in the POA@SPION-exposed cochlea (103.255 ± 6.497 ms) compared with the 
untreated side (121.666 ± 11.677 ms). These data suggest a slight, but insufficient passage of 
POA@SPIONs through the middle-inner ear barriers.    
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Figure 4. Quantitative comparison of T2-weighted signal intensities of the inner ear between left cochleae 
receiving intracochlear POA@SPIONs and right nontreated cochleae. Signal in the perilymph of the left 
cochleae was diminished by the nanoparticles leaving only the endolymph in the scala media with bright 
signal (A). Quantification showed a significant decrease in the signal intensity in the perilymph of both the 
cochlea and ampulla at 2 h postintracochlear injection of POA@SPIONs (normalized signal intensity =  
signal intensity in the region of interest/signal intensity in reference) (B). The signal intensity changes 
persisted for the 6 h of observation time. *p < 0.05; **p < 0.01 (paired Student t-test). Am: Ampulla; Coch: 
Cochlea; IC: Intracochlear; L: Left; PC: Polyurethane catheter; R: Right; Ref: Reference region in brain; 
SE: Standard error; SM: Scala media.   
 
 
Figure 5. T2-weighted images of the inner ear after intratympanic administration of POA@SPIONs to the 
left ears. There was no visible signal change observed in the left side (L) compared with the untreated right 
side (R) at either 2 h (A) or 1day (B) postadministration. The bright signal in the left cochlea as indicated 
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by the arrow is of unknown origin and was consistently observed in all cochleae. Am: Ampulla; Mod: 
Modiolus; ST: Scala tympani; SV: Scala vestibuli.  
 
POA@SPIONs did not pass through the blood-endolymph and blood-perilymph 
barriers 
Before IV injection, baseline T2-weighted images were taken, which showed bright signals in 
both endolymph and perilymph compartments within the cochlea and vestibular organ. The 
endolymph was indistinguishable from the perilymph (Fig. 6A). Images of the inner ear 
acquired at defined time points post-POA@SPIONs IV delivery did not show visible changes, 
indicating that POA@SPIONs was not detected in the inner ear (Fig. 6B). Quantitation 
confirmed that no statistically significant signal intensity changes were observed for up to 
210 min after IV administration of POA@SPIONs (p > 0.05; ANOVA) (Fig. 6C). 
 
 
Figure 6. T2-weighted imaging of the inner ear after intravenous POA@SPIONs administration. A 
baseline image taken before nanoparticle delivery demonstrated the cochlear anatomy and ampulla (A). 
After 150min, no signal change was observed (B). Signal intensity dynamics (normalized by brain signal 
intensity) obtained up to 210min did not show statistically significant differences (C).Am: Ampulla; CN: 
Cochlear nerve; L: Left; Mod: Modiolus; OSL: Osseous spiral lamina; R: Right; SE: Standard error; ST: 
Scala tympani; SV: Scala vestibuli.  
 
5. 3. Internalization of HPNPs in the cochlear cells both in vitro and in vivo     
 
Internalization of HPNPs in rat primary cochlear cell culture  
After 24 h of incubation, efficient internalization of HPNPs was observed in primary rat 
cochlear cells at all concentrations tested. The level of HPNPs internalized by the cells was 
dose-dependent; the higher the HPNP concentration applied to the cell culture medium, the 
greater fluorescent intensity in the cochlear cells. This positive correlation was statistically 
significant (p<0.001, ANOVA). Nuclear entry of HPNPs was detected in different cochlear 
cell types, including hair cells and spiral ganglion cells at different concentrations. The higher 
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the concentration of HPNPs, the more nuclear localization of HPNPS was observed (Fig. 7). 
In cochlear cells that were incubated with HPNPs at concentrations from 3.87 x 10-7 mol/L to 
6.25 x 10-6 mol/L, a homogenous and condensed distribution of HPNPs was detected 
throughout the nuclei (Fig. 8). Nuclear permeation of propidium iodide, which indicates cell 
death, was also observed in cochlear cells treated with HPNPs at this concentration interval 
(Fig. 8). HPNPs were included in both cytoplasmic and nuclear vesicles when the 
nanoparticle concentration was below 3.87 x 10-7 mol/L (Fig. 7). No permeation of propidium 
iodide was detected in the nuclei, indicating that these cells are living cells. However, nuclear 
permeation of propidium iodide was occasionally observed in spiral ganglion cells that were 
treated with HPNPs at 9.7 x 10-8 mol/L. Nucleolin expression was detected in the cochlear 
cells. Subcellular distribution of nucleolin was in both the cytoplasm and nucleus. An HPNP 
vesicle pathway from the cytoplasm towards the nucleolin positive nucleolus was also 
observed.  
 
HPNP internalization in rat cochlear organotypic culture 
In cochlear organotypic culture treated with HPNPs for 24 hours, an abundant of HPNPs 
appeared in diverse cell types: the modiolus, Corti’s organ, and the lateral wall (Fig. 9). The 
hair cell region was demonstrated by myosin 7A staining (Figs. 9A and B). Nuclear entry of 
HPNPs was frequently observed in these different cell types. 
 
HPNP distribution in adult rat cochlear cell populations after round window 
membrane permeation 
HPNPs were observed in the round window membrane, middle ear mucosa, Corti’s organ, 
spiral ganglion, stria vascularis, spiral ligament, and stapedial artery cells at 24 hours post-
round window membrane administration. HPNPs appeared in both layers of the round 
window membrane (Fig. 10A). A homogenous, condensed distribution of HPNPs was 
detected in the nuclei, and cytosolic HPNP vesicles were traveling from the outer layer 
towards the inner layer (Fig. 10A). Additionally, there was a gradient of cytosolic HPNP 
vesicles from the outer layer to the inner layer (Fig. 10A). More pronounced nuclear entry 
was also observed in the outer layer of the round window membrane than the inner layer. In 
the middle ear mucosal cells, HPNPs were observed in both the cytoplasm and nuclei. 
Distribution was condensed in the nuclei, and vesicles were at low levels in the cytoplasm 
(Fig. 10B). In the spiral ganglion cells, perinuclear distribution of HPNP vesicles was 
observed (Fig. 10C). In the Corti’s organ, HPNPs were detected in the cytoplasm of outer hair 
cells, inner hair cells, and supporting cells (Fig. 10D). In the stria vascularis, HPNP vesicles 
appeared in the tight junctions, cytoplasm, and perinuclear region of the marginal cells (Fig. 
10E). In the spiral ligament fibrocytes, HPNPs primarily appeared in the cytoplasm as 
vesicles (Fig. 10F). An abundant of HPNPs was also detected in the stapedial artery cells and 
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appeared as vesicles in both the cytoplasm and nuclei (Fig. 10G). 
 
 
  
Figure 7. HPNP vesicle formation in both the cytoplasm and nuclei was observed at concentrations below 
3.87 x 10-7 mol/L. (A): 3.87 x 10-7 mol/L, (B): 9.7 x 10-8 mol/L, (C): 2.4 x 10-8 mol/L, (D): 3 x 10-9 mol/L. 
Nuclear permeation of propidium iodide was not detected in these cells. Green: HPNPs. Blue: DAPI. Scale 
bar = 5 μm. 
 
 
 
Figure 8. Internalization of HPNPs induced permeation of propidium iodide in the primary cochlear cell 
culture. (A-C): The cochlear cells were incubated with HPNPs at a concentration of 6.25 x 10-6 mol/L. 
Nuclear permeation of propidium iodide was observed in all the cells (B). C is the merged images of A and 
B. (D-F): The cochlear cells were incubated with HPNPs at a concentration of 3.87 x 10-7 mol/L. Nuclear 
permeation of propidium iodide was observed in most of the cells (E). F is the merged images of D and E. 
(G-I): Internalization of HPNPs induced permeation of propidium iodide in a single cell (higher 
magnification). Homogenous and condense distribution of HPNPs was detected in the cytoplasm and entire 
nucleus (G). (I): merged image. Green: HPNPs. Red: propidium iodide permeation. Blue: DAPI. Scale bars 
= 100 μm. 
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Figure 9. Uptake of HPNPs in the cochlear organotypic culture. Figs. 3A and B are merged images of 
HPNPs, Myosin 7A, and DAPI in the modiolus (A) and Corti’s organ (B). Figs. 3C (low magnification) 
and D (higher magnification) are merged images of HPNPs, F-actin, and DAPI in the lateral wall. Green: 
HPNPs; Red: Myosin 3A (A, B), F-actin stained by TRITC-conjugated phalloidin (C, D). Blue: DAPI. 
Scale bars: A, C =100 μm, B, D =10 μm.  
 
 
 
Figure 10. Uptake of HPNPs in the cochlea at 24 hours post-round window membrane administration in an 
adult rat.  A: Lateral view of reconstructed 3D image of the round window membrane showing the gradient 
distribution of HPNPs, both condensed homogenous nuclear distribution of HPNPs (arrow head) and 
HPNP vesicles (arrow) were observed. B: Middle ear mucosal uptake of HPNPs. Condensed homogenous 
nuclear distribution of HPNPs (arrow head) and HPNP vesicles (arrow) were detected. C: Perinuclear 
distribution of HPNPs was observed in the spiral ganglion cell (arrow). D: HPNPs were found in the 
Corti’s organ, cytoplasmic distribution of HPNPs was observed in the hair cells, and both cytoplasmic and 
peri-nuclear distribution of HPNPs was detected in the supporting cells (Border cells). E: Both cytoplasmic 
and nuclear distribution of HPNPs was detected in the stria marginal cells, the typical tight junctions of the 
stria marginal cells are shown using F-actin staining (arrow). F: Abundant HPNPs were observed in the 
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spiral ligament fibrocytes. G: Abundant HPNPs were detected in the endothelium of the stapedial artery 
including the nuclear HPNP vesicles (arrow). Green: HPNPs; Red: TRITC-conjugated phalloidin; Blue: 
DAPI. BC: Border cell; IHC: inner hair cell; IS: inner side of the RWM; OHC: outer hair cell; OS: outer 
side of the round window membrane; 1, 2, 3: row 1, row 2, and row 3 of OHC. Scale bar = 10 µm. 
 
HPNP-mediated gene transfection in cell culture 
After 24 h of incubation, NIH 3T3 cells were transfected with the pGeneClipTM hMGFP 
plasmid using HPNPs. To determine the optimum N/P (w/w) ratio, the N/P (w/w) ratio was 
varied from 1:1 to 6:1. The N/P (w/w) ratios of 4:1 and 5:1 resulted in the maximum level of 
GFP expression. HPNP-mediated transfection efficiency in NIH 3T3 cells was 29.8% at a 5:1 
N/P (w/w) ratio.  The HPNP-mediated transfection efficiency in primary cochlear cells was 
8.7% at a 5:1 N/P (w/w) ratio, which was higher than the Lipofectamine-mediated 
transfection efficiency of 6.0%.  
 
5. 4. Math1 expression in vitro and intracellular trafficking of the Math1 
protein 
 
Lipofectamine-mediated transfection of pcDNA6.2/C-EmGFP-Math1 plasmid in 
defined cell types 
NIH 3T3 cells were transfected with the pcDNA6.2/C-EmGFP-Math1, pcDNA6.2/C-
EmGFP-BDNF and PCLIG-Math1 plasmids using Lipofectamine 2000.  After 24 h of 
incubation, variable transfection efficiencies were observed for the three plasmids. The 
plasmid pcDNA6.2/C-EmGFP-Math1 showed the highest transfection efficiency, 11.7%; 
pCLIG-Math1 showed the lowest transfection efficiency, 3.0%; and the transfection efficiency 
of pcDNA6.2/C-EmGFP-BDNF was 7.2%. Using microscopy, the fluorescence of the 
EmGFP-Math1 fusion protein in NIH 3T3 cells was a vivid emerald, which was bright and 
easily detected, while EGFP fluorescence in NIH 3T3 cells that was expressed by the PCLIG-
Math1 plasmid was faint (Fig. 11G). MSCs and primary cochlear cells were also successfully 
transfected with pcDNA6.2/C-EmGFP-Math1 plasmids (Figs. 11F and 12). The transfection 
efficiencies were 2.9% in primary cochlear cells and 5.1% in MSCs. In primary cochlear cell 
culture, fibrocytes, spiral ganglion neurons, and hair cell-like cells were transfected with the 
pcDNA6.2/C-EmGFP-Math1 plasmid (Fig. 12). The transfection efficiency of the different 
cell populations was not quantified; however, fibrocytes and spiral ganglion neurons, the two 
major populations in the primary cochlear cells, were frequently observed as expressing 
EmGFP under a confocal microscope.  
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Figure 11. Subcellular localization of EmGFP-Math1 fusion protein in different cell types transfected by 
pcDNA6.2/C-EmGFP-Math1 plasmid using Lipofectamine. A-E: EmGFP-Math1 expression in NIH 3T3 
cells. F: EmGFP-Math1 expression in MSCs. G: EGFP expression in NIH 3T3 cell. H: EmGFP-BDNF 
expression in NIH 3T3 cell. Green: EmGFP-Math1 (A-F), EGFP (G), EmGFP-BDNF (H); Blue: DAPI. 
Red: TRITC-phalloidin. Scale bar = 10 μm.  
 
 
 
 
Figure 12.  Lipofectamine 2000 mediated transfection of mixed primary cochlear cells by pcDNA6.2/C-
EmGFP-Math1 plasmid. A: Lower magnification, transfection efficiency is 2.9%. B, D: fibrocytes. C: In 
the neuron, EmGFP-Math1 appeared in both the nucleus and axon. E: Outer hair cell-like cell. F: Spiral 
ganglion cell. Green: EmGFP-Math1; Blue: DAPI; Red: TRITC- phalloidin. HB: hair bundle. CP: cuticular 
plate. Scale bar = 100 μm (A), 10 μm (B-F).       
    
 
Subcellular location of the EmGFP-Math1 fusion protein 
In most cells, the EmGFP-Math1 fusion protein was primarily localized to the nucleus when 
transfected by pcDNA6.2/C-EmGFP-Math1 plasmid (Figs. 11A, C, E and F; Figs. 12B and 
D-F). A unique subcellular localization for EmGFP-Math1 was also observed in certain cell 
populations: EmGFP-Math1 fusion protein simultaneously appeared in both the nucleus and 
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cytoplasm (Figs. 11B, D; Fig. 12C). Both cytoplasmic and nuclear EmGFP-Math1 localized 
to vesicles of varying sizes, with a diameter between 0.4 μm to 2.3 μm (Figs. 11C, D, and F; 
Fig. 12B). Certain vesicles appeared fused, as both the vesiculated and homogeneous 
EmGFP-Math1 fusion protein was observed (Fig. 11E). In contrast, NIH 3T3 cells that were 
transfected with the pCLIG-Math1 plasmid did not show trafficking vesicles, and the EGFP 
expressed by the pCLIG-Math1 plasmid was localized to the cytoplasm (Fig. 11G). Further, 
the EmGFP-BDNF fusion protein was localized only to the cytoplasm (Fig. 11H). 
 
MSCs demonstrate a neuronal-like phenotype when transfected with the 
pcDNA6.2/C-EmGFP-Math1 plasmid  
After 10 days of transfection with the pcDNA6.2/C-EmGFP-Math1 plasmid, enhanced 
volume and polarization were observed in certain MSCs. After two weeks, neuron-like cells 
with axons and dendrites were observed, while certain cells remained at earlier stages with the 
appearance of a growth cone. In these cells, the cellular body was spherically shaped (Figs. 
13A, B). In the differentiated neuron-like cell, neurofilament was detected, which represents a 
neural-specific protein (Fig. 13B). In contrast, neither MSCs transfected with the 
pcDNA6.2/C-EmGFP-CAT plasmid (control plasmid) nor MSCs treated with BDNF and 
GDNF alone differentiated into neuron-like cells (Figs. 13C, D). 
 
Liposome nanoparticle-mediated Math1 expression in defined cell types  
After 24 h of incubation, internalization of TRITC-tagged liposome nanoparticles, LPX-PEG 
and LPX in NIH 3T3 cells was identified by the appearance of red vesicles in the cytoplasm. 
Quantitation of the fluorescence intensity showed concentration- dependent internalization of 
both PEGylated lipoplexes and unPEGylated lipoplexes (p < 0.05). However, no significant 
difference was observed between pegylated lipoplexes and unPEGylated lipoplexes when 
cells were treated with same concentrations (p > 0.05). The EmGFP-Math1 fusion protein was 
expressed in NIH 3T3 and primary cochlear cells 24 h following transfection (Figs. 13E-H). 
When the pcDNA6.2/C-EmGFP-Math1 plasmid was delivered with LPX-PEG (PEGylated) 
and LPX-DOPE (1.2:1) (lipid/plasmid molar charge ratio of 1.2:1) in NIH 3T3 cells, the 
transfection efficiency was 0.7% and 0.8%, respectively. The two additional lipoplexes, LPX 
(unPEGylated) and LPX-DOPE (2:1) (lipid/plasmid molar charge ratio of 2:1) showed higher 
transfection efficiencies 3.8% and 3.6%, respectively. The transfection efficiency of LPX was 
higher than LPX-PEG. LPX-DOPE (2:1) showed higher transfection efficiency than LPX-
DOPE (1.2:1). However, all nanoparticles showed lower transfection efficiencies compared to 
Lipofectamine 2000.  
 
 
 
 
 
 
Subcellular location of the EmGFP-Math1 fusion protein in cells transfected with lipoplexes 
was similar to cells transfected with Lipofectamine 2000, which was primarily distributed in 
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the nuclei and sparsely retained within the cytoplasm. Vesicles of various sizes, with 
diameters between 0.4 μm to 3 μm, appeared in these cells (Figs. 13E, F), and several were 
fused (Fig.  13E). Vesicles were also observed in both the nucleus and cytoplasm (Fig. 13F).  
 
 
 
 
                                
                                  
Figure 13. Neuron-like cell differentiation of MSCs transfected with pcDNA6.2/C-EmGFP-Math1 plasmid 
and liposome nanoparticles mediated transfection of the pcDNA6.2/C-EmGFP-Math1 plasmid. A: Bright 
field image of B. B: Neuron-like cells stained with neurofilament. C: MSCs treated with 10 ng /ml BDNF 
and 10 ng /ml GDNF alone for two weeks. D: MSCs were transfected with pcDNA6.2/C-EmGFP-CAT 
plasmid plus treatment with BDNF and GDNF for two weeks. No neurofilament-positive cells were 
detected in C and D. Liposome nanoparticles mediated transfection of the pcDNA6.2/C-EmGFP-Math1 
plasmid in NIH 3T3 cells (E, F: transfection with unPEGylated LPX. H: transfection with PEGylated LPX-
PEG), primary cochlear cell (G: transfection with unPEGylated LPX). Arrow heads: unipolar cell indicates 
neuron-oriented differentiation; Arrow: bipolar shape of the neuron-like cell. Green:  EmGFP-Math1; Red: 
neurofilament (B), liposome nanoparticles (E-H). Blue: DAPI; Scale bars (A-D) = 25μm, (E-H)  = 7.5 μm.   
 
5. 5. Internalization of liposome nanoparticles functionalized with the TrkB 
ligand  
 
Internalization of liposome NPs in primary cochlear cells 
Primary cochlea cell culture showed efficient internalization of both A371-functionalized 
liposome nanoparticles liposome nanoparticles and non-functionalized liposome nanoparticles, 
which were observed in the primary cochlear cells, including spiral ganglion cells, fibrocytes, 
and stria vascularis intermediate cells (Fig.15). Cytosolic and perinuclear localization of 
liposome nanoparticles was observed in different cell types. Internalization differences for 
liposome nanoparticles were not statistically significant between A371-functionalized liposome 
nanoparticles and non-functionalized liposome nanoparticles (p>0.5). The lipoplex signal 
intensity was significantly dependent on the lipoplex concentration in the medium (p<0.01). 
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Lipoplex internalization and GFP expression in cochlear explants 
Dynamic uptake of liposome nanoparticles in both neurofilaments and spiral ganglion cells 
was observed, with liposome nanoparticles accumulating in the spiral ganglion satellite cells 
and gradually appearing on the neurofilament and in the spiral ganglion cells (Fig.14). 
Abundant distribution of liposome nanoparticles with and without functional TrkB peptides 
was observed in the neurofilament (Fig.14). Internalization differences for liposome 
nanoparticles was not statistically significant between A371-functionalized liposome 
nanoparticles and non-functionalized liposome nanoparticles (p>0.5). Likely aggregated 
EGFP expression was observed in the explants on day 2 post-treatment with A371-
functionalized liposome nanoparticles carrying the pGeneClipTM hMGFP plasmid DNA 
encoding shRNA to transiently silence Id2. More EGFP expression was detected on day 4 
post-treatment. EGFP expression was also detected in the explants on day 4 post-treatment 
with non-functionalized liposome nanoparticles carrying the same plasmid DNA as the A371-
functionalized liposome nanoparticles.  
 
 
 
Figure.14. Confocal microscopy showing the internalization of liposome nanoparticles in rat cochlear explants. 
A371-functionalized liposome nanoparticles carrying plasmid pGeneClipTM hMGFP DNA appeared adjacent to 
neurofilaments at 1 h post-treatment (A), abundantly attached to neurofilaments at 2h post treatment (B), and 
distributed in the spiral ganglion cells at 2 h post-treatment (C). Two days post-gene delivery with A371-
functionalized liposome nanoparticles carrying plasmid pGeneClipTM hMGFP DNA, Likely EGFP expression 
was seen in cells (D). Non-functionalized liposome nanoparticles carrying plasmid pGeneClipTM hMGFP 
DNA attached to neurofilaments (E) at 1 h post-treatment; greatly accumulated on neurofilament (F) and within 
spiral ganglion cells (G) at 2 h post treatment. Red: liposome nanoparticles; Green: neurofilaments (A-C and E-
F), GFP (D); Blue: DAPI. Scale bar =10 μm.     
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Figure 15. Confocal microscopy showing the internalization of liposome nanoparticles in primary rat 
cochlear cell cultures. For A371-functionalized liposome nanoparticles without plasmid DNA, efficient 
uptake was observed in the cytoplasmic and perinuclear regions of type I (A) and type II (B) spiral 
ganglion cells and stria intermediate cells (C). For the non-functionalized liposome nanoparticles without 
plasmid DNA, efficient internalization occurred in spiral ganglion cells (D) and fibrocytes (E). Red: 
liposome nanoparticles; Green: FITC-conjugated phalloidin; Blue: DAPI. Scale bar=10 μm. 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Confocal microscopy showing the distribution of liposome nanoparticles in the spiral ganglion 
region and hair cell region of the rat cochlea at 24 h post-RWM permeation. Abundant A371-functionalized 
liposome nanoparticles were detected in the spiral ganglion cells (A) and inner hair cells and adjacent 
supporting cells (D). After treatment with non-functionalized liposome nanoparticles, fewer liposome 
nanoparticles appeared in the SGCs (B) and inner hair cells (E). Few liposome nanoparticles were detected 
in the pillar cells (D and E). In the untreated controls, faint red autofluorescence was also detected in SGCs 
(C) and the inner hair cells (F). Red: liposome nanoparticles; Green: FITC-conjugated phalloidin; Blue: 
DAPI. NC: untreated control; SC: satellite cell; SGC: spiral ganglion cell. BC: border cells; IHC: inner hair 
cell; PC: pillar cell. Scale bar =10 μm.  
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Lipoplex distribution in cochlear cell populations after round window membr-
ane permeation  
In the adult rat cochleae receiving round window membrane permeation with A371-
functionalized liposome nanoparticles, greater particle distribution was observed in the spiral 
ganglion region than in cochleae treated with non-functionalized liposome nanoparticles 
(Figs.16A, B). This difference was not statistically significant, which likely due to the small 
sample size (p>0.05) (Fig. 17). No EGFP expression was detected in the spiral ganglion cell 
and spiral ganglion satellite cells with lipoplex internalization. In the inner hair cell region, 
there was significantly greater uptake of functionalized liposome nanoparticles than non-
functionalized liposome nanoparticles (p<0.05) (Figs. 16D, E and Fig.17). Lipoplex uptake 
was also observed in the lateral wall, including the spiral ligament and stria vascularis, but 
was not significantly different between the functionalized and non-functionalized liposome 
nanoparticles (p>0.05) (Fig.17). No uptake was detected in the outer hair cell region for 
cochleae treated with either A371-functionalized liposome nanoparticles or non-functionalized 
liposome nanoparticles (Fig. 16).   
 
 
 
 
Figure 17. Quantification of the lipoplexes distribution in different cell populations of adult rat cochleae at 24h 
post-round window membrane permeation. There was a significantly greater distribution of A371-functionalized 
liposome nanoparticles compared to non-functionalized liposome nanoparticles in the inner hair cells. There was 
also a tendency toward enhanced distribution of A371-functionalized liposome nanoparticles compared to non-
functionalized liposome nanoparticles in the spiral ganglion cells. There was no difference in the nanoplex 
distribution in the spiral ligament of the lateral wall. IHC: inner hair cell; SGC: spiral ganglion cell; SL: spiral 
ligament. 
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6. DISCUSSION   
6. 1. Difference in gadolinium permeability of perilymphatic and endolym-   
phatic barriers and indication for diagnosis 
This experiment is the first to show MR imaging with visualization of uptake of Gd-DOTA 
administered by IV or IT routes in the perilymph of the mouse. Gd-DOTA administered 
intratympanically passed through the round window membrane efficiently and appeared in the 
perilymphatic spaces of the cochlea and vestibule but not in the endolymphatic spaces. This 
finding is in agreement with previous MRI results from the inner ears of guinea pigs and 
humans (Zou et al., 2009; Zou et al., 2005a). High resolution visualisation of the contrast-
enhanced perilymphatic space allows for some investigation into the process by which 
contrast material may pass through the round window membrane into the inner ear. High 
resolution scanning with the 4.7 T machine revealed some details of the soft tissues within the 
lateral wall of the cochlea. A dark border was revealed between ST and LW in the basal turn 
near the hook region. This structure might represent the tissues that did not pass Gd-DOTA 
such as the stria vascularis and the twisted basilar membrane near the hook region. However, 
this appearance needs to be elucidated in further studies. 
 
The intravenous administration of Gd-DOTA demonstrated passage through the blood-
perilymph barrier, but not through the blood-endolymph barrier, which is also consistent with 
results in guinea pigs and humans (Counter et al., 2003; Counter et al., 2000; Zou et al., 2009). 
The dynamic uptake of Gd-DOTA into the perilymph of the mouse and humans has been seen 
to occur more slowly than in the guinea pig. It is possible that there is some structurally based 
regulation of this uptake and that these results reflect the closer genetic similarities between 
the mouse and humans. In addition to the cochlear glomeruli of Schwalbe within the modiolus, 
saccular capillaries and capillaries in the spiral limbus may contribute to the uptake of Gd-
DOTA in the mouse perilymph (Franz et al., 1993). In humans, injury to the inner ear 
appeared to accelerate the rate of gadolinium uptake into the perilymph following IV injection, 
which indicated a possible change in the regulation of the blood-perilymph barrier (Zou et al., 
2009).                                                                                                                                                                     
 
Some slight differences were observed in the uptake of Gd-DOTA within the lateral wall and 
modiolus between IV and IT administrations. One of the differences was that the IT delivered 
Gd-DOTA may more efficiently pass into the ‘‘perimodiolar lymph”, it could indicate that the 
barrier between the scala tympani and the modiolus is more porous than the potential IV route 
of passage through the cochlear glomeruli of Schwalbe within the modiolus. The second 
difference was that more Gd-DOTA accessed to the lateral wall after IT administration than 
IV approach suggested a more efficient transport from round window membrane to the spiral 
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ligament extracellular space than from the local capillaries to the extracellular space. A 
difference in efficiency of passage of Gd-DOTA into the modiolus and lateral wall would 
raise the possibility that drug delivery to these areas of the cochlea might be similarly favored 
by IT route. There are other potential advantages of IT administration over IV. IT treatment is 
likely to cause less systemic effects because of its local administration and lower dose 
requirement. The total dose of Gd-DOTA required for visualisation of the inner ear using the 
IT route was significantly less than IV administration, with Gd-DOTA maximum 0.014 
mmol/kg for IT versus 1.5 mmol/kg for IV. 
 
In principle, IV administration of Gd-DOTA might be used to investigate the integrity of the 
stria vascularis, especially the intercellular junctions of strial marginal cells and endothelium 
of strial capillaries. Interference with the endothelial barrier of the capillaries supplying the 
stria vascularis, which is a component of the blood-endolymph barrier, has resulted in an 
intrastrial electric shunt that ablated endocochlear potentials and induced hearing loss (Cohen-
Salmon et al., 2007). Rupture of Reissner’s membrane has been shown to produce bright 
signal within the scala media using IV gadolinium (Zou et al., 2003a; Zou et al., 2003b). This 
disruption of the endo-perilymph barrier caused a mixing of endolymph with perilymph and 
eliminated endocochlear potentials (Jin et al., 1990).  
 
6. 2. POA@SPION are a “super” MR contrast agent for inner ear imaging 
The inner ear endolymph and perilymph of the cochlea and vestibular organ where most of 
the nanoparticles should appear are known to generate very bright signals on T2-weighted 
images (Counter et al., 2003; Counter et al., 1999). POA@SPIONs was demonstrated to be an 
efficient T2 contrast agent within the rat inner ear. When infused into the perilymph, there 
was a consistent dramatic reduction of signal intensity on T2-weighted images compared with 
the persisting bright signal of the endolymph, which did not take up POA@SPIONs and 
lacked the negative contrast effect. These results support previous work that POA@SPIONs is 
a potent T2 negative contrast agent in vivo(Qin et al., 2007). POA@SPION, when introduced 
into the perilymph compartment, caused a marked suppression of T2 signal that produced the 
effect of showing the endolymphatic compartment as a bright, isolated structure. It is apparent 
that significant amounts of POA@SPIONs did not pass through the perilymph–endolymph 
barrier into the endolymph, resulting in a remarkable opportunity to observe the isolated 
endolymphatic space with bright T2 signal compared with the darkened perilymph, which 
contained POA@SPIONs. It suggests the potential for studying the integrity of the perilymph-
endolymph barriers, such as Reissner’s membrane, which might be injured during acute 
endolymphatic hydrops or impulse noise exposure (Flock et al., 2003; Fraysse et al., 1980; 
Konishi et al., 1982; Valk et al., 2006; Zou et al., 2003b). 
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Intracochlear delivery of nanoparticles to investigate their distribution as potential drug or 
gene carriers has been reported by workers in the Nanoear consortium (Scheper et al., 2009; 
www.nanoear.org/, 2009). Although the IC administration of POA@SPIONs is an invasive 
procedure, not suitable for an office setting, it may be applied clinically as a diagnostic or 
therapeutic agent in the future, perhaps in conjunction with cochlear implantation. Therefore, 
the information acquired from IC delivery is important both in present animal studies to track 
nanoparticles through the cochlea and to plan for future clinic work with cochlear implants. 
POA@SPIONs have demonstrated sufficient contrast effects and IC distribution to justify 
their further development as a label to trace the passage of drugs, genes, and nanoparticles 
within the inner ear in vivo. Application of therapy into the middle ear which is a minimally 
invasive approach would be favorable for use in the out-patient clinic, but probably depend 
upon passage through the middle-inner ear barriers (round window and oval window) in order 
to access the inner ear. It has been reported that positively enhancing T1 MRI contrast agents, 
gadolinium chelates, have excellent passage through the middle–inner ear barriers after IT 
administration in guinea pigs (Zou et al., 2009; Zou et al., 2005a), rats (Zou et al., 2010) and 
humans (Zou et al., 2009; Zou et al., 2005a). However, the longitudinal relaxivity (r1) of 
gadolinium chelates decreases rapidly at high field strengths, reducing the sensitivity of these 
contrast agents at high field (Sosnovik et al., 2008). Besides, Gadolinium is not practical in 
molecular imaging, which requires high magnetic field strength. Finally, a high concentration 
of gadolinium was reported to be ototoxic in a preliminary study (Kakigi et al., 2008). The 
permeation of nanoparticles through the middle-inner ear barriers of the rat has been observed 
with lipid nanocapusules (Zou et al., 2008). Nanoparticles that would be detectable with MRI 
would provide an excellent means to evaluate the efficacy of their transport through the 
middle-inner ear barriers in vivo. Although the passage of naked POA@SPIONs through the 
middle-inner ear barriers was inefficient in this study, it is possible that if they were to be 
downsized or manufactured with altered surface characteristics (charge and ligands) similar to 
other nanoparticles, POA@SPIONs may penetrate the middle-inner ear barriers more 
efficiently in future studies (www.nanoear.org/, 2009). 
 
The IV route is another desirable approach to introduce contrast agents that may be taken up 
into the perilymph or endolymph under normal or pathological circumstances. Gadolinium 
has been shown to enhance the perilymphatic space in T1 MR images after IV injection 
(Counter et al., 2003; Counter et al., 1999). The integrity of the blood-perilymph and blood-
endolymph barriers, which are critical for the proper functioning of inner ear physiology, can 
be studied with contrast agents. These barriers may become ‘leaky’ when injured and their 
integrity could be evaluated with the use of contrast imaging agents that do not normally pass 
through. As an example, changes in the blood-perilymph barrier or blood-endolymph barrier 
permeability to gadolinium have been observed in MRI (Counter et al., 2000; Mark et al., 
1992). POA@SPIONs delivered intravenously did not produce detectable signal changes 
within the inner ear, suggesting that neither the blood-perilymph barrier nor blood–
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endolymph barrier were permeable to them. Their larger particle size and differences in 
surface properties, in comparison to Gd-DOTA, likely contribute to the difficulties in 
transport through the blood-perilymph barrier. The doses of gadolinium that have been 
employed for IV use have been in excess of those typically given in clinical circumstances 
(Counter et al., 1999; Zou et al., 2009). There are concerns that high doses of IV gadolinium 
might increase the risk of adverse effects, such as nephrogenic systemic fibrosis (High et al., 
2007; Thakral et al., 2009). However, the potential for toxicity from SPIONs can be limited 
by manipulating the polymer/iron mass ratio (Mahmoudi et al., 2009b). The concentration of 
Fe3+ in POA@SPIONs (4.3–5.6 mM) is far below the maximum levels previously tested and 
no toxicity has yet been demonstrated at any concentrations (Mahmoudi et al., 2009a). As 
opposed to gadolinium, SPIONs do not lose T2 contrast effects at higher Tesla strengths. For 
all of these reasons, POA@SPIONs remains an important contrast agent that should be 
studied as an alternative to gadolinium. By conjugating with different ligands, POA@SPIONs 
may be developed that will penetrate the different inner ear barriers and that may serve as a 
molecule-specific contrast agent to detect pathologic molecular expression within the inner 
ear of proteins such as TNF- alpha and VEGF (Zou et al., 2005b).  
 
6. 3. Nuclear entry of HPNPs into the cochlear cells 
The success of nonviral gene therapy has been largely limited by inefficient gene delivery to 
cochlear cells due to the nuclear envelope barrier. Our primary intention in this study was to 
demonstrate the potential for HPNPs as carriers to deliver genes to cochlear cell nuclei. 
Although it has been discovered that nanoparticles can enter the cytoplasm of cochlear cells, 
nuclear delivery remains problematic (Scheper et al., 2009; Zou et al., 2008). HPNPs were 
detected in both cochlear cell cytoplasm and nuclei in primary cell culture, in organotypic 
culture, and in vivo via intratympanic administration. The results herein contrast the results of 
an in vivo study performed in guinea pigs using hyperbranched polylysine nanoparticles 
(Scheper et al., 2009). A likely explanation is that the HPNP’s nuclear entry is concentration-
dependent; in the in vivo study, cochlear cells were exposed to much lower HPNP 
concentrations than in vitro. The cells that are integrated into the organ may behave 
differently than individual cells. Nuclear localization of HPNPs was intense in rat round 
window membrane cells but was rarely observed in cochlear cells. The different HPNP 
delivery methods and the biological differences between rats and guinea pigs should also be 
considered as explanations for the results.  
 
Concentration-dependent toxicity was observed in the primary cochlear cell culture, and most 
of the cells died when treated with concentrations greater than 3.87 x 10-7 mol/L.  Spiral 
ganglion cells died when treated with HPNPs at 9.7 x 10-8 mol/L. This finding indicates that 
spiral ganglion cells might be more vulnerable to HPNP treatment as neurons are highly 
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sensitive to hazardous substance exposure. In primary cochlear cells incubated with higher 
HPNP concentrations, homogenous nuclear staining with propidium iodide indicated cell 
death. No permeation of propidium iodide was detected in the nuclei when the cochlear cells 
were treated with HPNPs at concentrations less than 3.87 x 10-7 mol/L, verifying the viability 
of these cells. Furthermore, the nuclear distribution of HPNP vesicles indicated the active 
transport of HPNP into living cells. It should also be pointed out that HPNP-containing 
vesicles are only detectable in living cells, as passive diffusion of HPNPs into the nuclei 
following cell death would not generate HPNP-containing vesicles but would show a 
homogenous distribution. As a result, HPNP nuclear entry was a meaningful biological 
process instead of a consequence of cell death.  
 
There are several potential mechanisms behind HPNP-mediated gene transfection’s greater 
efficiency than liposomes. First, HPNPs can condense DNA into a relatively smaller size than 
cationic liposomes, which is crucial for gene transfer. Second, HPNPs have a better ability to 
mediate endosomal escape than liposomes via the “proton sponge” hypothesis (Boussif et al. 
1995). Finally, HPNPs transport the plasmid into the nucleus directly and induce high 
transfection efficiency, as the nuclear localization of HPNPs is observed. However, it could 
not be excluded that, as mentioned in the review, HPNPs may aid in the nuclear import of 
DNA via other indirect mechanisms, including enhanced DNA protection and cytoplasmic 
mobility. 
 
Regarding the mechanism of nuclear import, there are several potential pathways.  
Nuclear localization signal (NLS)-mediated nuclear transport of HPNPs is a potential 
mechanism (Berry et al., 2007; Tkachenko et al., 2003). NLS-mediated nuclear transport 
requires certain cytosolic factors and ATP (Adam et al., 1990; Cserpan et al., 1995). Although 
the nuclear pore complex (NPC) can only transport macromolecules with diameters of up to 
39 nm (Pante et al., 2002), the PDI of HPNPs is large (PDI = 1.9), which means that a certain 
amount of HPNPs have sizes less than 39 nm.  Conformational change is expected in HPNPs 
with sizes greater than 39 nm, which is different from the solid rigid gold nanoparticles that 
were employed to investigate nuclear pore complex transportation (Pante et al., 2002).  
 
In addition, HPNPs may also enter the nucleus through other unknown NPC-independent 
mechanisms. Robert’s work proved that large size (122 nm-203 nm) polyplexes could also 
enter the nucleus (Carlisle et al., 2001). He inhibited nuclear pore function by co-
microinjection of wheat germ agglutinin (WGA). The failure of WGA to inhibit PEI/DNA 
complexes suggests that PEI/DNA may enter the nuclei of cells through an NPC-independent 
mechanism. One such potential mechanism by which HPNPs mediate nuclear entry may be 
that they are internalized and transported into the nucleus via nucleolin binding. Nucleolin is a 
ubiquitous eukaryotic protein that is conserved from yeast to mammals and is found in the 
nucleoli and nucleoplasm, as well as on the cell surface (Ginisty et al., 1999; Mongelard et al., 
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2007). Nucleolin is able to shuttle between the plasma membrane, and cytoplasm, as well as 
the nucleus, and it regulates many aspects of DNA and RNA metabolism (Ginisty et al., 1999; 
Srivastava et al., 1999). It has been reported that nucleolin is the cell surface target of DNA 
nanoparticles and that nucleolin is essential for the internalization and/or transport of the 
DNA nanoparticle from the cell surface into the nucleus (Chen et al., 2008). This process was 
also indicated in our study, as demonstrated by the HPNP vesicle pathway from the cytoplasm 
towards nucleolin-positive nucleolus. A recent report showed that the nucleolin-mediated 
cellular trafficking of DNA nanoparticles is lipid raft- and microtubule-dependent and can be 
modulated by glucocorticoid (Chen et al., 2010). Another potential NPC-independent 
mechanism for HPNP nuclear internalization in cochlear cells is nuclear envelope penetration 
or fusion (Godbey et al., 1999a; Godbey et al., 1999b; Verma et al., 2010). It is possible that 
the internalized cytoplasmic HPNPs are retained and tethered to the inner surface of the 
vesicles and, thereafter, are transported into the nuclei by molecular machines (such as 
dyneins) along cytoskeletal tracks (Godbey et al., 1999a; Godbey et al., 1999b; Verma et al., 
2010).  
 
Finally, HPNP internalization by cochlear cells was not specific for a cell population. This 
finding did not meet our goal of targeted gene delivery into the cochlea. However, HPNP 
functionalization with peptides specific for a definite cellular cochlear population may 
introduce the targetability of these nanoparticles. Herein, in the present studt, potential 
targetability with TrkB affinity peptide-functionalized liposome nanoparticles was observed 
in the spiral ganglion and inner hair cell regions of adult rat cochleae. Additionally, validating 
results were observed by our NanoEar project partner in spiral ganglion neurons using PEG-
PCL polysome nanoparticles functionalized with the same peptide (Roy et al., 2010). HPNPs 
can also be included in other nanoparticles to achieve both ideal targetability and efficient 
gene expression. 
 
6. 4. Importance of nuclear localization of Math1 in transcription  
PCR amplification, gene sequencing, and Western blot analysis confirmed the structure, 
integrity, and gene expression capacity of the newly constructed plasmid pcDNA6.2/C-
EmGFP-Math1. Using Lipofectamine, this novel pcDNA6.2/C-EmGFP-Math1 plasmid 
induced significantly higher transfection efficiencies than the pCLIG-Math1 plasmid, which 
was developed using the Moloney murine leukemia virus. An additional advantage of 
pcDNA6.2/C-EmGFP-Math1 is that EmGFP is fused to the Math1 protein, thus, it is possible 
to observe subcellular localization of the EmGFP-tagged Math1 protein. Furthermore, 
mutations have been introduced into GFP that further enhance and shift its spectral properties 
such that they emit vivid emerald fluorescence, thus, GFP is easier to visualize.  
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Several cell types, including NIH 3T3 cells, MSCs, and primary cochlear cells, showed 
efficient transfection of the pcDNA6.2/C-EmGFP-Math1 plasmid using lipofectamine. In 
addition, NIH 3T3 and primary cochlear cells were successfully transfected with the 
pcDNA6.2/C-EmGFP-Math1 plasmid using liposome nanoparticles. This result proved that 
the new Math1 plasmid is valuable for non-viral-vector-mediated Math1 gene delivery. NIH 
3T3 cells demonstrated the highest transfection efficiency among all cell types tested, using 
either lipofectamine or liposome nanoparticles. There is important significance in using 
autologous fibroblasts for the cell replacement deafness treatment mediated by Oct3/4, Sox2, 
c-Myc, Klf4, and Math1 (Oshima et al., 2010; Takahashi et al., 2006). Poor transfection 
efficiencies in primary cochlear cells, compared with other cell types, can be explained by cell 
cycle-correlated gene transfection efficiency, in which the more differentiated the cell is, the 
worse the transfection efficiency is for gene delivery. Usually, non-dividing cells are more 
difficult to transfect than dividing cells, and this can be attributed to the absence of mitotic 
activity in non-dividing cells. In dividing cells, DNA is passively transported into the nucleus 
during the M-phase in cell division, during which the nuclear membrane temporarily 
disintegrates (Tseng et al., 1999). For non-dividing cells, the presence of an intact nuclear 
membrane limits the entry of pDNA into the nucleus. The mechanism of pDNA cyto-
nucleoplasmic transport into non-dividing cells is likely a process mediated by the interaction 
of soluble cytoplasmic factors with minimal nuclear transport machinery (Munkonge et al., 
2009).   
  
A unique subcellular localization of EmGFP-fused Math1 was observed in the transfected 
cells. In certain cells, EmGFP-Math1 fusion proteins were detected in both the nuclei and 
cytoplasm. Their multiple locations within a single cell suggest that Math1 proteins are 
transported from the cytoplasm to the nucleus. In the majority of the cells, EmGFP-Math1 
fusion proteins appeared in the nucleus, suggesting that the cytoplasmic-nuclear transport 
event was rapid. This observation strongly supports the fusion of EmGFP onto Math1 does 
not disrupt Math1 intracellular trafficking. We cannot confirm whether EmGFP-Math1 enters 
the neucleus through the nuclear pore complex. However, the fact that EmGFP-Math1 fusion 
proteins were encapsulated into the vesicles was in accordance with the nuclear transport 
mechanism of vesicle fusion events (Zuleger et al., 2008). The simultaneous appearance of 
vesiculated and homogeneous EmGFP-Math1 fusion proteins in the same nuclei demonstrated 
the process of vesicle fusion events. Therefore, promoting vesicle fusion may be important in 
realizing the function of each Math1 molecule. Likely, Ca2+ and inositol 1, 4, 5-trisphosphate 
(IP3) receptors contribute to this effort (Sullivan et al., 1993).   
 
It has been reported that Math1-fused GFP induces the development of hindbrain neurons in 
mice (Rose et al., 2009). EmGFP fusing to the C-terminal end of Math1 should not disrupt the 
interaction between Math1 and chromosomal E-box, at the N-terminal end of Math1. We were 
unable to evaluate the binding efficacy of the Math1 protein to the chromosomal E-box 
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directly, although it is a critical step in Math1 transcription. Our observation that MSCs 
differentiated into neural progenitor cells and then into neuron-like cells, following treatment 
with BDNF and GDNF, further supported a preserved transcription function for EmGFP-
fused Math1. It has been reported that the role of Math1 protein in these sequential events is 
to direct neural progenitor differentiation (Flora et al., 2007). The maturation of the 
differentiated neural progenitor is maintained by BDNF and GDNF treatment, which induces 
neural cone growth (Anderson et al., 2006). Although neural-oriented differentiation of MSCs 
without Math1 stimulation has been reported, agents other than BDNF and/or GDNF (such as 
retinoid acid and β - mercaptoethanol) have been added to the cell culture medium (Sanchez-
Ramos, 2002). However, BDNF and GDNF do not necessarily induce MSC differentiation 
alone, and the role for Math1 has not been diproved in our study. MSCs are a source of 
progenitors for inner ear hair cells in cell replacement treatment (Jeon et al., 2007). The 
modification of MSCs with Math1, BDNF, and GDNF using a non-viral gene delivery 
technique may be applied in future therapies for deafness.    
 
Liposome nanoparticles are a beneficial application of in vivo gene therapy. However, the 
transfection efficiency of pcDNA6.2/C-EmGFP-Math1 plasmid mediated by liposome 
nanoparticles was lower than commercial Lipofectamine-mediated transfection. The 
following four characteristics should be considered: “endosomal escaping”, nanoparticle size, 
the surface charge of the nanoparticles, and the PEGylation effect in the medium. Endocytosis 
has been reported to be the major pathway of lipoplex internalization (Elouahabi et al., 2005; 
Rejman et al., 2006). The endosomal escape function, or ability to release DNA into the 
cytoplasm, is one of the key steps in the intracellular delivery of DNA by nonviral vectors 
(Cotten et al., 1992). The tested lipoplexes likely lacked the “endosomal escaping” capacity. If 
the pcDNA6.2/C-EmGFP-Math1 plasmid cannot be released into the cytoplasm by breaking 
the endosomal membrane, then it may be diretced to lysosomes where DNA is destroyed 
before executing its function. Lipoplex size was reported to be a major factor influencing in 
vitro lipofection efficiency (Almofti et al., 2003; Ross et al., 1999). Lipoplex size plays a key 
role in gene transfer to actively endocytosising cells (Rejman et al., 2006; Ross et al., 1999). 
Our results showed that a 255 nm lipoplex has higher transfection efficiency than other 
lipoplex sizes. This finding is consistent with previous reports showing that optimal 
transfection efficiencies are obtained in vitro with lipoplexes 200 – 400 nm in size (Ma et al., 
2007; Zhdanov et al., 2002). The relatively large lipoplexes induce higher transfection 
efficiencies, as the larger size facilitates membrane contact and fusion (Escriou et al., 1998). 
Furthermore, larger lipoplexes may delay DNA dissociation from the lipid, thereby enhancing 
DNA transfection efficiency (Lian et al., 2003). 
The surface charge of the lipoplexes is also an important parameter that can influence 
transfection efficiency (Ma et al., 2007). It has been reported that by increasing the lipid/DNA 
charge ratio, the lipoplex size decreases and it becomes more stable (Simberg et al., 2004). 
The size and stability of the lipoplexes depend on the cationic lipid/DNA charge ratio used in 
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lipoplex preparation (Eastman et al., 1997; Radler et al., 1997; Turek et al., 2000). The impact 
on lipoplex transfection efficiency of the lipid/DNA ratio is realized primarily by influences 
on lipoplex size and lipoplex stability. LPX-DOPE (2:1) has a higher lipid/DNA molar charge 
ratio than LPX-DOPE (1.2:1), while the former has a smaller size. In our experiment, the 
transfection efficiency of LPX-DOPE (2:1) was higher than LPX-DOPE (1.2:1). This result 
indicates that a lipid/DNA molar charge ratio of 2:1 is favorable for endocytosis and is more 
stable, which protects the plasmid DNA from degradation by cellular nucleases.  
 
The PEGylation of liposome nanoparticles can protect DNA against degradation by serum, 
but it also inhibits the transfection capacity (Pedroso de Lima et al., 2001). In our study, 
unPEGylated LPX showed higher transfection efficiency than PEGylated LPX-PEG, which 
was inconsistent with a previous report (Kwon et al., 2010). PEGylation affects transfection 
efficiency by adversely interacting with the intracellular trafficking of nanoparticles (Kwon et 
al., 2010; Mishra et al., 2004). However, a recent report showed that lipoplex PEGylation did 
not hamper internalization but did interfered with the intracellular release of DNA from 
lipoplexes (Jellema et al., 2010). No difference in internalization was observed between 
PEGylated and unPEGylated lipoplexes in our study, supporting the second hypothesis. Our 
results indicate that PEGylation affects the release of DNA but not the internalization of 
nanoparticles. 
 
6. 5. Targetability of TrkB ligand-functionalized liposome nanoparticles 
In primary cochlear cell culture and explants, no cell type-specific internalization of A371-
functionalized liposome nanoparticles was observed. The uptake of non-functionalized 
liposome nanoparticles in the cochlear cells was as efficient as A371-functionalized liposome 
nanoparticles. This finding indicates that the TrkB receptor pathway is not involved in the 
internalization of liposome nanoparticles in spiral ganglion cells, although TrkB 
internalization occurs upon binding to BDNF. There are two possible explanations for the 
different behavior of A371 peptide-functionalized liposome nanoparticles and BDNF in spiral 
ganglion cells. First, as a modification of the natural sequence of amino acids 84-100 from the 
structure of NGF, A371 does not have the full functionality of either NGF or BDNF. Second, 
coupling the peptide to liposome nanoparticles significantly increases the size of A371, such 
that it is much larger than BDNF and NGF. The large size of A371-coupled liposome 
nanoparticles may prevent internalization of TrkB upon binding. As they were equally 
exposed to the liposome nanoparticles, every cell population displayed the same amount of 
internalization.  
 
For the in vivo study, the relative accumulation of A371-functionalized liposome nanoparticles 
in the spiral ganglion and inner hair cell regions was the result of targeting. In our previous 
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study, we observed the round window membrane permeation of lipid nanocapsules PEGylated 
with DSPE-PEG- 2000, the same coating material used for liposome nanoparticles herein. In 
the earlier study, we showed that the nanocapsules primarily appeared in the spiral ganglion 
region, correlated nerve fibers, the inner hair cell region, and the spiral ligaments of the lateral 
wall (Zou et al., 2008). Thus, there is a greater chance that the cells and tissues in these 
regions were exposed to nanoparticles upon round window membrane permeation. In the case 
of A371-functionalized liposome nanoparticles, affinity for TrkB at the surface of spiral 
ganglion cells and neuron peripheral processes enhanced the distribution of the liposome 
nanoparticles in the spiral ganglion and inner hair cell regions (Tan et al., 2006). We propose 
the following mechanism for lipoplex distribution: after permeating the porous modiolar wall 
of the scala tympani, A371-functionalized liposome nanoparticles bind to TrkB on non-
myelinated type II spiral ganglion cells and certain peripheral processes, and the level of 
liposome nanoparticles along the nerve pathway was enhanced (Rask-Andersen et al., 2006; 
Zou et al., 2008). This process supplies more liposome nanoparticles to the inner hair cell 
region (Zou et al., 2008). Movement of liposome nanoparticles along nerve fibers was 
demonstrated in the cochlear explant study, which showed that an abundance of liposome 
nanoparticles were attached to neurofilaments. The access of nanoparticles to the lateral 
cochlear wall was directly related to the round window membrane and perilymph and was not 
limited by the nerve pathway (Zou et al., 2008). Therefore, internalization of non-
functionalized liposome nanoparticles in spiral ligament fibrocytes and lateral wall 
intermediate cells was as efficient as that of A371-functionalized liposome nanoparticles.   
 
In the cells successfully transfected by liposome nanoparticles, pGeneClipTM hMGFP 
plasmid DNA encoding shRNA transiently silenced Id2 in the host cells. Id2 (E47 protein) is 
reportedly involved in cell survival, cell cycle progression, lipid metabolism, stress response, 
and lymphoid maturation (Schwartz et al., 2006). The poor gene transfection efficiency of 
liposome nanoparticles can be attributed to the absence of mitotic activity in most cochlear 
cell populations during the gene transfer process. Many studies have confirmed that, in cells 
with non-viral vector-mediated cytoplasmic plasmid delivery, only those cells with evidence 
of nuclear plasmid localization showed efficient transgene expression (James et al., 2000; 
Tachibana et al., 2002). Typically, transfection efficiency is facilitated in dividing cell 
populations, wherein the nuclear envelope disassembles during mitosis, thus largely 
eliminating this barrier. For non-dividing cochlear cells, the intact nuclear membrane limits 
the nuclear entry of the cytoplasmic plasmid delivered by liposome nanoparticles. Poor gene 
transfection efficiency for liposome nanoparticles might be resolved by using nuclear 
localization signal peptides. Furthermore, efficient internalization of hyperbranched 
polylysine nanoparticles was observed in both the cochlear cell cytoplasm and the nuclei of 
cochlear cell culture, cochlear organotypic culture, and in vivo. Thus, nuclear gene delivery 
induced by hyperbranched polylysine nanoparticles is also an option for improving transgene 
expression in in vivo. 
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7. SUMMARY AND CONCLUSIONS    
 
The summary and conclusions to be drawn from the main findings in the present studies are 
as follows: 
 
1. Contrast agent MRI is capable of discerning fine structures of the inner ear and inner ear 
     barrier function in mice. The normal blood-endolymph barrier is tighter than the blood- 
     perilymph barrier. This finding can be applied to future investigations into the pathologi- 
     cal mechanisms for SNHL in different etiologies in mouse models. POA@SPIONs are a 
     promising T2 negative contrast agent that is detectable within the rat inner ear by MRI. 
     Normal blood-perilymph, blood-endolymph, and perilymph-endolymph barriesr restrict 
     the passage of POA@SPIONs. Novel POA@SPIONs may be further surface modified by 
     peptides or antibodies to increase their use as diagnostic agents and traceable therapeutic 
     nanoparticle in SNHL molecular imaging. 
      
2.  HPNPs were efficiently internalized by the cochlear cells in primary cell culture, in orga- 
     notypic culture, and in vivo. Both the cytoplasm and nucleus showed HPNP distribution 
     This finding suggests that HPNPs have a potential use in gene delivery to the cochlea. 
       
3. Plasmid pcDNA6.2/C-EmGFP-Math1 is suitable for non-viral gene delivery of Math1.  
     Unique intracellular trafficking of Math1 was demonstrated using this novel plasmid. 
     The modification of MSCs by Math1 gene delivery, together with BDNF and GDNF         
     treatment, is an option for cell replacement treatment of cochlear spiral ganglion cell  
     loss in deafness. 
 
4. The potential targetability of TrkB ligand-functionalized liposome nanoparticles was  
     observed in rat cochlea but not in primary cochlear cell culture and cochlear explants.  
     However, gene transfection efficiency mediated by liposome nanoparticles was poor.  
     Further improvement in transfection efficacy and targetability should be realized by   
     nanoparticles functionalized with peptides or antibodies. 
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Magnetic resonance imaging (MRI), supplemented by contrast agents, is a powerful tool that can be used
to visualise the structures of the inner ear in vivo and assess some aspects of physiology, such as the per-
meability of agents through membranes. The mouse is an excellent animal species for investigating
human diseases, including hearing loss but detailed MRI studies with contrast have not been reported.
In this work, we aimed to demonstrate the limits of MR imaging resolution of the ﬁne inner ear structures
in the mouse and to explore the permeability of the intracochlear barriers to gadolinium-tetra-azacyclo-
dodecane-tetra-acetic acid (Gd-DOTA) administered by intravenous injection (IV) or intratympanic (IT)
routes. Twenty-three female FVB mice were imaged with a 4.7-T MR scanner using both 2D and high res-
olution 3D sequences. Inner ear region of interest (ROI) signal intensities and perilymph volumes were
evaluated. Finer structures were studied using 3D acquisition and reconstruction techniques and compar-
isons were made to similarly oriented histological sections that were examined by light microscopy. Gd-
DOTA enhancement occurred in the perilymphatic compartment and highlighted the contiguous inner
ear structures, but enhancement did not appear within the endolymph. The dynamic uptake of Gd-DOTA
in the perilymphatic compartments reached an initial plateau 80 min after IV administration and contin-
ued to slightly increase to a maximum level by 100 min. The perilymph volume demonstrated by Gd-
DOTA uptake was statistically signiﬁcantly larger in the IV group (1.72 mm3) than in the IT group
(1.28 mm3) (p < 0.05).
 2009 Elsevier B.V. All rights reserved.1. Introduction lymph, communications between perilymph-containing spaces,With the help of contrast agents, MRI is a powerful tool to visu-
alise the anatomy and some aspects of physiology of different or-
gans in vivo. Imaging of guinea pig cochleae with gadodiamide
enhancement demonstrated normal and impaired function of the
barriers within the inner ear (Counter et al., 1999, 2000). MR imag-
ing of guinea pigs has revealed some of the possible origins of peri-ll rights reserved.
ar nerve; EDTA, ethylenedi-
train; Gd-DOTA, gadolinium-
ral semicircular canal; LW,
ina; PSCC, posterior semicir-
enhancement; Sa, saccule;
SaN, saccular nerve; SatFC,
limbus; SM, the scala media;
micircular canal; ST, the scala
ricular macula; UtN, utricular
: +358 3 35517700.and pathological changes in endolymphatic hydrops and perilym-
phatic ﬁstulae (Counter et al., 2003; Zou et al., 2003a,b, 2005,
2007). Although mice are widely used in hearing research, such
studies have not been done on the inner ears of mouse models.
Contrast agent-enhanced MRI has been applied to visualise the
mouse central auditory system activity (Yu et al., 2005, 2008;
Watanabe et al., 2008). High resolution MR imaging of the mouse
inner ear in vivo could provide new insights into the mechanisms
of various inner ear disorders. Of particular interest could be hear-
ing losses of genetic origin, such as connexin 26 mutation, connex-
in 30 mutation, Caludin 14 knockout, Foxi1 knockout, COCH
mutation, and age related hearing loss, among others (Zheng
et al., 1999; Cohen-Salmon et al., 2002; Ben-Yosef et al., 2003;
Kudo et al., 2003; Teubner et al., 2003; Robertson et al., 2008).
In this work, we demonstrated the limits of MRI resolution of
the ﬁne inner ear structures in the mouse and explored the perme-
ability of the intracochlear barriers to gadolinium administered by
intravenous injection or round window membrane application
(intratympanic administration). We used the friend leukemia virus
J. Zou et al. / Hearing Research 259 (2010) 36–43 37B strain sensitive mouse (FVB mouse), which is an inbred strain for
the Fv1b allele that was derived from an outbred Swiss colony NIH
General Purposes at NIH. This strain is preferred for transgenic
analyses, including transgenic/knockout models (Taketo et al.,
1991).Fig. 1. Mouse cochlear structures in coronal 2D MR images with IT administration
of Gd-DOTA (23 mm coil) (180 min time point). Gelfoam was soaked with 5 ll
0.5 mol/L Gd-DOTA and placed in the middle ear cavity to cover the round window
of the left ear. (A) T2-weighted image shows Gd-DOTA enhanced signal in the
cochlea except for the OSL. SM appears slightly darker than the perilymphatic
compartments. (B) T1-weighted image shows much more intense Gd-DOTA
enhanced signal in the perilymphatic compartments, ST and SV compared to the
bright signal in the T2-weighted image A. SM is dark and clearly distinguishable
from the perilymphatic compartments and LW. LW, lateral wall; Mod, modiolus
OSL, osseous spiral lamina; SM, the scala media; ST, the scala tympani; SV, the scala
vestibuli; 1st, the basal turn; 2nd, the second turn. Scale bar = 1 mm.2. Materials and methods
2.1. Animals
Twenty-three albino female FVB mice, weighing from 18 to 55 g
were provided by Experimental MRI Laboratory, Department of
Neurology, Helsinki University Central Hospital, FIN-00029 HUS,
Helsinki, Finland. All animal experiments were approved by the
Ethical Committee of the University of Tampere (permission:
STH527 A ESLH-2006-07528/Ym23). Animal care and experimen-
tal procedures were conducted in accordance with the European
legislation. All experimental procedures were performed under
general anaesthesia, induced and maintained by intraperitoneal
injections of medetomidine hydrochloride (0.5 mg/kg) and keta-
mine (75 mg/kg).
2.2. Administration of the contrast agent
For intravenous administration, the gadolinium-tetra-azacyclo-
dodecane-tetra-acetic acid (Gd-DOTA, Guerbet, Aulnaysous-Bois,
France, 500 mmol/L) was injected into the tail vein (IV) at dosages
of 1.5, 0.75, or 0.3 mmol/kg via canula during MR scanning (Table
1). For intratympanic (IT) delivery, a portion of gelfoam was soaked
in Gd-DOTA diluted in physiological saline to concentrations of
500, 100, 50, or 25 mmol/L, and placed in the middle ear cavity
against the round window through a myringotomy (Table 1).
Excess solution was removed by absorption with a small piece of
cotton. It is estimated that the gelfoam pieces measured
1  1  3.5 mm3 when wet and contained approximately 5 ll Gd-
DOTA, i.e. ranging from 0.014 to 0.0045 mmol/kg.
2.3. MRI measurements
MR imaging was performed with a 4.7-T MR scanner with bore
diameter of 155 mm (PharmaScan, Bruker BioSpin, Germany) using
a dedicated mouse head coil (linear bird cage coil with diameter of
38 mm for mice >50 g and 23 mm for mice <25 g). The maximum
gradient strength was 300 mT/m with a 80-ls rise time. The body
temperatures of the animals were maintained by circulating warm
water (with 38 mm coil) and their ventilations were recorded with
Physio Tool-1.0.b.2 program (Bruker BioSpin, Germany). Mice were
placed in the magnet with the ears positioned at the isocenter. Both
2D and 3D MRI measurements were performed with either IT
administration of Gd-DOTA at different concentrations or IV admin-
istration of Gd-DOTA at different dosages (Table 1). Head coils ofTable 1
Animals were grouped according to administration approaches and dosages of the
contrast agent.
Groups/dosages n Coil size Histology/embedding
IT 25 mmol/L 2 23 mm
50 mmol/L 2 23 mm
100 mmol/L 2 23 mm
500 mmol/L 2 23 mm/38 mm
IV 0.3 mmol/kg 1 23 mm
0.75 mmol/kg 3 23 mm/38 mm
1.5 mmol/kg 9 23 mm/38 mm 2/parafﬁn
NT – 2 – 2/JB4
IT, intratympanic; IV, intravenous; n, number of the animal; NT, non-treatment.
Fig. 2. Mouse cochlear structures in MPR multi view of T1-weighted images with IT
administration of Gd-DOTA (23 mm coil) (180 min time point). Gelfoam soaked
with 5 ll, 500 mmol/L Gd-DOTA was placed into the left ear. In the enlarged
window A, LW and Mod are slightly highlighted by Gd-DOTA uptake in addition to
more pronounced enhancement in ST and SV. The structure adjacent to ST is
suspected to be CA with signal intensity similar to ST. LW demonstrated brighter
signal than SM. A dark border appeared between ST and LW in the basal turn near
the hook region. OSL is seen as a sharp dark line. Small window B is a relative
perpendicular cut through the centre of plane A. Small window C is a relative axia
cut through the centre of the cochlea in window A. Small window D is the
minimised image of window A. CA, cochlear aqueduct; LW, lateral wall; Mod
modiolus; MPR, multiplanar reconstruction; OSL, osseous spiral lamina; SM, the
scala media; ST, the scala tympani; SV, the scala vestibuli; 1st, the basal turn; 2nd
the second turn.,
;l
,
,
Fig. 3. Light microscopy of a mouse inner ear (parafﬁn embedding and H&E
staining) after MRI study with IT administration of Gd-DOTA. SL locates lateral to
SM, ST, and SV. CO, Corti’s organ; Mod, modiolus; MS, macula sacculi; OSL, osseous
spiral lamina; RM, Reissner’s membrane; SL, spiral ligament; SM, the scala media;
ST, the scala tympani; SV, the scala vestibule. Scale bar = 200 lm.
Fig. 4. Mouse vestibular structures in MPR multi view of T1-weighted images with
IT administration of Gd-DOTA (23 mm coil) (180 min time point). Gelfoam was
soaked with 5 ll, 500 mmol/L Gd-DOTA and placed in the left ear. In the enlarged
window A, the vestibular perilymph, including the Vest, Am, and SCC, show obvious
uptake of Gd-DOTA. The perilymph in the Vest merges with the perilymph in the
basal turn of SV. CA is seen adjacent to the basal turn of the ST. Small window B is a
relative perpendicular cut through the centre of plane A. Small window C is a
relative axial cut through the centre of the cochlea in window A. Small window D is
the minimised image of window A. Am, ampulla; CA, cochlear aqueduct; MPR,
multiplanar reconstruction; SCC, semicircular canal; SM, the scala media; ST, the
scala tympani; SV, the scala vestibuli; Vest, vestibulum.
Fig. 5. Comparison of Gd-DOTA distribution in the mouse inner ear between IT and
IV administration using surface rendering of T1-weighted 3D MRI scan (23 mm coil)
(180 min time point). (A) After IT Gd-DOTA delivery, ST, SV, LW, CA, Ut, Sa, PSCC,
and LSCC were highlighted. (B) After IV administration of Gd-DOTA, ST, SV, CA, Ut,
Sa, and all the three semicircular canals were demonstrated. Ap also showed uptake
of Gd-DOTA. Ap, apex; CA, cochlear aqueduct; LW, lateral wall; LSCC, lateral
semicircular canal; PSCC, posterior semicircular canal; SSCC, superior semicircular
canal; Sa, saccule; ST, the scala tympani; SV, the scala vestibuli; Ut, utricle.
38 J. Zou et al. / Hearing Research 259 (2010) 36–43either 38 or 23 mmwere used, depending on the size of the animal,
and the smallest possible coil was utilised to maximise resolution.
T2-weighted 2D imageswere acquiredwith the rapid acquisition
with relaxation enhancement (RARE) sequence (TR/TEeff 25,000/
40 ms, RARE factor 8, matrix size 256  256, slice thickness
0.5 mm, ﬁeld of view 3 cm, resolution 0.156  0.156 mm2, number
of averages 3). T1-weighted 2D imageswere acquiredwith RARE se-
quence (TR/TEeff 500/10 ms, RARE factor 4, matrix size 256  192,slice thickness 0.5 mm, ﬁeld of view 2.5 cm, resolution 0.098 
0.13 mm2, number of averages 33). High resolution T1-weighted
3D images were acquired with RARE sequence (TR/TEeff 500/43 ms,
RARE factor 16, matrix size 64 64 64, ﬁeld of view 0.5 cm, resolu-
tion 0.078 0.078 0.078 mm3, number of averages 2).
For IT delivery, serial MR imaging was obtained from 1.5 to 4 h
after Gd-DOTA administration. The inner ear geometry was estab-
lished by taking three 2D images at perpendicular orientations
using T2-weighted sequence. Then 2D and 3D T1-weighted images
were acquired.
For IV administration, 2D imaging was performed with RARE T1.
A baseline image was taken with RARE T1 after obtaining satisfac-
tory geometry. A series of images were acquired with 10 min inter-
Fig. 6. Correlation of signal intensity in the perilymphatic compartments to the Gd-
DOTA concentration of IT administration (23 mm coil). Regions of interest were
selected at the outer points of ST and SV at the basal turn. The signal intensity was
corrected by the background intensity of each image to avoid artifact. There were
linear correlations between the signal intensities in the perilymphatic compart-
ments and Gd-DOTA concentrations applied to the middle ear (R = 0.445, p < 0.05,
ANOVA test). The signal intensity in ST was higher than that in SV while it was
variable in Vest. ST, the scala tympani; SV, the scala vestibuli; Vest, vestibulum.
J. Zou et al. / Hearing Research 259 (2010) 36–43 39vals to study serial dynamic uptake over a period of 120 min follow-
ing the Gd-DOTA injection in a group of animals using the 38 mm
coil. It was noted that the 23 mmcoil could potentially limit the ani-
mals’ ventilatory excursions. Consequently, most of the serial dy-
namic uptake observations made with the 23 mm coil were
performed at longer time intervals, immediately, 90 min, and
180 min after Gd-DOTA injection and using 3D sequences, which re-
duce the time of acquisition. Animals imaged with the 23 mm coil
were removed from the machine between scans (Table 1).
2.4. Quantiﬁcation of Gd-DOTA in the inner ear ﬂuids
Paravision (Bruker, Germany) and Adobe Photoshop CS3 soft-
ware were used for post-production processing of images for the
quantiﬁcation of signal intensity in regions of interest (ROIs) and
for labeling, and demonstration of perilymph in the scala tympani,
scala vestibuli, and vestibulum, and of endolymph in the scala
media.
2.5. 3D volume rendering of the inner ear MRI
OsiriX v3.3.2 (OsiriX Foundation, Geneva, Switzerland) software
was applied for volumetric calculations and 3D rendering of the 3D
raw stacked MR images of the inner ear. ROIs were manually
drawn outlining the Gd-DOTA signal-enhancing perilymph on each
of the 3D stacked slices and a volume algorithm was applied to
yield an estimated perilymph volume for each inner ear. 3D vol-
ume renderings were created for visualisation of the inner ear
structures with the ability to rotate the images into various orien-
tations and to create photographs and movies.
2.6. Morphological study
Two bullae were processed for parafﬁn embedding after MRI
measurements to show gross anatomic comparison between MRI
and histology. Two non-treated control bullae were prepared with
JB-4 embedding to demonstrate more detailed structures of the
normal inner ear vascular system and to avoid any potential injury
by Gd-DOTA or MR scanning. Cardiac perfusion was performed
with 4% paraformaldehyde and 1% glutaraldehyde in PBS (pH 7.4,
0.1 mol/L) after removing the blood by ﬂushing with saline
containing 0.5 IU/ml heparin. The bullae were ﬁxed with the same
ﬁxative solution overnight. For parafﬁn embedding, decalciﬁcation
with 10% EDTA was performed at room temperature for at least
4 weeks. Dehydration was carried out by using graded series of
ethanol. Parafﬁn embedding and 4 lm thick sectioning was per-
formed. After dewaxing and rehydrating, the slides were stained
with Haematoxylin & Eosin (H&E). The bullae for JB-4 embedding
were decalciﬁed with RDO Rapid Decalciﬁer (Apex Engineering
Products Corporation, Aurora, USA) at room temperature for 5 h.
Dehydration was carried out by using 35%, 70%, 90%, and 95% eth-
anol for 10 min each, and absolute ethanol twice for 15 min. After
inﬁltrating with JB-4 inﬁltration solution, samples were embedded
in the solution JB-4 embedding solution on ice and further poly-
merized at 4 C for 2 days. Two micrometer sections were made
with a glass knife on a microtone section machine (LEICA
RM2265, Germany) and were stained with toluidine blue. The
slides were observed under light microscope (Leica DM 2000, Ger-
many), and digitally photographed with Olympus DP 25 (Japan).
2.7. Statistical analysis
Statistical analysis was done with the SPSS 11.5 software and
the means and SDs were calculated for levels of signal intensity
of Gd-DOTA enhancement in the scala tympani, scala vestibuli, sca-
la media, and vestibulum. Differences in levels of signal intensityover time in these regions were analysed by ANOVA. The peri-
lymph volumes were compared between IV and IT groups using
Student’s t-test with p < 0.05 accepted as an indication of statistical
signiﬁcance.3. Results
3.1. The mouse inner ear structures delineated by MRI with
intratympanic Gd-DOTA administration
T1 and T2 signal characteristics were compared using a 2D
imaging protocol in animals imaged with the 23 mm diameter coil.
The T2-weighted sequences showed that the inner ear ﬂuids gen-
erated bright signal, including the perilymph in the scala tympani,
scala vestibuli, vestibulum, semicircular canals and endolymph in
the scala media. The modiolus demonstrated grey signal while
the osseous spiral lamina was dark (Fig. 1A). T2 signal was more
intense in the ears treated with Gd-DOTA. In comparison, T1-
weighted images showed that endolymph in the scala media and
ampullae of the semicircular canals were dark while perilymph be-
came bright. The modiolus was also bright, although less so than
the perilymph. The contralateral non-treated side showed diffuse
grey signal (Fig. 1B). The scala tympani and vestibuli were also dis-
tinguishable from the scala media in Gd-DOTA contrasted, T1-
weighted images when using the 38 mm coil.
3D images using T1-weighted sequences revealed greater con-
trasts and details within the inner ear than 2D images. For exam-
ple, the lateral wall in the basal turn of the cochlea contained a
grey appearing region that likely represented the spiral ligament
seen against the dark endolymph. A dark border appeared between
ST and LW in the basal turn near the hook region (Fig. 2). Identiﬁ-
cation of the lateral wall on MR imaging, located lateral to the peri-
lymph and endolymph, was conﬁrmed by comparison with
histological sections (Fig. 3). The cochlear aqueduct, which origi-
nates in the scala tympani near the round window membrane,
was visible (Figs. 2 and 4). Vestibular perilymph was shown to
be continuous with the perilymph of the scala vestibuli and semi-
circular canals; however, the superior semicircular canal was infre-
quently visible (Figs. 4 and 5).
Fig. 7. Dynamic uptake of Gd-DOTA in the inner ﬂuids after IV administration at the dosage of 1.5 mmol/kg. (A) Signal intensities of ST plotted versus time imaged with 2D
T1-weighted sequences using the 38 mm coil. The uptake reached a plateau after 80 min and stepped to the second one after 100 min. (B) There was slightly increased signal
intensity from 90 to 180 min time points when measured with 3D T1-weighted sequences using the 23 mm coil. The uptake in perilymphatic compartments was signiﬁcantly
greater than that in SM (**p < 0.01, paired samples t-test). N, number of the ears; SM, the scala media; ST, the scala tympani; SV, the scala vestibuli; Vest, vestibulum.
40 J. Zou et al. / Hearing Research 259 (2010) 36–43The images were acquired in the mice receiving IT administra-
tion of Gd-DOTA at concentrations of 500, 100, 50, and 25 mmol/L.
There were linear correlations between the signal intensities in the
perilymphatic compartments and Gd-DOTA concentrations
(R = 0.445, p < 0.05, ANOVA test). The Gd-DOTA uptake in the scala
tympani was consistently higher than that in the scala vestibule
while it was variable in the vestibulum (Fig. 6).3.2. Dynamic uptake of Gd-DOTA in the mouse inner ear ﬂuids with
intravenous administration
Inner ear images acquired after the IV administration of Gd-
DOTA were roughly similar to those obtained following IT delivery.
2D T1-weighted sequences were performed at 10 min intervals in
the 38 mm coil and demonstrated a strong linear increase in signal
Fig. 8. Mouse cochlear structures in MPR multi view of T1-weighted images IV
J. Zou et al. / Hearing Research 259 (2010) 36–43 41intensity within the perilymph of the scala tympani between 10
and 70 min. The enhancement within the perilymphatic compart-
ments reached an initial plateau 80 min after IV administration
and continued to slightly increase to a maximum level by
100 min (Fig. 7A).
3D images were acquired with T1-weighted sequences using
the 23 mm coil. At the time point 0, just after IV injection of Gd-
DOTA, there was insufﬁcient signal intensity within the perilymph
space to be quantiﬁed. Enhancement subsequently increased in the
perilymph of the scala tympani, scala vestibuli, and vestibulum
and showed a trend that the intensity strengthened from the
90 min to the 180 min scans, but the differences did not rise to sta-
tistical signiﬁcance (Fig. 7B) (p > 0.05, Student’s t-test). These re-
sults were consistent with the 2D observations that a plateau for
the uptake of Gd-DOTA was reached at around 90 min.
The signal intensities of perilymph were statistically signiﬁ-
cantly higher than that of endolymph (Fig. 7B) (p < 0.001, paired
samples t-test). Some ﬁner details of inner ear structures were bet-
ter deﬁned following IV administration of Gd-DOTA compared
with IT delivery. Uptake within the cochlear apex was slightly
greater in the IV group. The cochlear aqueduct and all semicircular
canals were better demonstrated in the IV group. However, the sig-
nal in the lateral wall and modiolus was slightly higher in the IT
group than in the IV group (Figs. 5 and 8).administration of Gd-DOTA (1.5 mmol/kg) (180 min time point) (23 mm coil). In the
enlarged window A, LW and Mod are highlighted by Gd-DOTA uptake in addition to
ST and SV. SM is darker than LW. Small window B is a relative perpendicular cut
through the centre of plane A. Small window C is a relative axial cut through the
centre of the cochlea in window A. Small window D is the minimised image of
window A. LW, lateral wall; Mod, modiolus; MPR, multiplanar reconstruction; SM,
the scala media; ST, the scala tympani; SV, the scala vestibule; Vest, vestibulum.3.3. Perilymph volume in the mouse inner ear
Perilymph volumes were measured in six animals receiving IV
Gd-DOTA and in four animals receiving it by IT route. Uptake in
the semicircular canals was signiﬁcantly stronger in the IV delivery
group. The volumes of inner ear perilymph in mice that received
Gd-DOTA by IV administration ranged between 1.42 and
2.20 mm3 with a mean volume of 1.72 mm3 compared to IT deliv-
ery (using different concentrations) which ranged between 1.05
and 1.48 mm3, mean of 1.28 mm3 (Fig. 9). These differences were
statistically signiﬁcant (p < 0.05, Student’s t-test).Fig. 9. Comparison of the perilymph volumes in the mouse inner ears between IT
and IV administrations of Gd-DOTA. There was statistically signiﬁcant difference
between the two groups (p < 0.05, Student’s t-test).4. Discussion
Gd-DOTA administered intratympanically passed through the
round window membrane efﬁciently and appeared in the perilym-
phatic spaces of the cochlea and vestibule, but not in the endolym-
phatic spaces. This is in agreement with previous MR imaging
results from the inner ears of guinea pigs and man (Zou et al.,
2005, 2009). High resolution visualisation of the contrast-en-
hanced perilymphatic space allows for some investigation into
the process by which contrast material may pass through the
round windowmembrane into the inner ear. The passage appeared
to be concentration dependant based on a correlation between Gd-
DOTA concentration and signal intensity within the perilymph of
the scala tympani and vestibule.
The intravenous administration of Gd-DOTA demonstrated pas-
sage through the blood–perilymph barrier, but not through the
blood–endolymph barrier, which is also consistent with results in
guinea pigs and man (Counter et al., 2000, 2003; Zou et al.,
2009). The dynamic uptake of Gd-DOTA into the perilymph of
the guinea pig has been seen to occur more rapidly than in either
the mouse or in humans. It is possible that there is some structur-
ally based regulation of this uptake and that these results reﬂect
the closer genetic similarities between the mouse and humans.
In addition to the cochlear glomeruli of Schwalbe within the modi-
olus, saccular capillary and capillary in the spiral limbus may con-
tribute to the uptake of Gd-DOTA in the mouse perilymph (Franz
et al., 1993; Fig. 10). In man, injury to the inner ear appeared to
accelerate the rate of gadolinium uptake into the perilymph fol-lowing IV injection, which indicated a possible change in the regu-
lation of the blood–perilymph barrier (Zou et al., 2009).
This report is the ﬁrst to show MR imaging with visualisation of
uptake of Gd-DOTA in the perilymph of the mouse. High resolution
scanning with the 4.7 T machine revealed some details of the soft
tissues within the lateral wall of the cochlea. A dark border was re-
vealed between ST and LW in the basal turn near the hook region
(Fig. 2). This might represent the tissues which did not pass Gd-
DOTA such as the stria vascularis and the twisted basilar mem-
brane near the hook region. However, this appearance needs to
be elucidated in the further study.
Fig. 10. Light microscopy of a non-treatment a mouse inner ear (JB4 embedding and toluidine blue staining). (A) The correlation between neural structures and SMBV inside
the modiolus. SMBV locates between SGC and CN. (B) The correlation between neural structures and SaCap inside the vestibulum. SaCap locates in adjacent to SaN. (C) Cap
locates beside SatFC in the 1st turn of SLim. (D) Cap locates beside SatFC in the 2nd turn of SLim. CN, cochlear nerve; SaCap, saccular capillary; SaMa, saccular macula; SaN,
saccular nerve; SatFC, satellite ﬁbrocyte; SGC, spiral ganglion cell; Slim, spiral limbus; SMBV, spiral modiolar blood vessel; UtMa, utricular macula; UtN, utricular nerve. Scale
bar: (A) 200 lm; (B) 100 lm; (C and D) 20 lm.
42 J. Zou et al. / Hearing Research 259 (2010) 36–43We observed some slight differences in the uptake of Gd-DOTA
within the lateral wall and modiolus between IV and IT administra-
tions. One of the differenceswas that the IT delivered Gd-DOTAmay
more efﬁciently pass into the ‘‘perimodiolar lymph”, it could indi-
cate that the barrier between the scala tympani and the modiolus
ismoreporous than the potential IV route of passage through the co-
chlear glomeruli of Schwalbe within the modiolus (Franz et al.,
1993; Zou et al., 2003a,b; Rask-Andersen et al., 2006). The second
difference that more Gd-DOTA accessed to the lateral wall after IT
administration than IV approach suggested a more efﬁcient trans-
port from roundwindowmembrane to the spiral ligament extracel-
lular space than from the local capillaries to the extracellular space.
A difference in efﬁciency of passage of Gd-DOTA into the modiolus
and lateral wall would raise the possibility that drug delivery to
these areas of the cochlea might be similarly favored by IT route.
There are other potential advantages of IT administration over IV.
IT treatment is likely to cause less systemic effects because of its lo-
cal administration and lower dose requirement. The total dose of
Gd-DOTA required for visualisation of the inner ear using the IT
route was signiﬁcantly less than IV administration, with Gd-DOTA
maximum 0.014 mmol/kg for IT versus 1.5 mmol/kg for IV.
In principle, IV administration of Gd-DOTA might be used to
investigate the integrity of the stria vascularis, especially the inter-
cellular junctions of strial marginal cells and endothelium of strial
capillaries. Interference with the endothelial barrier of the capillar-
ies supplying the stria vascularis, which is a component of the
blood–endolymph barrier, has resulted in an intrastrial electric
shunt that ablated endocochlear potentials and induced hearing
loss (Cohen-Salmon et al., 2007). Rupture of Reissner’s membrane
has been shown to produce bright signal within the scala media
using IV gadolinium (Zou et al., 2003a,b). This disruption of the
endo-perilymph barrier caused a mixing of endolymph with peri-
lymph and eliminated endocochlear potentials (Jin et al., 1990).
The perilymphatic compartments, including the scala tympani
and the scala vestibuli, and the endolymphatic compartment, thescala media, contain a tiny amount of ﬂuid in every animal spe-
cies (Salt, 1995). Measurement of these ﬂuid volumes is challeng-
ing. Thorne et al. reported an MRI study on isolated preserved
mouse cochleae, but the cochlear ﬂuid volumes were likely differ-
ent from in vivo because the ﬁxation method employed in their
study induced shrinkage of Reissner’s membrane by an average
of 15.1% (Brunschwig and Salt, 1997; Thorne et al., 1999). It is
not presently possible to consistently demonstrate all of the per-
ilymphatic space, including the cochlear aqueduct or semicircular
canals. Our in vivo MRI study showed that the mean total volume
of mouse inner ear perilymph, including cochlea, cochlear aque-
duct, and vestibule was 1.28 mm3 for IT and 1.72 mm3 for IV
administration of Gd-DOTA. The larger volumes seen with IV
delivery likely reﬂect more efﬁcient uptake, within the observed
time, of Gd-DOTA into the perilymphatic space including the
apex, cochlear aqueduct, and semicircular canals by vascular dis-
tribution compared to the IT route, in which diffusion occurs after
passage through the round window membrane. It is possible that
a longer observation period following IT administration may ulti-
mately result in similar ﬁlling of the entire perilymphatic space.
The whole inner ear perilymph volume obtained with MRI in this
study (1.72 mm3) was three times that of cochlear perilymph vol-
ume (0.62 mm3) which was obtained on ﬁxed cochlea (Thorne
et al., 1999). Measurements of inner ear volumes might be useful
in the evaluation for endolymphatic hydrops in mouse models in
the future (Megerian et al., 2008; Takumida et al., 2008). It would
be anticipated endolymphatic hydrops would induce a decrease
in the total volume of inner ear perilymph as a result of enlarge-
ment of the endolymph space into the scala vestibuli (Zou et al.,
2003a,b; Nakashima et al. 2009). Reduction of the scala vestibuli
could cause a decrease of up to 0.3 mm3 (Thorne et al., 1999). In
other inner ear diseases with reduced endolymph secretion, an
increase in volume of perilymph would be expected (Pace et al.,
2001; Jin et al., 2006). Variations in the volume of perilymph
measured with IT or IV administration of contrast agent may
J. Zou et al. / Hearing Research 259 (2010) 36–43 43become a clinically useful measure of endolymphatic compart-
ment pathology.
In conclusion, ﬁne structures within the inner ear of the mouse
were demonstrated using Gd-DOTA enhanced MRI. Visualisation of
important inner ear structures can be obtained by either IT or IV
administration of contrast agent. IV administration yielded more
information on the permeability of the barriers. This study can
be applied to future investigations of the pathological mechanisms
of sensorineural hearing loss of different etiologies in mouse
models.
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MRI manifestation of novel superparamagnetic iron 
oxide nanoparticles in the rat inner ear
MRI of the delicate structure of the inner ear has 
been addressed with higher field-strength mag-
nets and various contrast agents. The inner ear 
is housed in dense bone and subdivided into dif-
ferent fluid-filled compartments, making it pos-
sible to evaluate the barrier function using MRI 
(Figure 1 & Table 1). The challenge for inner ear MRI 
today is to distinguish the inner ear fluids (endo-
lymph and perilymph) using contrast agents and 
eventually identify the pathological changes. One 
promising group of contrast agents was derived 
from superparamagnetic iron oxide nanoparticles 
(SPIONs). SPIONs are an effective MRI T2 con-
trast agent and have been used in high-resolution 
MRI for tracing apoptosis and gene transcription 
in animal models of cerebral ischemia [1–5]. At 
present, multifunctional nanoparticles are being 
developed and investigated as a means for con-
trolled targeted drug delivery to selected cochlear 
cell populations for treating sensorineural hear-
ing loss [101]. Labeling of these nanoparticles with 
imaging contrast materials is being carried out 
in order to visualize their distribution through 
the cochlea in vivo [6,101]. SPIONs are potent sup-
pressors of signal on T2-weighted MRI sequences 
creating a negative, or dark contrast, against the 
intensely bright signal in proton-rich fluids that 
do not c ontain SPIONs.
We have previously reported on the develop-
ment of a novel type of SPION that is water sol-
uble, a characteristic that can be invaluable for 
medical applications [7]. They are constructed, 
using temperature-decomposition methods, 
from iron oxide nanoparticle cores with a hier-
archical coating consisting of a surface layer of 
Pluornic® F127 copolymer (PF127) that overlays 
a layer of oleic acid on the surface of the iron 
oxide nanoparticles. PF127/oleic acid@SPIONs 
are hereafter abbreviated as POA@SPIONs. The 
PF127 coating is an ABA-type triblock copoly-
mer consisting of polypropylene oxide (PPO) 
and polyethylene oxide (PEO) that serves to 
make the nanoparticles water soluble. The PF127 
block copolymer was selected as a suitable can-
didate for surface modification because it has 
been approved by the US FDA and has been 
used in experimental medicine and pharmaceu-
tical sciences for decades [8–13]. A comprehen-
sive report on the toxicity of SPIONs indicated 
that the cells did not undergo apoptosis due to 
SPION exposure, even at high molarities up to 
200 mM [14]. POA@SPIONs contain extremely 
low concentrations of Fe3+ (4.3–5.6 mM); there-
fore, it would be expected to be safe when applied 
in vivo.
In order to access certain compartments 
within the cochlea, nanoparticles must pass 
through one or more biological barriers, includ-
ing the tympanic cavity–inner ear barrier 
(round window membrane), blood–perilymph 
barrier, blood–endolymph barrier and peri-
lymph–endolymph barrier. The permeability 
Aim: Superparamagnetic iron oxide nanoparticles hierarchically coated with oleic acid and Pluronic® 
F127 copolymers (POA@SPION) have shown exceptional T2 contrast enhancement. The aim of the present 
work was to investigate the MRI manifestation of POA@SPION in the inner ear. Materials & methods: 
A total of 26 male Wister rats were selected for testing POA@SPION administered through intracochlear, 
intratympanic and intravenous routes. MRI was performed with a 4.7 T MR scanner. Results & conclusion: 
POA@SPION can be introduced into the perilymph space, after which it becomes widely distributed and 
can demonstrate the integrity of the perilymph–endolymph barrier. Positive highlighting of the 
endolymph compartment against the darkened perilymph was visualized for the first time. POA@SPION 
passed through the middle–inner ear barriers in only small amounts, but stayed in the perilymph for 
3 days. They did not traverse the blood–perilymph barrier or blood–endolymph barrier. The inner ear 
distribution of POA@SPION was confirmed by histology. POA@SPION is a promising T2 negative 
contrast agent.
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of each barrier to SPIONs would be expected 
to be different depending on factors that affect 
passive diffusion or active transport. Since the 
inner ear is dominated by large fluid-filled 
spaces containing endolymph and perilymph 
that are well visualized on T2-weighted MR 
images [6], we proposed the hypothesis that 
POA@SPIONs should produce a detectable 
darkening of T2/T2*-weighted images if they 
enter a compartment in sufficient concentra-
tion. Such darkening due to the reduction of 
T2/T2* signal intensity within the cochlea 
should be recognizable against the brighter 
signal in the compartments that lack the nega-
tive contrast from the SPIONs. POA@SPIONs 
were administered to rat models to study the 
ability of POA@SPIONs to enter the cochlea, 
either by penetration through the middle–inner 
barriers (round window and oval window) or 
by the intravenous (IV) route. Intratympanic 
applications were carried out by placing gela-
tine sponge soaked in POA@SPIONs into the 
round window niche. These results were com-
pared with direct installation of POA@SPIONs 
into the cochlear perilymph in order to study 
the dynamics and the distribution through the 
cochlea, entering the cochlea in a manner simi-
lar to the introduction of a cochlear implant. 
Such an application could accompany cochlear 
i mplantation or occur s ubsequent to it. 
Figure 1. Illustration of rat inner ear anatomy. The passage of substances from the middle ear to 
the inner ear is through the round window membrane (1) and annular ligament (2), which surrounds 
the stapes footplate within the oval window and comprises the stapediovestibular joint (3). The 
stapedial artery (4) is a prominant structure in the rat middle ear, which runs through the obturator 
foramen of the stapes and inferior to the round window niche. The inner ear is composed of the 
cochlea (5) and vestibule. The vestibule contains three semicircular canals, including the lateral (6), 
posterior (7) and superior canals (8), the saccule (9) and the utricle (10). The crista (11), which is 
located in each ampulla, is the sensory structure of the semicircular canals. The macula (12) is the 
sensory structure of both the saccule and the utricle. The cochlea contains three chambers, which are 
the scala tympani (13), the scala vestibuli (14) and the scala media (15). The scala tympani and 
vestibuli are filled by perilymph (high sodium-containing fluid). The scala media is filled with 
endolymph (high potassium-containing fluid) and also contains the sensory structure, the organ of 
Corti (16). The basilar membrane (17), which extends from the osseous spiral lamina (18), separates 
the scala media from scala tympani. Reissner’s membrane (19) separates the scala media from scala 
vestibuli. Spiral ganglion cells (20), which are located in the modiolus, send peripheral processes to 
the hair cells and central processes to the cochlear nuclei via the cochlear nerve. Capillaries in the 
modiolus (21) and spiral ligament (22) contribute to the blood–perilymph barrier. Capillaries in the 
stria vascularis (23) are attributable to the blood–endolymph barrier.
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Materials & methods
n Manufacturing & characterization 
of POA@SPIONs
FeCl
3
.6H
2
O (99%) and sodium oleate (85%) 
were purchased from Sigma (Aldrich Gmbh, 
Munich, Germany), and a cellulose membrane 
bag (molecular weight cut-off: 25 kDa) from 
Spectrum Inc. (Breda, The Netherlands). All 
organic solvents were of reagent grade and used 
without further purification, and deionized 
water was obtained from a Milli-Q system.
A total of 0.903 g FeCl
3
.6H
2
O (3.34 mmol) 
and 3.046 g sodium oleate (10.02 mmol) were 
dissolved in a mixed solvent, including 25 ml 
ethanol, 20 ml deionized water and 45 ml hex-
ane. The resulting solution was heated to 62°C 
and refluxed for 4 h. Upon completion of the 
reaction, the iron oleate complex containing 
organic phase was washed with deionized water 
three times. After the evaporation of hexane, 
2.90 g waxy Fe oleate complex (3.23 mmol) 
and 0.47 g oleic acid (1.67 mmol) were dis-
solved in 20 ml dioctyl ether at 70°C. The 
reaction mixture was heated to 290°C with a 
constant heating rate of 3°C/min and kept at 
this temperature for 1.5 h. A total of 30 ml 
ethanol was added to the reaction mixture, and 
the nanoparticles were collected by centrifu-
gation at 6000 rpm. The nanoparticles were 
redispersed in 20 ml hexane, and precipitated 
by adding 30 ml ethanol followed by centrifu-
gation. This procedure was repeated three 
times in order to remove impurities. Finally, the 
SPIONs were dispersed in 40 ml tetrahydrofu-
ran (THF) in the presence of 100 µl oleic acid 
and stored at 4°C for further use. To achieve 
transfer from organic phase to water phase, a 
2 ml solution of SPIONs in THF was mixed 
with 2 ml 10 mg/ml Pluronic F127 aqueous 
solution at room temperature. After 30 min 
of vigorous agitation, the organic solvent was 
evaporated overnight to obtain a stable aqueous 
suspension of SPIONs. The aqueous solution of 
SPIONs was then dialyzed against 1 l of deion-
ized water for 48 h to remove free-standing 
PF127 polymers. The particle suspension was 
filtered by 200 nm syringe filter (Whatman) 
and stored at 4°C.
Transmission electron microscopy images 
were taken by using JEOL JEM-2100F at an 
acceleration voltage of 200 kV. X-ray diffraction 
(XRD) patterns of the SPIONs were recorded by 
a PANalytical X’Pert Pro system using a mono-
chromatized x-ray beam with a nickel-filtered 
Cu Ka radiation.
n Relaxivity of POA@SPIONs & their 
release profile from gelatine sponge 
A 4.7 T magnetic resonance (MR) scanner with 
bore diameter of 155 mm (PharmaScan, Bruker 
BioSpin, Germany) was used to measure the 
r2 and r1 relaxivity of POA@SPIONs and the 
release profile of the nanoparticles from gelatine 
sponge. The maximum gradient strength was 
300 mT/m with an 80 -µs rise time. A dedicated 
Table 1. Terms and abbreviation of the 
rat inner ear structures.
Terms Abbreviations
Ampulla Am
Cochlea Coch
Cochlear nerve CN
Corti’s organ CO
Crusta ampullaris CrAm
Lateral semicircular canal LSCC
Maculae sacculi MaSa
Modiolus Mod
Osseous spiral lamina OSL
Posterior semicircular canal PSCC
Reissner’s membrane RM
Saccule Sa
Round window RW
Round window membrane RWM
Scala media SM
Scala tympani ST
Scala vestibuli SV
Spiral ligament SL
Spiral ganglion cell SGC
Stria vascularis StrV
Superior semicircular canal SSCC
Utricle Ut
Table 2. Animals were grouped according to administration 
approaches and MRI time post-POA@SPION delivery.
Groups n Dosages† MRI time Ears for histology
SPION-IC:
SC 3 10–20 µl/rat Day 0 (1–6 h) –
PC 6 5 µl/rat Day 0 (1–6 h) 3
SPION-IT‡:
Day 0 8 20 µl/rat Day 0 (2–3 h) 1
Day 1 2 20 µl/rat Day 1 –
Day 3 2§ 20 µl/rat Day 3 –
Day 7 2§ 20 µl/rat Day 7 1
SPION-IV 3 2.37 µl/kg Day 0 –
†Fe+ concentration: 1.0 mg/ml (4.3 mM) –1.3 mg/ml (5.6 mM).
‡POA@SPION was delivered to the left middle ear cavity.
§Animals were also imaged on day 0.
IC: Intracochlear; IT: Intratympanic; IV: Intravenous; POA: PF127/oleic acid; PC: Custom-made 
polyurethane catheter (OD: 0.25 mm, ID: 0.12 mm, AgnTho’s AB, Sweden); SC: silicon catheter 
connected to a reservoir (tubing OD: 0.64 mm, ID: 0.3 mm, MedEl, Innsbruck, Austria);  
SPION: Superparamagnetic iron oxide nanoparticle.
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rodent head coil (linear bird cage coil) with a 
diameter of 38 mm was used for the phantom 
and animal studies. Samples were prepared 
for imaging by filling plastic phantom tubes 
(400 µl, AgnTho’s AB, Sweden) with POA@
SPIONs solutions and arranging the tubes con-
centrically within a 50 ml syringe. Negative 
controls were prepared using plain physiologi-
cal saline. Each sample was prepared in dupli-
cate. The release profile of POA@SPIONs from 
gelatine sponge (Gelfoam™), which was used 
in the intratympanic (IT) administration of 
the nanoparticles, was analyzed in a phantom 
test. A series of gelatine sponge, of dimensions 
15.6 mm3 (double the size of the pledgets used 
against round window membrane because of a 
larger volume of solution), was saturated with 
150 µl of POA@SPIONs, at a concentration 
of 1.0 mg/ml (4.3 mM). Pledgets were placed 
into Eppendorf vials containing 450 µl of physi-
ological saline, creating a final volume of 600 µl. 
Fluid from each sample was aspirated for MRI 
measurements after allowing the pledgets to 
dwell for varied durations, including 30 min, 
60 min, 90 min, 3.5 h and 4 h. A positive 
control was prepared to simulate a complete 
release of all POA@SPIONs into the solution 
by directly mixing 150 µl of POA@SPIONs to 
450 µl of physiological saline. The positive con-
trol has a high concentration of contrast agent, 
which reduced the T2 value below the detec-
tion limit of conventional MRI methods. The 
positive control sample was, therefore, diluted 
fivefold with physiological saline to produce a 
MRI signal that could be measured. Samples 
were prepared for imaging by filling plastic 
phantom tubes (400µl, AgnTho’s AB) with the 
aspirates from each sample and arranging the 
tubes concentrically within a 50 ml syringe. 
Negative controls were prepared using plain 
physiological saline. Each sample was prepared 
in duplicate. A multi slice multi echo sequence, 
based on Carr–Purcell Meiboom–Gill spin echo 
was used for T2 relaxation time determination 
(repetition time [TR]: 1500 ms; echo time [TE]: 
7–229 ms; 32 TEs; matrix size: 128 × 128; sin-
gle slice; slice thickness: 1.0 mm; field of view 
[FOV]: 5.0 cm; resolution: 0.098 × 0.130 mm2; 
number of excitations [NEX]: 3). The center of 
the tubes was defined as the ‘region of interest’ 
for the measurements of signal intensities and 
T2 relaxation times. T1 maps were determined 
by rapid acquisition with relaxation enhance-
ment (RARE) sequence with variable TR (TR: 
100, 432, 859, 1458, 2472 and 7500 ms; TE
eff
: 
8.7 ms; RARE factor: 2; NEX: 1; matrix size: 
128 × 128; FOV: 5 cm; single slice with slice 
thickness: 2.0 mm).
n Animal protocol
A total of 26 male Wister rats weighing from 
218 to 470 g with normal Prey’s (hearing) reflex 
provided by the Experimental MRI Laboratory 
(Department of Neurology, Helsinki University 
Central Hospital, Finland) were included 
in the study. All animal experiments were 
approved by the Ethical Committee of the 
University of Tampere, Finland (permission: 
LSLH-2006–4143/Ym23). Animal care and 
experimental procedures were conducted in 
accordance with European legislation. Animals 
were randomly assigned to one of eight groups 
(Table 2). Overall, the study was designed with 
three arms of POA@SPIONs administra-
tion, including intracochlear (SPIONs-IC), 
Figure 3. Transmission electron microscopy images of superparamagnetic 
iron oxide nanoparticle in (A) tetrahydrofuran and (B) water after being 
coated with PF127. The inset of (A) is a selected area electron diffraction pattern 
indexed with the corresponding inverse spinel structure.
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Figure 2. Rat round window exposure and cochleostomy. Round window 
membrane was identified above the stapedial artery and scala tympani locates 
below the artery (A). Cochleostomy was performed on the lateral wall of scala 
tympani (B).
RW: Round window; SA: Stapedial artery; ST: Scala tympani.
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IT (SPIONs-IT) and IV (SPIONs-IV) routes. 
The SPIONs-IC arm was subdivided into two 
groups based on whether a silicon catheter (SC) 
or polyurethane catheter (PC) was employed for 
the IC injection. Animals in the SPIONs-IT arm 
underwent MRI at varied time intervals follow-
ing POA@SPIONs administration ranging from 
day 0 through day 7. All experimental proce-
dures were performed under general anesthesia, 
induced and maintained by intraperitoneal injec-
tions of medetomidine hydrochloride (0.5 mg/
kg, Domitor, Orion, Finland) and ketamine 
(75 mg/kg, Ketalar, Pfizer, UK) with the ani-
mal’s eyes protected by Viscotears® (Novartis 
Healthcare A/S, Denmark).
In the SPIONs-IC arm, the left bulla was 
exposed through a postauricular approach. 
Working under the operating microscope, a 
hole was drilled through the bulla with a 2 mm 
diameter burr. The round window membrane 
was identified superior to the stapedial artery 
(Figure 2). The scala tympani in the basal turn 
was opened with a 0.5 mm cutting burr infe-
rior to the stapedial artery and the round win-
dow. POA@SPIONs were slowly injected either 
through a SC group that was connected to a res-
ervoir (tubing outer diameter: 0.64 mm; inner 
diameter: 0.3 mm; MedEl, Innsbruck, Austria) 
or through a custom made polyurethane cath-
eter (outer diameter: 0.25 mm; inner diam-
eter: 0.12 mm; AgnTho’s AB; PC group). The 
SC-reservoir drug-delivery system was designed 
to administer multifunctional nanoparticles into 
the human cochlea and was, therefore, included 
in the present study. However, the catheter was 
excessively large for insertion into the cochlea 
of a rat, which necessitated our design of an 
appropriately sized polyurethane catheter drug-
delivery system.
In the SC group, the catheter tip was inserted 
into the scala tympani just through the opening 
and was sealed circumferentially with Histoacryl 
(enbucrilate) glue (Aesculap AG, Tuttlingen, 
Germany). In the PC group, the catheter tip 
was slowly advanced atraumatically approxi-
mately 2.0–3.0 mm into the scala tympani and 
a piece of muscle was placed around the tube 
and sealed with Histoacryl glue. After the glue 
was dry, 10–20 µl (in SC group) or 5 µl (in PC 
group) POA@SPIONs were slowly instilled over 
1 min into the scala tympani. Visible leakage 
of nanoparticles was observed in both the SC 
group and PC group, with a greater amount in 
the SC group. The wound was sutured closed. 
MRI scanning commenced immediately after 
the POA@SPIONs administration.
In the SPIONs-IT arm, POA@SPIONs were 
administered through a postauricular middle ear 
operation, as described above, or through a trans-
canal approach with a myringotomy over the 
round window. In the postauricular approach, a 
small pledget of gelatine sponge (approximately 
8 mm3) soaked in POA@SPIONs was placed 
against the round window membrane. A muscle 
plug was used to fill the opening made in the 
bulla and the wound was sutured closed.
Figure 4. X-ray diffraction pattern of the as-synthesized 
superparamagnetic iron oxide nanoparticles.
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In the transcanal approach, an anterior myr-
ingotomy was initially made to relieve any air 
bubbles. A posterior myringotomy was then 
made and a similar sized gelatine sponge soaked 
in POA@SPIONs was placed into the round 
window niche and allowed to fill the posterior 
middle ear cavity. A control procedure was 
carried out through a similar approach on the 
contralateral side and the gelatine sponge was 
soaked only in physiological saline.
In the SPIONs-IV arm, the lateral tail vein 
was dilated by soaking the tail in warm water 
followed by topical application of 70% alcohol. 
The vein was cannulated with a 30-gauge needle 
connected to catheter tubing and taped securely 
into position. Saline containing 5% heparin was 
initially instilled to maintain patency. Baseline 
pretreatment MRI scans were obtained as a con-
trol. POA@SPIONs were slowly injected intrave-
nously. MRI scanning commenced i mmediately 
after the contrast agent administration.
At the end of the experiments, ten bullae 
were processed for histology in order to identify 
POA@SPIONs using Prussian blue staining to 
detect Fe
3
O
4
 within the inner ear tissue. Four bul-
lae from two rats were selected for whole cochlear 
Fe
3
O
4
 staining and six bullae from six rats were 
processed for Fe
3
O
4
 staining on sections.
n Animal MRI measurements
The body temperatures of the rats were main-
tained by circulating warm water and their res-
pirations were recorded with Physio Tool 1.0.b.2 
program (Bruker). Rats were placed in the mag-
net with the ears positioned at the isocenter. 2D 
MRI measurements were performed on phan-
tom and animal studies. 3D MRI measurements 
were performed in some selected animals.
In the animal studies, T2-weighted 2D images 
were acquired with RARE 2D sequences (TR/
TE
eff
: 2500/40 ms; RARE factor: 8; matrix size: 
256 × 256; slice thickness: 0.5 mm; FOV: 2.5 cm; 
resolution: 0.156 × 0.156 mm2; NEX: 5). T2 map 
acquired with multi slice multi echo sequence (TR: 
1500 ms; TE: 15–480 ms; 32 TE; one slice; slice 
thickness: 1.0 mm; matrix size: 256 × 128; FOV: 
3.0 cm; resolution: 0.117 × 0.234 mm2; NEX: 
1). T2*-weighted 2D images were acquired with 
fast low-angle shot (FLASH; TR: 350 ms; TE: 
4–15 ms; flip angle: 40°; matrix size: 128 × 256; 
slice thickness: 0.5 mm; FOV: 3.0 cm; resolution: 
0.234 × 0.117 mm2; NEX: 30). T2-weighted 3D 
images were acquired with RARE 3D sequences 
(TR/TE
eff
: 500/43 ms; RARE factor: 16; matrix 
size: 64 × 64 × 64; FOV: 0.5 cm; resolution: 
0.078 × 0.078 × 0.078 mm3; NEX: 2).
For IC delivery, the MRI was obtained imme-
diately after the operation. The inner ear geometry 
was established by taking three 2D T2-weighted 
images at perpendicular orientations using RARE 
2D sequences (FOV: 3.0 cm; matrix: 256 × 256; 
slice thickness: 0.8 mm; NEX: 3). Then, 2D 
T2-weighted images were acquired at different 
time points post-POA@SPIONs administration 
(1–6 h). T2*-weighted 2D imaging, T2 map 
and 3D T2-weighted imaging was performed in 
one animal each (Table 1). OsiriX v3.3.2 (OsiriX 
Foundation, Geneva, Switzerland) software was 
applied for 3D rendering of the 3D raw stacked 
MR images of the inner ear.
For IT delivery, the MRI was obtained imme-
diately after POA@SPIONs administration and 
followed for up to 7 days (Table 1). MRI was 
measured at 2 h post-POA@SPIONs adminis-
tration in the day 0 group, on day 1 post-POA@
SPIONs administration in the day 1 group, on 
day 3 post-POA@SPIONs administration in the 
day 3 group, and on day 7 post-POA@SPIONs 
administration in the day 7 group. The inner 
ear geometry set-up and T2-weighted images 
were performed in the same way as for IC 
delivery animals. 
For IV administration, baseline 2D T2- 
weighted images were taken after obtaining 
satisfactory geometry of the cochlea. A series of 
images were acquired with 30 min intervals over 
a period of 210 min following the POA@SPIONs 
injection. 
n Quantification of signal intensity
ParaVision 4.0 (PharmaScan, Bruker BioSpin) 
software in combination with Adobe Photoshop 
CS3 was used for postprocessing of images for 
signal intensity quantification, labeling, and 
demonstration of cochlear compartments and 
the vestibules. Quantification was performed on 
2D T2-weighted images. The whole cochlear 
region from both ears was selected for signal 
intensity measurements. The ampulla of the 
horizontal semicircular canal was selected as 
representative of the vestibule for signal inten-
sity measurements. The nearby brain region 
was selected as a reference to normalize the 
signal intensity. In phantom studies, the physi-
ological saline tube was chosen as a reference to 
n ormalize the signal intensity of the specimens. 
n Prussian blue staining of the 
inner tissue
PF127/oleic acid@superparamagnetic iron oxide 
nanoparticles in the inner ear tissues were iden-
tified by staining Fe
3
O
4
 with Prussian blue. 
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After MRI, bullae were immediately fixed by 
cardiac perfusion with 4% paraformaldehyde 
and 1% glutaraldehyde in phosphate-buffered 
saline (PBS; pH 7.4; 0.1 mol/l) after remov-
ing the blood by flushing with saline contain-
ing 0.5 IU/ml heparin. The inner ear was dis-
sected out of the skull and perfused with the 
same solution by opening the round window, 
oval window and apex. It was then further fixed 
with the same fixative solution overnight. For 
the staining of Fe
3
O
4
 in whole cochlea prepara-
tions, the osseous otic shell was elevated and 
the cochlea was washed three times for 5 min 
each with 0.1 mol/l PBS. Equal parts of 20% 
hydrochloric acid and 10% potassium ferrocya-
nide were mixed immediately before use and the 
cochlea was then immersed in the solution for 
20 min, rinsed in water three times for 5 min 
each, counterstained with nuclear fast red for 
5 min and rinsed in water again. The specimens 
were observed under a stereomicroscope (Stemi 
2000-C, Carl Zeiss, Germany) and the images 
were recorded with a digital camera (Invenio 3S, 
DeltaPix, Danmark). For the Fe
3
O
4 
staining on 
sections, the bullae were washed with 0.1 mol/l 
PBS for three times for 5 min each, and decalci-
fied with 10% EDTA at room temperature for 
4 weeks. After washing with PBS, specimens 
Figure 6. Intracochlear administration of PF127/oleic acid@superparamagnetic iron oxide 
nanoparticles induced changes in the surface renderings of T2-weighted 3D scans of rat 
inner ears. Both perilymph and endolymph were demonstrated as bright images in the nontreated 
(without negative contrast) right cochleae (A). Only endolymph in the scala media remained bright 
following the intracochlear injection of the negative contrast agent, POA@SPIONs, into the left 
cochlea of the same rat (C). The signal from the utricular perilymph was also diminished by the 
negative contrast effect of the POA@SPIONs (D) in comparison to the nontreated right side (B).
Am: Ampulla; Am LSCC: Ampulla of the LSCC; Am PSCC: Ampulla of the PSCC; Am SSCC: Ampulla 
of the SSCC; Coch: Cochlea; LSCC: Lateral semicircular canal; POA: PF127/oleic acid; PSCC: Posterior 
semicircular canal; Sa: Saccule; SSCC: Superior semicircular canal; SM: Scala media;  
SPION: Superparamagnetic iron oxide nanoparticle; Ut: Utricle.
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were dehydrated by using a graded series of etha-
nol, paraffin embedded, and sectioned with the 
thickness of 4 µm. After dewaxing and rehydrat-
ing, the slides were stained for Fe
3
O
4
 with the 
same method as above, observed under a light 
microscope (Leica DM 2000, Germany), and 
digitally photographed with Olympus DP 25 
(Japan). Hematoxylin and eosin staining was 
performed on one nontreated cochlear slice to 
demonstrate the structures.
n Statistics
Statistical analysis was carried out with SPSS 
11.5 software and the means and standard 
deviations were calculated for levels of signal 
intensity in the cochlear region. Difference in 
levels of signal intensity in the whole cochlea 
was compared between left and right ears of 
IC and IT groups using a paired samples t-test. 
Differences in levels at different time points 
for post-POA@SPIONs administration were 
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Figure 7. Quantitative comparison of T2-weighted signal intensities of the inner ear 
between left cochleae receiving intracochlear PF127/oleic acid@superparamagnetic iron 
oxide nanoparticle and right nontreated cochleae. Signal in the perilymph of the left cochleae 
was diminished by the nanoparticles leaving only the endolymph in the scala media with bright 
signal (A). Quantification showed a significant decrease in the signal intensity in the perilymph of 
both the cochlea and ampulla at 2 h postintracochlear injection of PF127/oleic acid@
superparamagnetic iron oxide nanoparticle (normalized signal intensity = signal intensity in the region 
of interest/signal intensity in reference) (B). The signal intensity changes persisted for the 6 h of 
observation time.  
*p < 0.05; **p < 0.01 (paired Student t-test).  
Am: Ampulla; Coch: Cochlea; IC: Intracochlear; L: Left; PC: Polyurethane catheter; R: Right; 
Ref: Reference region in brain; SE: Standard error; SM: Scala media. 
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compared using analysis of variance (ANOVA). 
Any p-values below 0.05 were accepted as an 
i ndication of statistical significance. 
Results
n Characteristics of POA@SPIONs
The obtained water-soluble particles have a hier-
archical surface structure due to the amphiphi-
lic nature of the PF 127 molecule that contains 
two hydrophilic PEO tails and one hydrophobic 
PPO part in the middle. When PF 127 is added 
to the nanoparticle suspension, the hydropho-
bic PPO segment of PF 127 associates with the 
alkyl chain of oleic acid present on the surface of 
nanoparticles, while the hydrophilic PEO chains 
are facing outwards, allowing the particle to be 
dispersed in aqueous systems [7]. 
Both size and shape of the SPIONs were 
retained after phase transfer from THF to 
water (Figure 3). The average diameter of the 
SPIONs was determined to be 12.1 nm (stand-
ard deviation ~5%). The colloidal solution of 
POA@SPIONs stayed stable on the shelf for up 
to 6 months or longer. The crystal structure of 
SPIONs was identified with XRD (Figure 4). The 
peaks are labeled with the indexed Bragg reflec-
tions of the magnetite structure and the particles 
were found to be highly crystalline. The aver-
age size of a crystallite was determined by the 
Debye–Scherrer equation to be 11.5 nm, which 
fits well with the average diameter measured 
from transmission electron microscopy images, 
indicating that the particles are single crystal-
line. The relaxivities of POA@SPIONs mea-
sured in 4.7 T were as follows: r2: 169.5 s-1mM-1; 
r1: 0.234 s-1mM-1; r2/r1 ratio: 724.4.
n Dynamic release of POA@SPIONs 
from gelatine sponge
Dynamic signal changes were observed with T2 
map images (Figure 5). The T2 relaxation rate of 
samples taken at 30 min (79.94 ± 0.37 s-1) was 
above that of the five-times diluted positive con-
trol sample (70.50 ± 28.27 s-1), which indicated 
that more than 20% of POA@SPIONs were 
released into the surrounding saline by 30 min. 
At 3.5 h, the relaxation rate (1.7 s-1) was close to 
the value of physiological saline, which indicates 
that almost all the POA@SPIONs were released 
from the gelatine sponge. 
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Figure 8. T2*-weighted imaging showed signal changes in the spiral ganglion region 3.5 h 
after intracochlear administration of PF127/oleic acid@superparamagnetic iron oxide 
nanoparticle. The cochlear fluids were not demonstrated when using a fast low-angle shot 
sequence with repetition time/echo time 350/15 ms and Flip angle 40° (A); when echo time was 
6 ms, higher signals were generated from the cochlear fluids and spiral ganglion region (B); the 
optimal image was acquired using echo time of 4 ms (C). The signal in the spiral ganglion region 
became dark in the left cochlea (D, L) after receiving injection of PF127/oleic acid@
superparamagnetic iron oxide nanoparticles. The spiral ganglion region of the nontreated 
contralateral cochlea (D, R) remained gray. A light microscopy normal rat transmodiolar histological 
image using paraffin embedding and hematoxylin and eosin staining is inserted to help with 
orientation of the magnetic resonance images. It demonstrates the location of spiral ganglion cells. 
BS: Brain stem; Coch: Cochlea; L: Left; R: Right; SGC: Spiral ganglion region.
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n MRI manifestation of POA@SPIONs 
in the inner ear after IC administration 
Without any contrast agent, the inner ear flu-
ids, including perilymph and endolymph, gen-
erated an intense signal on T2-weighted MRI. 
Therefore, the cochlear and vestibular compart-
ments were highlighted on the volume rendering 
of T2-weighted 3D scan (Figure 6a & b).
In the IC–PC subgroup, 3D rendered images 
acquired at 180 min after IC delivery showed that 
the areas of high signal in the cochlea and vestibu-
lum were greatly decreased in comparison to the 
no-treatment contralateral side (Figure 7C & D). The 
disappearance of signal in the perilymph signal 
was attributed to the presence of POA@SPIONs 
within that compartment. The quantifications 
performed on 2D images demonstrated statisti-
cally significant decreases in the signal intensities 
(normalized by the nearby brain signal intensity; 
POA@SPIONs treatment side vs no-treatment 
side) in both cochlea (p < 0.001, paired Student 
t-test) and ampulla at 2 h post-IC injection 
(p < 0.05, paired Student t-test) (Figure 7). The 
signal changes persisted over the observation time 
of 6 h (Figure 7b). In another measurement, T2 
relaxation time (mean ± standard deviation) in 
the perilymph of the scala vestibuli after treatment 
with POA@SPIONs (25.608 ± 5.351 ms) 
was lower than that of the no-treatment side 
(130.5 ± 71.9 ms).
In general, signal decrease in the perilymph 
of rats in the IC–SC subgroup, which received 
a larger injected volume of nanoparticles to 
compensate for a leak at the round window, was 
greater than in the IC–PC subgroup, which were 
exposed to a smaller volume of POA@SPIONs 
(5 µl). The cochlea is a special organ that is com-
posed of fluids, soft tissue and bone. Soft tissues, 
such as the spiral ganglion region, are expected 
to show gray signals against the brighter signal 
of adjacent cochlear fluids on T2*-weighted 2D 
images. We made imaging with different param-
eters and we found out that the present sequence 
is optimal to show both the cochlear fluids (gener-
ate bright signal in T2-weighted image) and soft 
tissue containing spiral ganglion cells. The very 
high r2/r1 ratio of POA@SPIONs is favorable 
for T2- and T2*-weighted imaging. Moreover, 
the low concentration of injected contrast agent 
diminished the T1-weighted effect. On T2*-
weighted images there was a susceptibility arti-
fact, the size of which increased with increasing 
TE from 4 to 15 ms. The FLASH sequence with 
TR/TE 350/4 ms and a flip angle of 40° yielded 
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Figure 9. T2-weighted images of the inner ear after intratympanic administration of  
PF127/oleic acid@superparamagnetic iron oxide nanoparticles to the left ears. There was no 
visible signal change observed in the left side (L) compared with the nontreated right side (R) at 
either 2 h (A) or 1 day (B) postadministration. The bright signal in the left cochlea as indicated by the 
arrowhead is of unknown origin and was consistently observed in all cochleae. The image in the 
middle was produced by paraffin embedding and hematoxylin and eosin staining.  
Am: Ampulla; L: Left; Mod: Modiolus; R: Right; ST: Scala tympani; SV: Scala vestibuli.
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an optimal mildly T2*-weighted image (Figure 8). 
POA@SPIONs injection eliminated the signals 
in these regions (Figure 8). 
n Limited passage of POA@SPIONs 
through the middle–inner ear barriers
T2*-weighted images are not sensitive to the 
inner ear f luids (perilymph and endolymph) 
where most of the nanoparticles should accumu-
late. POA@SPIONs were delivered to the round 
window membrane and T2-weighted MRI was 
performed at different time points from 2 h to 
7 days (Table 2). In the 2D MR images, no visible 
difference was observed between the left inner 
ears, which were exposed to the round window 
membrane administration of POA@SPIONs, 
and the right side, which were exposed to physi-
ological saline (Figure 9). The quantification 
showed no statically significant difference at 2 h 
through 7 days post-round window membrane 
administration (p > 0.05; paired t-test) (Table 3). 
However, the data did show slight decreases in 
the signal intensities on the left cochleae 1 and 
3 days after POA@SPIONs delivery, and on the 
left ampullae on day 1 through day 7. At the time 
point of 3.5 h postnanoparticle administration, 
there was no difference in T2 relaxation time 
between the cochlea exposed to POA@SPIONs 
(123.510 ± 4.640 ms) and the no-treatment 
cochlea (124.005 ± 22.526 ms). Following this, 
1 week later, a slight decrease in T2 relaxation 
time was observed in the POA@SPION-exposed 
cochlea (103.255 ± 6.497 ms) in comparison to the 
no-treatment side (121.666 ± 11.677 ms). These 
data suggested a slight, but insufficient passage 
of POA@SPIONs through the middle–inner 
ear barriers.
n No passage of POA@SPIONs through 
the blood–endolymph and 
blood–perilymph barriers
Before IV injection, baseline T2-weighted 
images were taken, which showed bright sig-
nal in both endolymph and perilymph com-
partments, within the cochlea and vestibular 
organ. The endolymph was not distinguish-
able from the perilymph (Figure 10a). Images of 
the inner ear acquired at defined time points 
post-POA@SPIONs IV delivery did not show 
visible changes, indicating that POA@SPIONs 
was not detected in the inner ear (Figure 10b). 
Quantified measurements confirmed that no 
statistically significant signal intensity changes 
were observed for up to 210 min after IV 
administration of POA@SPIONs (p > 0.05; 
ANOVA) (Figure 10C). 
n Appearance of Fe3O4 in the 
inner ear tissues
In the whole-mount specimen of the animal 
showing pronounced MRI signal changes in the 
IC–SC subgroup, abundant Fe
3
O
4
 was detected 
in the lateral surface of scala vestibuli. An inter-
mediate amount of Fe
3
O
4
 appeared in the modi-
olar surface of scala vestibuli and scala tympani, 
the lateral surface of scala tympani and the organ 
of Corti (Figure 11). In the para ffin-embedded sec-
tions of the IC–PC subgroup, Fe
3
O
4 
was detected 
in the epithelium of scala tympani, spiral gan-
glion region, fibrocytes beneath the Crusta 
ampullaris and surrounding the perilymphatic 
space of the saccule (Figure 12a–D). In the sections 
of the IT group, Fe
3
O
4
 was detectable only in 
the perilymphatic space of saccule (Figure 12e & F). 
Fe
3
O
4 
was not detected in n ontreated inner ear 
specimens (Figure 12g).
Discussion
T2-weighted sequences were applied in all 
studies because it is the most sensitive method 
to show the inner ear fluids (perilymph and 
endolymph) where most of the nanoparticles 
should appear. T2*-weighted images were taken 
to view the tissue, including the spiral ganglion 
region. POA@SPIONs were demonstrated to 
be an efficient T2 contrast agent within the rat 
inner ear. When infused into the perilymph, 
there was a consistent dramatic reduction of 
signal intensity on T2-weighted images com-
pared with the persisting bright signal of the 
endolymph, which did not take up POA@
SPIONs and lacked the negative contrast 
effect. These results support previous work that 
POA@SPIONs are a potent T2 negative con-
trast agent in vivo [7]. The inner ear endolymph 
and perilymph of the cochlea and vestibular 
organ are known to generate very bright signals 
on T2-weighted images [6,15]. POA@SPION, 
when introduced into the perilymph compart-
ment, caused a marked suppression of T2 signal 
that produced the effect of showing the endo-
lymphatic compartment as a bright, isolated 
Table 3. Signal changes in T2-weighted images of the inner ear 
received intratympanic superparamagnetic iron oxide 
nanoparticles administration.
Groups n Pairs (left side–right side) (mean ± SD)
Cochlea Ampulla
2 h 5 0.9748 ± 0.1310 0.1144 ± 0.1392
1 day 2 -0.0209 ± 0.053 -0.1343 ± 0.193
3 day 2 -0.1041 ± 0.146 -0.1461 ± 0.1674
7 day 2 0.0074 ± 0.0886 -0.0357 ± 0.0328
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Figure 10. T2-weighted imaging of the inner ear after intravenous superparamagnetic iron 
oxide nanoparticle administration. A baseline image taken before nanoparticle delivery 
demonstrated the cochlear anatomy and ampulla (A). After 150 min, no signal change was 
observed (B). Signal intensity dynamics (normalized by brain signal intensity) obtained up to 210 min 
did not show statistically significant differences (C).
Am: Ampulla; CN: Cochlear nerve; L: Left; Mod: Modiolus; OSL: Osseous spiral lamina; R: Right; 
SE: Standard error; ST: Scala tympani; SV: Scala vestibuli.
structure. It is apparent that significant amounts 
of POA@SPIONs did not pass through the 
perilymph–endolymph barrier into the endo-
lymph, resulting in a remarkable opportunity to 
observe the isolated endolymphatic space with 
bright T2 signal compared with the darkened 
perilymph, which contained POA@SPIONs. 
It also suggests the potential for studying the 
integrity of the perilymph–endolymph barriers, 
such as Reissner’s membrane, which might be 
injured during acute endolymphatic hydrops or 
impulse noise exposure [16–20]. 
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Intracochlear delivery of nanoparticles to 
investigate their distribution as potential drug 
or gene carriers has been reported by workers in 
the Nanoear consortium [21,101]. Although the IC 
administration of POA@SPIONs is an invasive 
procedure, not suitable for an office setting, it may 
be applied clinically as a diagnostic or therapeutic 
agent in the future, perhaps in conjunction with 
cochlear implantation. Therefore, the informa-
tion acquired from IC delivery is important both 
in present animal studies to track nanoparticles 
through the cochlea and to plan for future clinic 
work with cochlear implants. Histological stud-
ies have shown that most of the nanoparticles 
became widely distributed throughout the cochlea 
within the perilymphatic space and vestibular 
organ. Similarly, POA@SPIONs introduced by 
the IC route in this study were widely distributed 
throughout the inner ear. Histological results 
demonstrated distribution of POA@SPIONs 
in the cochlea and vestibule. Abundant Fe
3
O
4
 
was detected in the endothelium lining the scala 
vestibule in both whole-mounted specimens 
and paraffin-embedded sections (Figures 11 & 12). 
POA@SPIONs that were detected in the spiral 
ganglion region may have arrived by diffusion 
from the cochlear perilymph through modiolar 
meshes into ‘perimodiolar lymph’ [22]. Fe
3
O
4
 was 
not detected as extensively as would have been 
expected based on the MRI results. It is possible 
that the process of paraffin embedding may have 
caused some artifactual loss of nanoparticles, espe-
cially those suspended in the perilymph or lying 
on the surface of the epithelium. Additional stud-
ies designed to minimize such artifactual losses 
would be desirable to obtain histological quan-
tification of POA@SPIONs distribution within 
the inner ear. POA@SPIONs have demonstrated 
sufficient contrast effects and IC distribution to 
justify their further development as a label to trace 
the passage of drugs, genes and nanoparticles 
within the inner ear in vivo. 
Minimally invasive approaches to deliver 
drugs and genes into the inner ear are being 
sought. Applications of therapy into the mid-
dle ear would be favorable for use in the out-
patient clinic, but probably depend upon passage 
through the middle–inner ear barriers (round 
window and oval window) in order to access 
the inner ear. The permeation of nanoparticles 
through the middle–inner ear barriers of the rat 
has been observed with lipid nanocapusules [23], 
hyperbranched polylysine nanoparticles, poly-
ethylene glycol and polycapro-lactone nanopar-
ticles, and chitosan nanoparticles [Zou  J et al., 
Unpublished Data]. Nanoparticles that would be 
detectable with MRI would provide an excellent 
means to evaluate the efficacy of their transport 
through the middle–inner ear barriers in vivo. 
Although the passage of naked POA@SPIONs 
through the middle–inner ear barriers was inef-
ficient in this study, it is possible that if they were 
to be downsized or manufactured with altered 
surface characteristics (charge and ligands) simi-
lar to other nanoparticles, POA@SPIONs may 
penetrate the middle–inner ear barriers more 
efficiently in future studies [101]. 
As an alternative, positively enhancing T1 
MRI contrast agents, gadolinium chelates, have 
been shown to have excellent passage through 
the middle–inner ear barriers after IT admin-
istration in guinea pigs [24,25], mice [26], rats [27] 
and humans [24,25]. However, the longitudinal 
relaxivity (r1) of gadolinium chelates decreases 
rapidly at high field strengths, reducing the sen-
sitivity of these contrast agents at high field [28]. 
Gadolinium is not practical in molecular imag-
ing, which requires high magnetic field strength. 
A high concentration of gadolinium was reported 
to be ototoxic in a preliminary study [29].
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Figure 11. Identification of PF127/oleic acid@superparamagnetic iron oxide 
nanoparticles in the cochlea by Prussian blue staining on whole cochlear 
tissue after intracochlear delivery (IC–SC subgroup). Abundant nanoparticles 
were detected in the LSSV (A10; C). Medium amount of nanoparticles appeared in 
the MSSV (A8; B), MSST (A7; B), LSST (A9; C) and CO (A5; B).  No nanoparticles 
were detected in the nontreated cochlea (D). Also illustrated are the three 
chambers of the cochlea, the scala tympani (A1), the scala vestibuli (A2) and the 
scala media (A3), the basilar membrane (A4) and spiral ganglion cells (A6).
BC: Blood clot; BM: Basilar membrane; CO: Organ of Corti; IC: Intracochlear; 
LSST: Lateral surface of scala tympani; LSSV: Lateral surface of scala vestibuli; 
MSST: Modiolar surface of scala tympani; MSSV: Modiolar surface of scala 
vestibule; NP: Nanoparticle; SC: Silicon catheter; SPION: Superparamagnetic iron 
oxide nanoparticle. 
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The IV route is another desirable approach 
to introduce contrast agents that may be taken 
up into the perilymph or endolymph under nor-
mal or pathological circumstances. Gadolinium 
has been shown to enhance the perilymphatic 
space in T1 MR images after IV injection [6,15]. 
The integrity of the blood–perilymph and 
blood–endolymph barriers, which are critical 
for the proper functioning of inner ear physiol-
ogy, can be studied with contrast agents. These 
barriers may become ‘leaky’ when injured and 
their integrity could be evaluated with the use 
of contrast imaging agents that do not normally 
pass through. As an example, changes in the 
blood–perilymph barrier or blood–endolymph 
barrier permeability to gadolinium have been 
observed in MRI [30,31]. However, the doses of 
gadolinium that have been employed for IV use 
have been in excess of those typically given in 
clinical circumstances [6,25]. There are concerns 
that high doses of IV gadolinium might increase 
the risk of adverse effects, such as nephrogenic 
systemic fibrosis [32].
PF127/oleic acid@superparamagnetic iron 
oxide nanoparticles delivered intravenously, 
did not produce detectable signal changes 
within the inner ear, suggesting that neither the 
blood–perilymph barrier nor blood–endolymph 
barrier were permeable to them. Their larger par-
ticle size and differences in surface properties, 
in comparison to Gd-DOTA, likely contrib-
ute to the difficulties in transport through the 
blood–perilymph barrier. Unlike gado linium, 
iron ions do appear in extracellular fluids and 
cytoplasm in small physiological amounts. It 
is not necessary for POA@SPIONs to be inter-
nalized by the cells in order to investigate the 
integrity of biological barriers. The potential 
for toxicity from SPIONs can be limited by 
manipulating the polymer/iron mass ratio [33]. 
The concentration of Fe3+ in POA@SPIONs 
(4.3–5.6 mM) is far below the maximum levels 
previously tested and no toxicity has yet been 
demonstrated at any concentrations [14]. As 
opposed to gadolinium, SPIONs do not lose T2 
contrast effects at higher Tesla strengths. For 
all of these reasons, POA@SPIONs remains an 
important contrast agent that should be studied 
as an alternative to gadolinium. By conjugat-
ing with different ligands, POA@SPIONs may 
be developed that will penetrate the different 
inner ear barriers and that may serve as a mole-
cule-specific contrast agent to detect pathologic 
molecular expression within the inner ear of 
p roteins such as TNF-a and VEGF [34].
In conclusion, POA@SPIONs are a promis-
ing T2 negative contrast agent that is detect-
able within the inner ear by MRI. In their 
present form, they can be introduced into the 
peri lymphatic space along with cochlear implan-
tation. They can also demonstrate the integrity of 
the perilymph–endolymph barrier. Bright signal 
of the endolymphatic compartment in contrast 
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Figure 12. Identification of PF127/oleic acid@superparamagnetic iron oxide 
nanoparticles in the inner ear by Prussian blue staining on paraffin slices 
after intracochlear and intratympanic administration. The inner ear structures 
were illustrated in (A) and demonstrated histologically in (B). Intracochlear 
administration (IC–PC subgroup) resulted in nanoparticles being detected in the 
epithelium of the ST, SGC region, fibrocytes beneath the CrAm and surrounding 
the perilymphatic space of the Sa (C–F). Nanoparticles were detected in the 
perilymphatic space of the saccule after intratympanic delivery (G & H). There was 
no staining in the nontreated inner ear specimens (I).
Am: Ampulla; CrAm: Crista ampullaris; MaSa: Maculae sacculi; Mod: Modiolus; 
NP: Nanoparticle; PL: Perilymph; RM: Reissner’s membrane; Sa: Saccule; SGC: Spiral 
ganglion cell; SL: Spiral ligament; SM: Scala media; ST: Scala tympani; StrV: Stria 
vascularis; SV: Scala vestibuli; Ut: Utricle.
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to the darkened perilymph was visualized for the 
first time. Future modifications of POA@SPIONs 
may improve their ability to pass through the 
inner ear’s biological barriers, increasing their use 
as a diagnostic agent and traceable therapeutic 
nanoparticle using IT administration. 
Future perspective
The water solubility and high r2/r1 ratio make 
POA@SPIONs potentially important for medi-
cal application. Downsizing would be likely to 
enhance the penetration through the blood–
perilymph barrier and middle–inner ear bar-
riers and this is under development. Surface 
functionalization of POA@SPIONs is under 
development to make it serve as a molecule- 
specific contrast agent for the detection of 
pathologic molecular expression of proteins, 
such as TNF-a and VEGF, within the inner ear. 
Surface fabrication with HIV type 1 transactiva-
tor of transcription peptide is ongoing to make 
POA@SPIONs suitable for tracking IT drug or 
gene delivery. Last but not least, comprehensive 
toxicity evaluation of the finalized multifunc-
tional POA@SPIONs will be carried out. The 
above studies have been planned and will be 
completed over the next 5 years.
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Executive summary
Manufacturing & characterization of Pluronic® F127 oleic acid@superparamagnetic iron oxide nanoparticles
  Both size and shape of the superparamagnetic iron oxide nanoparticles (SPIONs) were retained after phase transfer from tetrahydrofuran 
to water. The final product, Pluronic® F127 oleic acid@SPIONs (POA@SPIONs), was water soluble and revealed a high r2/r1 ratio. 
MRI manifestation of POA@SPIONs in the inner ear after intracochlear administration 
  The endolymphatic compartment was visualized for the first time as isolated bright signal against the darkened perilymph, which 
contained negatively contrasting POA@SPIONs. This MRI manifestation of POA@ SPIONs in the perilymphatic space was confirmed 
by histology.
Limited passage of POA@SPIONs through the middle–inner ear barriers
  Following intratympanic administration, slight passage of POA@SPIONs through the middle–inner ear barriers was observed, but only by 
histology. MRI revealed no reliable detection of change in signal. 
No passage of POA@SPIONs through the blood–inner ear barriers
  POA@SPIONs did not pass through either the blood–perilymph barrier or the blood–endolymph barrier in their current form.
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Background: Gene therapy is a potentially effective therapeutic modality for treating 
 sensorineural hearing loss. Nonviral gene delivery vectors are expected to become extremely safe 
and convenient, and nanoparticles are the most promising types of vectors. However,  infrequent 
nuclear localization in the cochlear cells limits their application for gene therapy. This study 
aimed to investigate the potential nuclear entry of hyperbranched polylysine  nanoparticles 
(HPNPs) for gene delivery to cochlear targets.
Methods: Rat primary cochlear cells and cochlear explants generated from newborn rats were 
treated with different concentrations of HPNPs. For the in vivo study, HPNPs were adminis-
tered to the rats’ round window membranes. Subcellular distribution of HPNPs in different cell 
populations was observed with confocal microscope 24 hours after administration.
Results: Nuclear entry was observed in various cochlear cell types in vitro and in vivo. In the 
primary cochlear cell culture, concentration-dependent internalization was observed. In the 
cochlear organotypic culture, abundant HPNPs were found in the modiolus, including the spiral 
ganglion, organ of Corti, and lateral wall tissues. In the in vivo study, a gradient distribution of 
HPNPs through different layers of the round window membrane was observed. HPNPs were 
also distributed in the cells of the middle ear tissue. Additionally, efficient internalization of 
HPNPs was observed in the organ of Corti and spiral ganglion cells. In primary cochlear cells, 
HPNPs induced higher transfection efficiency than did LipofectamineTM.
Conclusion: These results suggest that HPNPs are potentially an ideal carrier for gene delivery 
into the cochlea.
Keywords: gene therapy, hearing loss, cochlea, internalization, nanoparticles, nuclear 
localization
Introduction
Gene therapy is a potentially effective therapeutic modality for treating congenital and 
acquired hearing loss by either changing mutant genes or upregulating critical gene 
expression.1–3 Regarding the gene delivery vectors, several viral vectors, including 
adenovirus,4,5 adeno-associated virus,6–8 lentivirus,9 herpes simplex virus type 1, and 
vaccinia virus,10,11 have shown encouraging results in gene therapy. However, their use 
is accompanied by potential toxicity, immunological complications, and insertional 
mutagenesis.12,13 Such genotoxic effects can result in oncogenesis or even death.14–16 
Therefore, they are still not regarded as safe systems for inner ear gene delivery.
Consequently, nonviral gene delivery vectors are expected to be safer and more 
convenient.17 Nanoparticles are the most promising gene carriers among the nonviral 
gene delivery vectors.18,19 Potential candidate nanoparticles, lipid nanocapsules, were 
International Journal of Nanomedicine 2011:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
536
Zhang et al
observed to distribute in the rat cochlear cell populations after 
round window membrane permeation.20 However, infrequent 
nuclear  localization in the cochlear cells limits their applica-
tion for gene therapy. Many studies have confirmed that in 
cells with cytoplasmic  plasmid delivery mediated by nonviral 
vectors, only those with evidence of nuclear plasmid local-
ization showed efficient transgene expression.21,22 Usually, 
transfection efficiency is facilitated in dividing populations 
of cells in which the nuclear envelope disassembles during 
 mitosis, thus largely eliminating this barrier. Unfortunately, 
most cochlear cell populations, especially spiral ganglion 
cells and hair cells, which are targets for gene therapy, do not 
actively undergo cell division during the gene transfer  process, 
making gene transfer mediated by cytoplasmic  plasmid deliv-
ery difficult. Thus, nuclear plasmid delivery induced by nano-
particles may be an option to improve transgene expression 
in nondividing or growth-arrested cells.23
Cationic polymers were reported to be potential  candidate 
nonviral vectors for nuclear delivery of plasmids which 
could promote transgene delivery to the nucleus in vitro.24–26 
 Hyperbranched polylysine nanoparticles (HPNPs) are 
 dendritic polymers with imperfectly branched or irregular 
structures, which are polydispersed and can be prepared in 
a single step on a large scale. Studies of the effects of such 
polymers on nuclear internalization by cochlear cells and 
on cell toxicity are scarce. Therefore, the present study was 
designed to investigate the potential nuclear entry of HPNPs 
in cochlear cells using both in vitro and in vivo experiments 
and depict information for developing novel  nanoparticles 
suitable for gene therapy in hearing loss. Nucleolin 
 distribution in the cultivated cochlear cells was analyzed. 
 Preliminary gene transfection mediated by HPNPs was tested 
in vitro. Furthermore, the viability of L929 mouse fibroblasts 
and cochlear cells treated by HPNPs was  evaluated by 
 CellQuanti-Blue reagent (BioAssay Systems, Hayward, CA) 
and propidium iodide, respectively.
Materials and methods
synthesis of hPNPs
HPNPs were synthesized by thermal polymerization of 
L-lysine hydrochloride and labeled with fluorescent dye, 
FITC (HPNPs without FITC tagging were used for gene 
transfection). The thermal polymerization of L-lysine 
hydrochloride was performed at 150°C in the presence of an 
alkaline metal base to neutralize the amine hydrochloride and 
to create the corresponding free amino acid base according 
to the procedure described by Scholl et al.27 Samples were 
purified by dialysis and gel filtration with a Sephadex column. 
The final product was recovered with 85% yield as an orange 
powder. Before usage in vitro or in vivo, the powder was dis-
solved in phosphate-buffered saline, resulting in a molecular 
concentration of 10–3 mol/L. The molecular weight, average 
hydrodynamic diameter, and polydispersity index of the 
HPNPs were determined by dynamic light scattering (Zeta-
sizer Nano ZS, Malvern  Instruments Ltd, UK; M
n
 = 22,000 g/
mol, hydrodynamic diameter = 73 nm,  polydispersity 
index = 1.9). The zeta potential of  polyplexes was also 
determined by dynamic light scattering. Encapsulation effi-
ciencies of plasmid DNA were calculated indirectly from 
the amount of nonencapsulated plasmid DNA recovered in 
the supernatant samples  collected upon centrifugation of the 
nanoparticles. The amount of recovered free plasmid DNA 
in the supernatant was determined by spectrophotometry 
 (NanoDrop® ND-1000, Wilmington, DE). The encapsulation 
efficiency was calculated as the ratio of the plasmid DNA 
loaded into the HPNPs to the total amount of plasmid 
DNA used for the preparation of the original mixture. The 
physicochemical characterization of polyplexes formed by 
complexation of HPNPs and plasmid DNA is summarized in 
Table 1. The surface morphology of the HPNPs was evaluated 
by scanning electron microscopy (Zeiss ULTRAplus, Bay-
ern, Germany), which showed spherical morphology and 
similar size to the dynamic light scattering measurement 
(Figure 1).
Primary cochlear cell culture
Thirteen newborn rats (1–5 days old) were decapitated after 
deep anesthesia and sterilization with 70% ethanol. The 
cochleae were isolated and cut into small pieces and then 
dissociated with a phosphate-buffered saline-based solution 
containing elastase 1 mg/mL (Sigma Aldrich, St Louis, MO), 
collagenase type I 1 mg/mL (Sigma Aldrich), and trypsin 
Table 1 Physicochemical characteristics of hyperbranched poly- 
 lysine nanoparticles loaded with pDNA (ie, pgeneclipTM hMgFP)
HPNPs/pDNA 
(w/w)a
Mean  
hydrodynamic 
diameter (nm)
Zeta  
potential 
(mV)
PDI EE (%)
1:1 234 ± 4.6 +17.1 0.192 83.4
2:1 155 ± 2.3 +14.1 0.236 82.8
3:1 139 ± 0.9 +19.8 0.204 85.5
4:1 147 ± 3.8 +20.3 0.216 87.9
5:1 134 ± 1.0 +23.3 0.222 92.6
6:1 137 ± 18.9 +19.1 0.254 91.7
Note: aN/P (w/w) ratio of polyplexes was varied from 1:1 to 6:1 (2.5 μg plasmid 
DNA and varying amounts of hPNPs were used to prepare the polyplexes).
Abbreviations: PDI, polydispersity index; EE, encapsulation efficiency; HPNPs, 
hyperbranched polylysine nanoparticles.
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0.5 mg/mL (Sigma Aldrich) for 30 minutes at 37°C. The 
digestion was terminated by adding 1 mL  DMEM-F12 (Sigma 
Aldrich) containing 10% fetal bovine serum (In vitrogen, 
Carlsbad, CA). After centrifugation for five minutes at 
250 × g, the cell pellets were  resuspended in 1 mL of defined 
medium (DMEM-F12 with B27 supplement, 1 mM n-acetyl-
L-cysteine, 1%  penicillin–streptomycin, and 20 ng/mL epider-
mal growth factor [Sigma Aldrich]) and plated into a four-well 
 Lab-Tek®II Chamber Slide (Nalge Nunc  International, 
Naperville, IL)  containing 1.0 mL defined medium/well. 
The cells were cultured at 37°C in a CO
2
 incubator overnight 
and then treated with HPNPs. HPNPs in defined cell culture 
medium with different  concentrations (final  concentrations: 
3 × 10−9 mol/L, 6 × 10−9 mol/L, 1.2 × 10−8 mol/L, 2.4 × 10−8 mol/L, 
4.8 × 10−8 mol/L, 9.7 × 10−8 mol/L, 1.94 × 10−7 mol/L, 
3.87 × 10−7 mol/L, 7.74 × 10−7 mol/L, 1.55 × 10−6 
mol/L, 3.13 × 10−6 mol/L, 5 × 10−6 mol/L, 6.25 × 10−6 mol/L) 
were freshly prepared, and 1 mL of each solution was applied 
to one well of the slide. After 24 hours of cell growth under 
the same conditions, the cells were incubated in defined 
DMEM-F12 medium containing 5 μg/mL propidium iodide 
(Sigma Aldrich) for 10 minutes, which was applied to evalu-
ate the change in cell membrane permeability and to identify 
the nuclei of dying cells in a population. After washing with 
phosphate-buffered saline for 3 × 1 minutes, cells were 
fixed with 4% paraformaldehyde for 30 minutes. The nuclei 
were stained with 4’, 6-diamidino-2-phenylindole (DAPI, 
10 ng/mL; Sigma Aldrich) for 10 minutes. Cells were then 
mounted with Fluoromount™ (Sigma Aldrich) for confocal 
microscopy (phosphate-buffered saline washes for 3 × 5 min-
utes were applied between each staining step). For nucleolin 
staining, the fixed cells were washed with phosphate-buffered 
saline for 3 × 1 minutes, incubated with 0.1% Triton X-100 
for 15 minutes, preinoculated goat serum (diluted at 1:20) for 
30 minutes, rabbit antinucleolin antibody (diluted at 1:100 
with 0.1% bovine serum albumin in phosphate-buffered 
saline [Sigma Aldrich]) overnight, TRITC-conjugated 
goat  antirabbit IgG (diluted at 1:400 with 0.1% bovine 
serum albumin in phosphate-buffered saline) for 60 minutes, 
and DAPI 10 ng/mL for 10 minutes. The cells were washed 
with phosphate-buffered saline containing 0.1% Tween 20 for 
3 × 2 minutes between each step and finally mounted with 
Fluoromount for confocal microscopy. For a negative control, 
the primary antibody was replaced with 0.1% bovine serum 
albumin in phosphate-buffered saline.
cochlear organotypic culture
Five newborn rats (1–5 days old) were decapitated after deep 
anesthesia and sterilization with 70% ethanol. Similar to the 
primary cochlear cell cultures, each cochlea was isolated, 
cut into 3–4 pieces, and plated into a four-well Lab-Tek®II 
Chamber Slide (Nalge Nunc International)  containing 
1.0 mL defined medium/well. The cochlear tissues were 
cultured at 37°C in a CO
2
 incubator  overnight and then 
treated with HPNPs at concentrations of 2.5 × 10−6 mol/L 
and 1 × 10−5 mol/L for 24 hours. At the end of the incubation, 
the cochlear tissues were washed with phosphate-buffered 
saline 3 × 3 minutes and fixed in 4% paraformaldehyde for 
30 minutes. After washing with phosphate-buffered saline, 
a selection of the specimens were counterstained with 
TRITC-labeled phalloidin 50 μg/mL (Sigma Aldrich) for 
40 minutes, DAPI 10 ng/mL for 10 minutes, and mounted 
with Fluoromount for confocal microscopy. The rest of the 
specimens were used for Myosin VIIA staining according 
to the following procedure. The specimens were incubated 
with 0.1% Triton X-100 for 15 minutes, preinoculated 
goat serum (diluted to 1:20) for 30 minutes, rabbit anti-
Myosin VIIA antibody (diluted to 1:100 with 0.1% bovine 
serum albumin-phosphate-buffered saline) overnight, 
TRITC-conjugated goat antirabbit IgG (diluted to 1:400 
0.1% bovine serum albumin-phosphate-buffered saline) 
for 60 minutes, and DAPI 10 ng/mL for 10 minutes. The 
specimens were washed with phosphate-buffered saline 
containing 0.1% Tween 20 for 3 × 2 minutes between each 
step, and were finally mounted with Fluoromount for con-
focal microscopy.
In vivo intratympanic hPNP 
administration
Six male Sprague-Dawley rats (3–10 months old) weighing 
400–750 g with a normal Preyer’s reflex were supplied by the 
Figure 1 scanning electron micrograph of hyperbranched polylysine nanoparticles. 
scale bar = 200 nm.
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experimental animal unit, University of Tampere. All animal 
experiments were approved by the University of Tampere 
ethical committee. Animal care and experimental procedures 
were conducted in accordance with European legislation. For 
intratympanic administration of HPNPs, the animals were 
under general anesthesia (medetomidine 0.5 mg/kg, Orion 
Pharma, Finland, and ketamine 75 mg/kg, Pfizer AB, Finland, 
given intraperitoneally). After local analgesia with lidocaine, 
a retroauricular incision was used to expose the left bulla. A 
hole was drilled on the bulla with a 2 mm diameter burr. After 
visualizing the stapedial artery, the round window membrane 
was identified above the artery. A small piece of gelatin sponge 
pledget (approximately 8 mm3 after saturation) saturated with 
10−3 mol/L HPNPs was placed on the round window mem-
brane for 24 hours. The operation was performed under sterile 
conditions. Atipamezole hydrochloride 2 mg/kg was injected 
intraperitoneally immediately after the operation to accelerate 
recovery from anesthesia. Saline 2 mL was administered by 
subcutaneous injection in the neck. L-Polamivet® 0.4 mL/kg 
was injected twice a day to relieve pain. After 24 hours, fol-
lowing intraperitoneal injections of pentobarbital 60 mg/
kg, the cochleae were fixed using cardiac perfusion with 
4% paraformaldehyde, and the bullae were collected and 
further fixed for 60  minutes. The cochleae were thoroughly 
washed with tap water for 30 seconds, opened by breaking 
the bony wall under a stereomicroscope, and then washed 
again with phosphate-buffered saline for 2 × 5 minutes. The 
bullae were incubated with DAPI 10 μg/mL for 10 minutes 
to stain the nuclei. After washing with phosphate-buffered 
saline for 3 × 5 minutes, the round window membrane, sta-
pedial artery, middle ear mucosa, lateral wall, and modiolus, 
together with the basilar membrane, were harvested using a 
stereomicroscope, placed on glass slides, and mounted with 
Fluoromount for confocal microscopy.
Cytotoxicity test in mouse fibroblasts
L929 mouse fibroblasts (American Type Culture  Collection 
number CCL 1, DSMZ, Braunschweig, Germany) were 
 cultured in DMEM culture medium (AppliChem,  Darmstadt, 
Germany) containing 4.5 mg/mL glucose, 10% fetal calf 
serum, 100 U/mL penicillin G, 100 μg/mL  streptomycin 
(PAA Laboratories, Cölbe, Germany), and NaHCO
3
 3.7 g/L 
at 37°C, 5% CO
2
, and 95% humidity. Cells were harvested 
by  trypsinization (PAA Laboratories) and seeded at a 
density of 2000 cells/well into a 96-well microtiter plate 
(Greiner Bio-one, Frickenhausen, Germany). The cells 
were cultured under the above  conditions for 24 hours and 
then treated with HPNPs. HPNPs were freshly prepared 
with cell  culture medium at different concentrations (final 
concentrations were 10−4 mol/L, 10−5 mol/L, 10−6 mol/L, 
10−7 mol/L, 10−8 mol/L, 10−9 mol/L, 10−10 mol/L, 10−11 mol/L, 
10−12 mol/L, 10−13 mol/L), and 200 μL of each solution was 
applied to one well of the microtiter plate. After 48 hours 
of incubation, the medium containing HPNPs was replaced 
by fresh medium containing 10% CellQuanti-Blue reagent, 
and the cells were cultivated for another two hours. Cellular 
reductase activity was quantified by resorufin fluorescence 
(Fluostar Optima, BMG, Offenburg, Germany; excitation 
wavelength 544 nm, emission wavelength 590 nm). Cel-
lular uptake of FITC-tagged HPNPs was quantified by cell 
fluorescence measurements (excitation wavelength 485 nm, 
emission wavelength 520 nm).
Preliminary hPNP-mediated  
gene transfection
We purchased the plasmid pGeneClipTM hMGFP, which 
encodes a shRNA to silence the inhibitor of differentiation 
and DNA binding-2 (Id2) transiently, and express the reporter 
gene EGFP (SuperArray, Bioscience Corp, Frederick, MD). 
NIH 3T3 cells (American Type Culture Collection, Manassas, 
VA) were cultured in flasks containing DMEM (Sigma 
Aldrich) supplemented with 10% fetal bovine serum 
(Invitrogen) and 4 mM L-glutamine (Sigma Aldrich). Four 
hours before transfection, the cells are trypsinized and 
replated into 12-well plates at a density of 3.5 × 105 cells per 
well in 1 mL of fresh medium. For each well to be transfected, 
2.5 μg plasmid DNA and varying amounts of HPNPs 
(N/P (w/w) ratios of polyplexes varied from 1:1 to 6:1) were 
added separately to 50 μL of 150 mM NaCl. Prior to addition 
to the culture, HPNP solution was added to the plasmid 
DNA solution and allowed to stand at room temperature for 
10 minutes. At four hours after transfection, another 1 mL 
fresh medium was added to the well, and the cells were 
incubated as before. Cochlear cells were also transfected 
with the pGeneClip hMGFP plasmid using HPNPs at an 
N/P (w/w) ratio of 5:1 and Lipofectamine 2000 (Invitrogen), 
respectively. Lipofectamine-mediated transfection was 
performed according to the manufacturer’s instructions. 
After 24 hours of transfection, the cells were fixed using 
4% paraformaldehyde. The nuclei were counterstained with 
DAPI for 10 minutes. Finally, the cells were mounted with 
Fluoromount for confocal microscopy.
confocal microscopy
The specimens were observed under an Olympus IX70 
microscope with ANDOR IQ installed. The excitation filters 
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were 488 nm (blue excitation) and 568 nm (green  excitation), 
and an Ar-Kr laser was used as the excitation source. The 
corresponding emission filters were 525/50 (FITC) and 
607/45 (TRITC). DAPI was excited with a 340–380 nm filter 
and detected using a 500 LP filter. The signal intensity was 
analyzed with Image J software.
statistical analysis
Cells expressing green fluorescent protein were counted 
as positive cells and cells with DAPI-counterstained 
nuclei were defined as total number of cells (104 cells 
were counted) using Image J software. Transfection 
efficiencies were calculated by dividing the number of 
green fluorescent protein positive-cells by the total number 
of cells. The signal intensity was corrected by the intensity 
of a randomly selected background region. The corrected 
mean values were analyzed with the SPSS program (v. 11.5, 
Chicago, IL). Differences in the levels of signal intensity 
among concentrations and cell populations were analyzed by 
analysis of variance. P , 0.05 was accepted as an indication 
of statistical significance.
Results
Internalization of hPNPs in primary 
cochlear cells
After 24 hours of incubation, efficient internalization of 
HPNPs was observed in primary rat cochlear cell cultures at 
all tested concentrations. The amount of HPNPs internalized 
by the cells was dosage-dependent, which means that the 
higher concentration of HPNPs applied to the medium, the 
greater the fluorescent intensity in the cochlear cells. This 
positive correlation was statistically significant (P , 0.001, 
analysis of variance, Figure 2). Nuclear entry of HPNPs was 
detected in different types of cochlear cells, including the 
hair cells and spiral ganglion cells at different concentrations 
(Figures 3–5). The higher the concentration of HPNPs, 
the more nuclear localization was observed (Figure 3). 
In the cochlear cells that were incubated with HPNPs at 
concentrations from 3.87 × 10−7 mol/L to 6.25 × 10−6 mol/L, 
homogenous and condensed distribution of HPNPs was 
detected in the entire nuclei (Figures 4 and 5). Nuclear 
permeation of propidium iodide, which indicates cell death, 
was also observed in cochlear cells treated with HPNPs at 
concentrations from 3.87 × 10−7 mol/L to 6.25 × 10−6 mol/L 
(Figures 4 and 5). In the outer hair cells, condensed 
distribution of HPNPs was visualized in the upper part of 
the cell body including cuticular plates, and nuclei. HPNP 
vesicles appeared in the hair bundles (Figures 5A–C). 
In the inner hair cells, cytoplasmic vesicles and condensed 
homogenous nuclear distribution of HPNPs were observed 
(Figures 5D–F). HPNPs were included in both cytoplasmic 
and nuclear vesicles when the cochlear cells were treated 
with HPNPs at concentrations below 3.87 × 10−7 mol/L 
(Figure 3). No permeation of propidium iodide was 
detected in the nuclei when the HPNPs concentration was 
lower than 3.87 × 10−7 mol/L, indicating that these cells 
were alive. Furthermore, the HPNP vesicles also indicate 
active nuclear entry of HPNPs into living cells instead of 
passive diffusion of HPNPs into the nuclei of dead cells in 
which homogenous and condensed distribution of HPNPs 
was detected in the entire nuclei (Figures 4G–I). However, 
nuclear permeation of propidium iodide was occasionally 
observed in spiral ganglion cells treated with HPNPs at a 
concentration of 9.7 × 10−8 mol/L (Figures 5G–I). Scarce 
perinuclear distribution of propidium iodide dots, together 
with HPNP vesicles, was observed in the cochlear cells 
(Figure 3B). Interestingly, nuclei compressed by HPNP 
vesicles and permeated with propidium iodide were also 
observed (Figures 5J–M). Nucleolin expression was detected 
in the cochlear cells. The subcellular distribution of nucleolin 
was in both the cytoplasm and nucleus (Figure 6). In the 
nucleus, most nucleolin was localized and condensed in 
the nucleolus. A HPNP vesicle pathway from the cytoplasm 
towards the nucleolin-positive nucleolus was also observed 
(Figure 6). Nucleolin was not detected in the negative control 
specimens.
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Figure 2 concentration-dependent internalization of hyperbranched polylysine 
nanoparticles in primary cochlear cell culture.
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hPNPs internalization in rat cochlear 
organotypic culture
In cochlear organotypic culture treated with HPNPs for 
24 hours, abundant HPNPs appeared in diverse cell types of 
the modiolus, organ of Corti, and the lateral wall (Figure 7). 
The hair cell region was demonstrated by Myosin VIIA 
staining (Figures 7A and B). Nuclear entry of HPNPs was 
frequently observed in these different cell types.
hPNPs in adult rat cochlear cells after 
round window membrane permeation
HPNPs were observed in the round window membrane, 
middle ear mucosa, organ of Corti, spiral ganglion, stria 
vascularis, spiral ligament, and stapedial artery cells at 
24 hours after round window membrane administration. 
HPNPs appeared in both layers of the round window 
membrane (Figure 8A). Homogenous condensed distribu-
tion of HPNPs was detected in the nuclei, and  cytosolic 
Figure 3 hPNP vesicle formation in both the cytoplasm and nuclei was observed at concentrations below 3.87 × 10−7 mol/L [A) 3.87 × 10−7 mol/L, B) 1.94 × 10−7 mol/L, 
C) 9.7 × 10−8 mol/L, D) 4.8 × 10−8 mol/L, E) 2.4 × 10−8 mol/L, F) 1.2 × 10−8 mol/L, G) 6 × 10−9 mol/L, and H) 3 × 10−9 mol/L]. Nuclear permeation of propidium iodide was 
not detected in these cells. Perinuclear distribution of dot-like propidium iodide vesicle was observed in B (arrow).
Notes: green: FITc-conjugated hPNPs. red: propidium iodide permeation. Blue: nuclear staining by DAPI. scale bar = 5 μm.
Abbreviation: hPNPs, hyperbranched polylysine nanoparticles.
HPNP vesicles were traveling from the outer layer 
towards the inner layer (Figure 8A). Additionally, there 
was a gradient of cytosolic HPNP vesicles from the outer 
layer to the inner layer ( Figure 8A). More pronounced 
nuclear entry was also observed in the outer layer of the 
round window membrane than in the inner layer. In the 
middle ear mucosal cells, HPNPs were observed in both 
the cytoplasm and nuclei ( Figure 8B). The distribution 
was condensed in the nuclei, and there was a very small 
amount of vesicles in the  cytoplasm. In the spiral gan-
glion cells, perinuclear distribution of HPNP vesicles 
was observed (Figure 8C). In the organ of Corti, HPNPs 
were detected in the cytoplasm of outer hair cells, inner 
hair cells, and supporting cells (Figure 8D). In the stria 
vascularis, HPNP vesicles appeared in the tight junctions, 
cytoplasm, and perinuclear region of the marginal cells 
(Figure 8E). In the spiral ligament fibrocytes, HPNPs 
mainly appeared in the  cytoplasm as vesicles ( Figure 8F). 
Abundant HPNPs were also detected in the stapedial artery 
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cells and appeared as vesicles in both the cytoplasm and 
nuclei (Figure 8G).
cytotoxicity of hPNPs in L929 cells
HPNPs at concentrations up to 10−7 mol/L were not toxic 
to L929 cells (Figure 9). However, higher concentrations 
of HPNPs showed low cytotoxicity, yielding an ED
50
 of 
10−6.2 mol/L. HPNPs labeled with FITC were visualized 
inside cells by confocal microscopy. The amount of HPNPs 
internalized by the cells was dosage-dependent, which 
was consistent with the results from the primary cochlear 
cells. The cell death rate was correlated with the HPNP 
internalization rate at concentrations up to 10−5 mol/L.
hPNPs-mediated transfection of the 
pgeneclip hMgFP plasmid in vitro
After 24 hours of incubation, NIH 3T3 cells were transfected 
with the pGeneClip hMGFP plasmid using HPNPs. 
To determine the optimum N/P (w/w) ratio, the N/P (w/w) 
ratio was varied from 1:1 to 6:1. N/P (w/w) ratios of 4:1 
and 5:1 resulted in the maximal level of green fluorescent 
protein expression. HPNP-mediated transfection efficiency 
in NIH 3T3 cells was 29.8% at an N/P (w/w) ratio of 5:1 
(Figure 10A). HPNP-mediated transfection efficiency in 
primary cochlear cell culture was 8.7% at an N/P (w/w) 
ratio of 5:1 (Figure 10B), which was higher than the 
Lipofectamine-mediated transfection efficiency of 6.0% 
(Figure 10C).
Discussion
The success of nonviral gene therapy has been largely 
 limited by inefficient gene delivery to cochlear cells due to 
the presence of the nuclear envelope barrier to gene transfer. 
The primary intention of this study was to demonstrate the 
potential of HPNPs as carriers for the delivery of genes to 
the nuclei of cochlear cells. Although it has been shown 
Figure 4 Internalization of hPNP-induced permeation of propidium iodide in primary cochlear cell culture. A–C) The cochlear cells were incubated with hPNPs at a 
concentration of 6.25 × 10−6 mol/L. B) Nuclear permeation of propidium iodide was observed in all the tested cells. C) shows the merged images of A and B. D–F) The 
cochlear cells were incubated with hPNPs at a concentration of 3.87 × 10−7 mol/L. E) Nuclear permeation of propidium iodide was observed in most of the cells. 
F) shows the merged images of D and E. G–I) Internalization of HPNP-induced permeation of propidium iodide in a single cell (higher magnification) at a concentration of 
6.25 × 10−6 mol/L. G) homogenous and condensed distribution of hPNPs was detected in the cytoplasm and entire nucleus. I) shows the merged images of G and H. 
Notes: green: FITc-conjugated hPNPs. red: propidium iodide permeation. Blue: nuclear staining by DAPI. scale bars: A–F = 100 μm, G–I = 10 μm.
Abbreviation: hPNPs, hyperbranched polylysine nanoparticles.
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that nanoparticles can enter the cytoplasm of cochlear cells, 
nuclear delivery remains problematic.20,28 HPNPs were 
detected in both the cytoplasm and nuclei of cochlear cells 
in primary cell culture, organotypic culture, and in vivo with 
intratympanic administration. The present results contrast 
with the results of an in vivo study performed in guinea pigs 
using HPNPs.28 Our explanation is that the nuclear entry of 
HPNPs is concentration-dependent; in the in vivo study, 
cochlear cells were exposed to much lower concentrations 
of HPNPs than in the in vitro study. The cells that are inte-
grated in the organ may behave differently from individual 
cells. Nuclear localization of HPNPs was intense in the round 
window membrane cells of rats, but was rarely observed 
in the cochlear cells. The different methods of delivering 
the HPNPs and the biological differences between rats and 
guinea pigs should also be considered as an explanation for 
our results.
Concentration-dependent toxicity occurred in the primary 
cochlear cell culture, and most of the cells died when treated 
with HPNPs at the concentration of 3.87 × 10−7 mol/L 
(10−6.4 mol/L), whereas the ED
50
 for HPNP-treated L929 cells 
was 10−6.2 mol/L. This finding indicated that certain cell types 
in primary cochlear cell cultures may be more vulnerable 
to HPNP treatment than L929 cells. Spiral ganglion cells 
died when treated with HPNPs at a concentration of 
9.7 × 10−8 mol/L, which further supported this hypothesis, 
because neurons are highly sensitive to hazardous substance 
exposure. It seems contradictory that dead cells take up the 
highest amount of nanoparticles (Figure 9, 10−5 mol/L HPNPs). 
Figure 5 Death of different cochlear cell populations was induced by hPNP internalization. A–F) Internalization of hPNPs by the cochlear hair cell. cytoplasmic vesicles 
and condensed homogenous nuclear distribution of hPNPs appeared in the outer hair cell incubated with 3.87 × 10−7 mol/L hPNPs (A–C) and inner hair cell incubated with 
5 × 10−6 mol/L hPNPs (D–F). Vesicles were observed in the hair bundles (arrows in A and C). Figures B and E showed the permeation of propidium iodide. G–I) spiral 
ganglion cell death was induced by hPNP internalization at a concentration of 9.7 × 10−8 mol/L (Arrow in G shows hPNPs in the neural soma of spiral ganglion cell). H) shows 
the permeation of propidium iodide. I) shows the merged images of G and H (Arrow: nerve fiber. Arrow head: nuclei of Schwann cell). J–M) The nucleus was compressed 
by hPNP vesicles, and propidium iodide permeated the nucleus when the cells were exposed to 3.87 × 10−7 mol/L hPNPs (arrows). M is the merged image. 
Notes: green: FITc-conjugated hPNPs. red: propidium iodide permeation. Blue: nuclear staining by DAPI. scale bars: A–C = 5 μm, D–F = 7.1 μm, G–M = 5 μm.
Abbreviation: hPNPs, hyperbranched polylysine nanoparticles.
Figure 6 A hPNP vesicle pathway from the cytoplasm towards the nucleolin-
positive nucleolus was observed in the primary cochlear cell culture exposed to 
hPNPs (arrows in A and C). 
Notes: green: FITc-conjugated hPNPs. red: nucleolin. Blue: nuclear staining by 
DAPI. scale bar = 10 μm.
Abbreviation: hPNPs, hyperbranched polylysine nanoparticles.
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Figure 7 Uptake of hPNPs in the cochlear organotypic culture. The tissues were incubated with 2.5 × 10−6 mol/L (A, B) and 1 × 10−5 mol/L (C, D) hPNPs for 24 hours. 
A and B are merged images of hPNPs, Myosin VIIA, and DAPI in the modiolus (A) and organ of corti (B). C) low magnification and D) higher magnification are merged 
images of hPNPs, F-actin, and DAPI in the lateral wall. 
Notes: green: FITc-conjugated hPNPs. red: Myosin VIIA (A, B), F-actin stained by TrITc-conjugated phalloidin (C, D). Blue: nuclear staining by DAPI. scale bars: 
A, C = 103.4 μm, B, D = 10 μm.
Abbreviation: hPNPs, hyperbranched polylysine nanoparticles.
Figure 8 Uptake of hPNPs in the cochlea 24 hours after round window membrane administration in an adult rat. A gelatin sponge was immersed in 10−3 mol/L hPNPs 
and placed on the round window membrane. A) Lateral view of reconstructed three-dimensional image of the round window membrane showing the gradient distribution 
of hPNPs; both condensed homogenous nuclear distribution of hPNPs (arrow head) and hPNP vesicles (arrow) were observed. B) Middle ear mucosal uptake of hPNPs. 
condensed homogenous nuclear distribution of hPNPs (arrow head) and hPNP vesicles (arrow) were detected. C) Perinuclear distribution of hPNPs was observed in 
the spiral ganglion cell (arrow). D) hPNPs were found in the organ of corti. cytoplasmic distribution of hPNPs was observed in the hair cells, and both cytoplasmic and 
perinuclear distribution of hPNPs was detected in the supporting (border) cells. E) Both cytoplasmic and nuclear distribution of hPNPs was detected in the stria marginal 
cells, the typical tight junctions of the stria marginal cells are shown using F-actin staining (arrow). F) Abundant HPNPs were observed in the spiral ligament fibrocytes. 
G) Abundant hPNPs were detected in the endothelium of the stapedial artery including the nuclear hPNP vesicles (arrow). 
Notes: green: FITc-conjugated hPNPs. red: F-actin stained by TrITc-conjugated phalloidin. Blue: nuclear staining by DAPI. scale bar = 10 μm.
Abbreviations: Bc, border cells; hPNPs, hyperbranched polylysine nanoparticles; Ihc, inner hair cell; Is, inner side of the round window membrane; Ohc, outer hair cell; 
Os, outer side of the round window membrane; 1, 2, 3: row 1, row 2, and row 3 of Ohc. 
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The fluorescence signal merely indicated fluorescence 
associated with material adhering to the bottom of the 
microtiter well. Microscopic inspection showed that the 
cells were damaged, which led to binding of the HPNPs to 
the DNA such that the nuclei were brightly labeled, which 
corresponded to a strong fluorescence signal. As a cell death 
indicator, the cochlear cells stained by propidium iodide had 
a dot-like appearance in the perinuclear region (Figure 3B) 
which was different from that reported in the literature.29 
It is obvious that the typical homogenous nuclear staining of 
propidium iodide indicated cell death. In primary cochlear 
cell cultures, higher concentrations of HPNPs incubation 
caused cell death (Figures 4 and 5). The dot-like perinuclear 
appearance of propidium iodide staining within the cochlear 
cells without nuclear staining suggested that these were viable 
cells (Figure 3B). The simultaneous nuclear distribution 
of HPNP vesicles and dot-like perinuclear appearance of 
propidium iodide (Figure 3B) also indicated active transport 
of HPNP in living cells. It should also be pointed out that 
HPNPs-containing vesicles are only detectable in living cells 
because passive diffusion of HPNPs into the nuclei following 
cell death will show homogenous distribution. As a result, 
nuclear entry of HPNPs was a meaningful biological process 
instead of a consequence of cell death.
Regarding the mechanism of nuclear import, there 
are potentially several pathways, such as nucleolin sig-
naling,  cellular membrane penetration, and the nuclear 
localization signal pathway, among others.30–33 One potential 
mechanism by which HPNPs mediate nuclear entry may be 
internalization and transport into the nucleus via binding to 
nucleolin.  Nucleolin is a ubiquitous eukaryotic protein that 
is conserved from yeast to mammals, and is found in the 
nucleoli, nucleoplasm, and on the cell surface.34,35 Nucleolin 
is able to shuttle between the plasma membrane, cytoplasm, 
and nucleus, and regulates many aspects of DNA and RNA 
metabolism.34,36 It has been reported that nucleolin is the 
cell surface target of DNA nanoparticles, and that nucleolin 
is essential for internalization and/or transport of the DNA 
nanoparticles from the cell surface to the nucleus.30 This 
was also indicated in our study, as demonstrated by the 
HPNP vesicle pathway from the cytoplasm towards the 
nucleolin-positive nucleolus (Figure 6). A recent report 
showed that nucleolin-mediated cellular trafficking of DNA 
nanoparticles is lipid raft- and microtubule-dependent, and 
can be modulated by glucocorticoids.37 Another potential 
mechanism is that the nuclear envelope penetration or fusion 
is potentially involved in the nuclear internalization of 
HPNPs by cochlear cells.25,33,38 It is possible that the HPNPs 
internalized within the cytoplasm are retained and tethered 
to the inner surface of the vesicle, and thereafter transported 
into the nuclei by molecular machinery (such as dyneins) 
along cytoskeletal tracks.33,38 Nuclear localization signal-
mediated nuclear transport of HPNPs is also a potential 
Figure 10 hPNP-mediated transfection in NIh 3T3 cells and primary cochlear cells with the pgeneclipTM hMGFP plasmid observed by fluorescent microscopy. 
A) The transfection efficiency mediated by HPNPs at an N/P (w/w) ratio of 5:1 in NIH 3T3 cells was 29.8%. B) The transfection efficiency mediated by HPNPs at an N/P 
(w/w) ratio of 5:1 in cochlear cells was 8.7%. C) Positive control, the transfection efficiency mediated by LipofectamineTM in cochlear cells was 6.0%, which is lower than the 
transfection efficiency mediated by HPNPs. 
Notes: green: Green fluorescent protein expression. Blue: nuclear staining by DAPI. Scale bar = 100 μm.
Abbreviation: hPNPs, hyperbranched polylysine nanoparticles.
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Figure 9 The cell viability of L929 mouse fibroblasts is dependent on the 
concentration of hPNPs applied. The eD50 was calculated as 10
−6.2 mol/L (dashed line). 
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mechanism, which requires the presence of cytosolic factors 
and adenosine triphosphate.39,40 We cannot rule out the pos-
sibility that HPNPs bind to specific cytosolic proteins in 
the primary newborn rat cochlea cells and pass through the 
nuclear pore complex. However, the present study did not 
prove or disprove this hypothesis.
Finally, the internalization of HPNPs by the cochlear cells 
was not specific for any cellular population. This did not meet 
our goal of targeted gene delivery into the cochlea. However, 
the functionalization of HPNPs with specific peptides for 
a definite cell population of the cochlea may improve the 
targetability of these nanoparticles. Specific targeting and 
higher binding affinity to spiral ganglion neurons has been 
observed in PEGylated polysome nanoparticles functional-
ized by a neurotrophin-derived peptide.41 HPNPs can also be 
included in other nanoparticles, such as lipid nanoparticles, 
to achieve both ideal targetability and efficient gene expres-
sion in cochlear cells.
Conclusion
In conclusion, efficient internalization of HPNPs was observed 
in both the cytoplasm and nucleus of cochlear cell culture, 
cochlear organotypic culture, and in vivo round window 
membranes. High transfection efficiencies were achieved in 
HPNP-mediated gene transfer in NIH 3T3 cells. These suggest 
that HPNPs have a potential application in gene delivery to 
the cochlea. To pass through the round window membrane 
and deliver genes into the cochlea efficiently, it is necessary 
to modify the nanoparticle surface to avoid early nuclear entry 
into the cells of the round window membrane.
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Abstract
Background In recent years, Math1 gene therapy was indicated to
be the future therapy for deafness in combination with other growth
factors. However, Math1 delivery using adenovirus-mediated gene delivery
or electroporation was impractical. The contribution of Math1 in the
combined procedure was not clearly elucidated using the existing plasmids.
Nonviral gene delivery vectors are expected to be extremely safe and
convenient. The present study aimed to construct the pCDNA6.2/C-EmGFP-
Math1 plasmid and evaluate its transfection efficiency and intracellular
trafficking of Math1 protein corresponding to transcription regulation
function.
Methods After constructing the pCDNA6.2/C-EmGFP-Math1 expression
plasmid, the plasmid was transfected into different cell lines and
primary cochlear cells using Lipofectamine 2000. Transfection efficiencies
of the plasmid were evaluated. Transfection efficiencies using liposome
nanoparticles containing Math1 plasmid were also assessed. Intracellular
trafficking of Math1 was monitored using confocal microscopy.
Results Different cell types can be transfected with high transfection
efficiencies by the pcDNA6.2/C-EmGFP-Math1 plasmid using Lipofectamine
2000. Liposome nanoparticles containing the Math1 plasmid expressed the
gene with variable efficiencies, depending on the particle size, surface
charge and PEGylation status. Unique intracellular trafficking of Math1
was demonstrated in different cell types.
Conclusions The newly-constructed plasmid pcDNA6.2/C-EmGFP-Math1
was suitable for nonviral gene delivery of Math1. Unique intracellular
trafficking of Math1 with dynamics from the cytoplasm to the nucleus was
demonstrated. The modification of mesenchymal stem cells by Math1 gene
delivery and by brain-derived neurotrophic factor and glial cell line-derived
neurotrophic factor treatments can potentially be applied to cell replacement
for the treatment of cochlear spiral ganglion cell loss in deafness. Copyright
 2011 John Wiley & Sons, Ltd.
Keywords gene therapy; gene transfer; Math1; nanoparticles; plasmid;
transfection
Introduction
Regenerative medicine represents the future therapeutic strategy for treating
deafness. The mouse atonal homologue Math1 was reported to be the master
Copyright  2011 John Wiley & Sons, Ltd.
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regulatory gene involved in the development of cochlear
hair cells and neurons in both the mouse and rat
[1–6]. Experimental overexpression of Math1 has been
demonstrated to induce the generation of new hair cells
in vitro [3,7] and in vivo [8–10]. Math1-based gene
therapy to produce functional supernumerary hair cells
in mouse [10] and to restore hearing in guinea pigs
deafened by ototoxic drug [9] has been proposed. In
all the reported studies, Math1 gene was delivered by
either adenovirus or electroporation. Obviously, naked
DNA delivery by electroporation is not an applicable
technique for use in clinical gene therapy. Although the
practice of using adenoviral vectors has been associated
with high transfection efficiency, there are safety problems
associated with these vectors, such as immunogenicity
and insertional mutagenesis [11–13]. Such side effects
can result in serious problems or even death [14,15].
Furthermore, adenoviral vectors have several intrinsic
drawbacks, including difficulties in large-scale production
yields, limited opportunity for repeated administrations,
limitations in the size of the carried therapeutic genes and
inefficient targeting to specific cells in vivo.
By contrast, nonviral vectors can circumvent many of
the problems associated with viral vectors. Nonviral vec-
tors have shown to be non-immunogenic or to induce a
low immunogenic response, and they do not have the
safety problems that have been associated with viral vec-
tors. Moreover, nonviral vectors have additional advan-
tages in terms of their ease of manipulation and large-scale
production, potential for cell specificity and high flexibil-
ity in the size of the delivered gene. Nanoparticles are
one of the most promising gene carriers among the non-
viral gene delivery vectors [16,17]. Potential candidate
nanoparticles, such as lipid nanocapsules and liposomes,
have been observed to distribute in the cochlear cells of
guinea pigs [18] and rats [19]. Data for the application of
nanoparticles as a gene carrier of Math 1 are unavailable.
In the present study, a novel non-viral vector to express
Math1-EmGFP (emerald green fluorescent protein) fusion
protein was constructed using the pcDNA 6.2/C-EmGFP-
DEST backbone. An advantage of this plasmid is that
visualization of the intracellular trafficking of Math1 pro-
tein is easy because of its bright signal, which is important
for the gene product to perform its transcription function.
Mouse embryonic and adult fibroblast have been induced
to become pluripotent stem cells and shown therapeutic
potential for spinal cord injury and inner ear hair cell
loss [20–22]. NIH 3T3 cells (a spontaneously immortal-
ized fibroblast cell line) have the potential to differentiate
into spiral ganglion neurons. A human neuroblastoma
cell line (SH-SY5Y cell) differentiated into neuronal cells
after retinoic acid and herbimycin A treatment [23]. Bone
marrow mesenchymal stem cells (MSCs) have the capa-
bility of differentiating into neuronal cells under specific
conditions [24,25]. Therefore, these three cell types were
transfected with the new Math1 expressing plasmid to
acquire data for future studies on the spiral ganglion neu-
ron orientated differentiation. Pluripotent stem cells from
the adult mouse inner ear are capable of differentiating
into hair cell-like cells after involvement of Math1 [26].
Because the regenerative capability of each cell popula-
tion within the cochlea has not been fully clarified, we
evaluated the transfection of mixed primary cochlear cell
cultures using our newly-constructed Math1 expression
plasmid as a pilot study in this application. Transfec-
tions were mediated by Lipofectamine 2000, and further
evaluated using liposome nanoparticles.
Materials and methods
Construction of pcDNA6.2/C-EmGFP-
Math1 plasmid
The Math1 coding fragment was amplified from pCLIG-
Math1 plasmid (provided by R. Kageyama Kyoto
University, Kyoto, Japan) by polymerase chain reaction
(PCR) using 5′-GCG ATG TCC CGC CTG CTG CA-3′ as
the forward primer and 5′-AAA ACT GGC CTC ATC
AGA GTC-3′ as the reverse primer. For generation of
an EmGFP C-terminally tagged Math1 expression clone,
we used the Gateway recombination system (Invitrogen).
The entry clone, pENTR/D-TOPO containing the Math1
open reading frame, was obtained using the pENTR
Directional TOPO Cloning Kit (Invitrogen). Once the
entry clone was obtained, a LR recombination reaction
was performed for transfer of Math1 open reading
sequence into a Vivid Colors pcDNA 6.2/C-EmGFP-DEST
vector to create an EmGFP C-terminally tagged Math1
expression clone. The EmGFP sequence from pcDNA
6.2/C-EmGFP-DEST was ligated to the 3′ end of the Math1
coding sequence with a short linking peptide (13 amino
acids). The pcDNA6.2/C-EmGFP-Math1plasmid was first
analyzed by PCR (M13 forward primer and M13 reverse
primer provided by Invitrogen) to confirm the presence
and the size of the insert. The plasmid was sequenced
to further verify the integrity of the Math1 gene and its
orientation in the vector.
Cell cultures and gene transfection
mediated by Lipofectamine
NIH 3T3 cells (ATCC, Boras, Sweden) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma,
St Louis, MO, USA) supplemented with 10% fetal
bovine serum (FBS) (Invitrogen, USA) and 4 mM L-
glutamine. SH-SY5Y cells (ATCC) were cultured in DMEM
supplemented with 15% FBS and 2 mM L-glutamine.
Bone marrow MSCs (Biosite, San Diego, CA, USA)
were cultured in Qualified RMSC medium (Biosite)
supplemented with 10% FBS. Primary cochlear cells were
obtained from newborn rats. Newborn (1–5-day-old) rats
were sacrificed by decapitation after deep anesthetization
and sterilization with 70% ethanol. After removing the
bony otic capsule in DMEM, membranous structures
of the whole cochleae were cut into small pieces,
Copyright  2011 John Wiley & Sons, Ltd. J Gene Med 2011; 13: 134–144.
DOI: 10.1002/jgm
136 W. Zhang et al.
Table 1. Tested nanoparticles
Code Fluorophore (TRITC) Gene Liposome size (nm) Lipoplexs size (nm)
No pDNA Math1 75 125± 15
LPX Yes pDNA Math1 90 125± 15
LPX-PEG Yes pDNA Math1 87 125± 15
LPX-DOPE (1.2:1) No pDNA Math1 64 3404
LPX-DOPE (2:1) No pDNA Math1 64 255
and then dissociated with a phosphate-buffered saline-
based solution containing elastase (1 mg/ml; Sigma),
collagenase type I (1 mg/ml; Sigma), and trypsin
(0.5 mg/ml; Sigma) for 30 min at 37 ◦C. The digestion
was terminated by adding 1 ml DMEM-F12 (Sigma)
containing 10% FBS. After centrifugation for 5 min
at 250 g, the cell pellets were resuspended in 1 ml
of defined medium [DMEM-F12 with B27 supplement,
1 mM n-acetyl-L-cysteine, 1% penicillin–streptomycin and
20 ng/ml epidermal growth factor (EGF) (Sigma)]. Cells
were cultured in four-well Lab-Tek II Chamber Slides
(Nalge Nunc International, Naperville, IL, USA) and
maintained at 37 ◦C in a humidified atmosphere of 5%
CO2 for all experiments.
The cells were transfected with pcDNA6.2/C-EmGFP-
Math1 plasmid using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA), in accordance with the manufac-
turer’s instructions. As a negative control of intracellular
trafficking of gene product, the pcDNA6.2/C-EmGFP-
BDNF plasmid was used to transfect NIH 3T3 cells and
shows the cytoplasmic location of brain-derived neu-
rotrophic factor (BDNF), which is different from the
nuclear distribution of Math1. Transfecting NIH 3T3 cell
with pCLIG-Math1 plasmid was performed as a refer-
ence. After 24 h of transfection, the cells were fixed
using 4% paraformaldehyde. The cytoplasm was counter-
stained with 50 µg/ml TRITC-labeled phalloidin (Sigma)
and nuclei were counterstained with 4′,6-diamidino-2-
phenylindole (DAPI) (Sigma). Finally, the cells were
mounted with fluoromount for confocal microscopy.
Biological function test of the EmGFP-
fused Math1 protein in MSCs
After 48 h, MSCs transfected with the pcDNA6.2/C-
EmGFP-Math1 plasmid and control plasmid pcDNA6.2/C-
EmGFP-CAT, which allows for the expression of a
C-terminally tagged chloramphenicol acetyl transferase
(CAT) fusion proteion described above, were digested
using trypsin. Fluorescence activated cell sorting was
performed to sort for EmGFP positive cells. EmGFP
positive cells were plated in a tissue culture dish and
treated with 10 ng/ml BDNF and 10 ng/ml glial cell
line-derived neurotrophic factor (GDNF) (Invitrogen).
MSCs which were treated only with 10 ng/ml BDNF and
10 ng/ml GDNF was also used as a control experiment.
After 2 weeks, the cells were fixed and treated with
0.5% Triton X-100, nonspecific binding sites were
blocked using goat serum (diluted 1:20 in 0.1% bovine
serum albumin), the neural specific protein was probed
with rabbit anti-neurofilament-200 (NF-200) (Sigma)
overnight at 4 ◦C, and immunoconjugates were detected
using fluorescein isothiocyanate (FITC)-labeled goat anti-
rabbit immunoglobulin (Ig)G (Sigma). After staining with
10 µg/ml DAPI, cells were mounted with fluoromount and
examined using confocal microscopy.
Preparation of lipoplexes
Dihexadecyldimethylammoniumbromide (DHAB), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N [meth-
oxy (polyethylene glycol)-2000] (ammonium salt) [DSPE-
PEG2000], egg phosphatidylcholine (EggPC) and 1,2-
dioleoyl-sn-glycero-3 phosphoethanolamine (DOPE) were
obtained from Avanti Polar Lipids (Alabaster, AL). N-(6-
tetramethylrhodaminethiocarbamoyl)-1,2-dihexade-
canoyl-sn-glycero-3-phosphoethanolamine, triethylam-
monium salt (TRITC-DHPE) was purchased from
Molecular Probes (Eugene, OR, USA). Liposome
nanoparticles were prepared as described previously [27].
The liposome nanoparticles were mixed with plasmid
DNA (Math1) at a lipid/DNA molar charge ratio (+/−)
of 1.2:1 or 2:1 to obtain liposome-DNA nanoparticles,
also termed lipoplexes. The final concentration of lipids
in both lipoplexes was 0.1 mM or 1 mM. The nanopar-
ticles obtained (Table 1) were: LPX (DHAB/eggPC
= 1:1), TRITC labeled LPX (DHAB/EggPC/TRITC =
0.5:0.47:0.03), LPX-PEG (DHAB/EggPC/TRITC/XDSPE-
PEG-2000 = 0.5:0.47:0.03:0.01), LPX-DOPE (1.2:1)
[DHAB/eggPC/DOPE = 0.5:0.4:0.1, lipid/DNA molar
charge ratio (+/−) of 1.2:1] and LPX-DOPE (2:1)
[DHAB/eggPC/DOPE = 0.5:0.4:0.1, lipid/DNA molar
charge ratio (+/−) of 2:1].
Liposome nanoparticles mediated gene
transfection
NIH 3T3 cells, SH-SY5Y cells and primary cochlear cells
were incubated with 0.2 mM or 0.02 mM lipoplexes in
DMEM medium without serum. After 6 h, the transfection
medium was replaced with fresh complete medium
and the cells were incubated for another 24 h under
the same incubation conditions. After confirmation
of EmGFP-fused Math1 using fluorescent microscopy,
cells were fixed with 4% paraformaldehyde, and the
nuclei were counterstained with DAPI and TRITC-labeled
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phalloidin. Cells were then mounted with fluoromount
for examination using confocal microscopy.
Western blot analysis
Nuclear proteins of NIH 3T3 cells transfected by
pcDNA6.2/C-EmGFP-Math1 plasmid were extracted by
CelLytic NuCLEAR Extraction Kit (Sigma). The pro-
teins were separated in a 10–20% Criterion Peptide
Gel (Bio-Rad, Hercules, CA, USA) and electrophoreti-
cally transferred onto a polyvinylidene fluoride membrane
(Bio-Rad). The membrane was probed with primary anti-
body, rabbit anti-GFP IgG (Invitrogen) and horseradish
peroxidase-conjugated secondary antibody, goat anti-
rabbit IgG (Thermo Fisher Scientific Inc., Waltham, MA,
USA). Hybridizing bands were visualized using a Pierce
ECL Western Blotting Substrate kit (Thermo Fisher Scien-
tific Inc.).
Fluorescent microscopy and confocal
microscopy
Cells transfected with the plasmids were observed and
imaged using a fluorescent microscope (Nikon ELLIPSE
TE2000; Nikon, Tokyo, Japan) or a confocal microscope.
Cells expressing GFP were counted as positive cells and
cells with DAPI counterstained nuclei or visualized by
bright field images were defined as total number of
cells using Image J (http://rsb.info.nih.gov/nih-image).
Transfection efficiencies were calculated by dividing the
number of GFP positive cells by the total number of
cells. The subcellular distributions of Math1 and BDNF
were observed in fixed cells using confocal microscopy.
An Olympus IX70 microscope installed with ANDOR IQ
was employed. The excitation filters were 488 nm (blue
excitation) and 568 nm (green excitation), and an Ar-Kr
laser was used as the excitation source. The corresponding
emission filters were 525/50 (FITC) and 607/45 (TRITC).
DAPI was excited using a 340–380 nm filter and detected
using a 500 LP filter.
Statistical analysis
Statistical analyses were performed using SPSS, version
11.5 (SPSS, Chicago, IL, USA). Significant differences
were identified using one-way analysis of variance and a
Bonferroni test was used for pairwise multiple compar-
isons. p < 0.05 was considered statistically significant.
Results
Characterization of the
pcDNA6.2/C-EmGFP-Math1 plasmid
Agarose gel electrophoresis of the PCR product using
pCLIG-Math1 plasmid as the template showed the product
Figure 1. (A) Agarose gel electrophoresis of PCR product using
pCLIG-Math1 plasmid as template. The size of the Math1
fragment inserted into the pcDNA6.2/C-EmGFP vector was 1050
bp. (B) Western blot analysis of nuclear proteins extracted from
NIH 3T3 cells after transfection with the pcDNA6.2/C-EmGFP-
Math1 plasmid. The size of the positive band is 60 kDa and
72 kDa [52–54], which corresponds to the EmGFP-Math1 fusion
protein. (B, 1) The positive band with 72 kDa is the size of
the EmGFP-Math1 fusion protein. (B, 2) The positive band with
60 kDa also is the size of EmGFP-Math1 fusion protein. (B, 3)
An unknown band was also detected at the position between
25 kDa and 35 kDa
size was 1050 bp, which is identical to the original
amplicon (Figure 1A). Sequencing of the final plasmid
pcDNA6.2/C-EmGFP-Math1 confirmed that the Math1
gene was cloned in the correct orientation and that the
integrity of the nucleotide sequence of the inserted gene
was completely consistent with Gene Bank annotation.
Lipofectamine-mediated transfection
of pcDNA6.2/C-EmGFP-Math1 plasmid
in defined cell types
NIH 3T3 cells were transfected with the pcDNA6.2/C-
EmGFP-Math1 plasmid, pcDNA6.2/C-EmGFP-BDNF plas-
mid and pCLIG-Math1 plasmid using Lipofectamine 2000.
After 24 h of incubation, variable transfection efficiencies
were observed for the three plasmids (Figure 2). The
plasmid pcDNA6.2/C-EmGFP-Math1 showed the high-
est transfection efficiency (11.7%); plasmid pCLIG-Math1
showed the lowest transfection efficiency (3.0%); and the
transfection efficiency of pcDNA6.2/C-EmGFP-BDNF was
7.2%. By microscopy, the fluorescence of EmGFP-Math1
fusion protein and EmGFP-BDNF fusion protein in NIH
3T3 cells was vivid emerald, which was very bright and
easily detected, whereas the fluorescence of GFP in NIH
3T3 cells expressed by the pCLIG-Math1 plasmid was
faint.
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Figure 2. Lipofectamine 2000 mediated transfection of NIH 3T3 cells with pcDNA6.2/C-EmGFP-Math1 plasmid, pcDNA6.2/C-EmGFP-
BDNF plasmid and pCLIG-Math1 plasmid shown by fluorescent microscopy. The transfection efficiencies of the three plasmids were
11.7%, 7.2% and 3.0%, respectively. (A) pcDNA6.2/C-EmGFP-Math1 plasmid. (B) pCLIG-Math1 plasmid. (C) pcDNA6.2/C-EmGFP-
BDNF plasmid. (D–F) Higher magnification of NIH 3T3 cell transfected with the pCLIG-Math1 plasmid without showing trafficking
vesicles. (D) EGFP in the cytoplasm. (E) Contrast staining of nuclei with DAPI. (F) Merged image of (D) and (E). Scale bar = 100 µm
(A–C), 10 µm (D–F)
Figure 3. Subcellular localization of EmGFP-Math1 fusion protein in different cell types transfected by pcDNA6.2/C-EmGFP-Math1
plasmid using Lipofectamine 2000 shown by confocal microscopy. (A–E) NIH 3T3 cells. (F–G) Bone marrow mesenchymal stem
cells (MSCs). (H) Positive control of NIH 3T3 cell transfected with pcDNA6.2/C-EmGFP-BDNF plasmid. Nuclear localization of
EmGFP-Math1 fusion protein demonstrated in NIH 3T3 cells and MSCs (A, C, E, F, G). Cytoplasmic localization of EmGFP-BDNF
fusion protein appeared in NIH 3T3 cells (H). Simultaneous cytoplasmic and nuclear localization of EmGFP-Math1 fusion protein
appeared in NIH 3T3 cells (B, D). Encapsulation of EmGFP-Math1 fusion protein into vesicles with variable sizes, with a diameter
in the range 0.4–2 µm, appeared in NIH 3T3 cells and MSCs (C, D, E, G). Green: EmGFP-Math1 fusion protein (A–G), EmGFP-BDNF
fusion protein (F); blue: contrast staining of nuclei with DAPI; red: F-actin stained by TRITC-conjugated phalloidin. Scale bar
= 10 µm
Western blot analysis of nuclear proteins extracted from
NIH 3T3 cells that were transfected with pcDNA6.2/C-
EmGFP-Math1 plasmid showed that the size of the positive
band was 60 kDa and 72 kDa, matching the size of Math1
protein tagged with GFP (Figure 1B).
MSCs and primary cochlear cells were also successfully
transfected with pcDNA6.2/C-EmGFP-Math1 plasmids
(Figs 3F, 3G, 4 and 5). The transfection efficiency of the
pcDNA6.2/C-EmGFP-Math1 plasmid varied in different
cell types: 2.9% in primary cochlear cells, 5.1% in MSCs
and 11.7% in NIH 3T3 cells (Figures 2A and 4A). In
primary cochlear cell culture, fibrocytes, spiral ganglion
neuron and hair cell-like cells were transfected with the
pcDNA6.2/C-EmGFP-Math1 plasmid (Figures 4 and 5).
The transfection efficiency of different cell populations
was not quantified; however, fibrocytes and spiral
ganglion neuron, the two major populations in the
primary cochlear cells, were frequently viewed to express
EmGFP under a confocal microscope.
Subcellular location of the EmGFP-
Math1 fusion protein
In most cells, the EmGFP-Math1 fusion protein was
mainly localized in the nucleus when transfected by
pcDNA6.2/C-EmGFP-Math1 plasmid (Figures 3A, 3C, 3E
to 3G, 4B, 4D and 5). A unique subcellular localization of
Math1-GFP was also observed in certain cell populations,
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Figure 4. Lipofectamine 2000 mediated transfection of mixed primary cochlear cells by pcDNA6.2/C-EmGFP-Math1 plasmid shown
by confocal microscopy. (A) Lower magnification, transfection efficiency is 2.9%. (B–F) Subcellular distribution of EmGFP-Math1
fusion protein was shown by higher magnification (C is a merged image of F). Nuclear localization of EmGFP-Math1 fusion protein
was observed in most transfected cells (B, D). Simultaneous nuclear and cytoplasmic distribution of EmGFP-Math1 protein was
detected in a small number of cells (C, E). In the neuron, EmGFP-Math1 protein appeared in both the nucleus and axon (C).
Vesicles composed of EmGFP-Math1 fusion protein with variable sizes, with diameter in the range 0.4–2.3 µm, were also observed
(B, E). Green: EmGFP-Math1 fusion protein; blue: contrast staining of nuclei with DAPI; red: F-actin stained by TRITC-conjugated
phalloidin. Scale bar = 100 µm (A), 10 µm (B–F)
Figure 5. Nuclear localization of EmGFP-Math1 protein in outer hair cell-like cell and the spiral ganglion cell shown by confocal
microscopy. (A) Outer hair cell-like cell. (B) Spiral ganglion cell. Green: EmGFP-Math1 fusion protein; blue: contrast staining of
nuclei with DAPI; red: F-actin stained by TRITC-conjugated phalloidin. HB, hair bundle; CP, cuticular plate. Scale bar = 10 µm
EmGFP-Math1 fusion protein simultaneously appeared
in both the nucleus and cytoplasm (Figures 3B, 3D, 4C
and 4E). Both cytoplasmic and nuclear EmGFP-Math1
localized to vesicles of varying sizes, with a diameter in the
range 0.4–2.3 µm (Figures 3C, 3D, 3E, 3G, 4B and 4E).
Some vesicles looked fused because both vesiculated and
homogeneous EmGFP-Math1 fusion protein was observed
(Figure 3E). By contrast, the EmGFP-BDNF fusion protein
was localized only to the cytoplasm (Figure 3H). Because
the subcellular localization of the EmGFP-Math1 fusion
protein and the visualization of vesicles can only be
observed under a confocal microscope with higher
magnification, it was difficult to quantify the ratio of
nuclear localized EmGFP-positive cells or the ratio of
vesicles composed EmGFP-positive cells compared to the
total EmGFP-positive cells.
Neuronal-like phenotype of MSCs
transfected with the
pcDNA6.2/C-EmGFP-Math1 plasmid
After 10 days of transfection with the pcDNA6.2/C-
EmGFP-Math1 plasmid, volume enlargement and polar-
ization were observed in certain MSCs. After 2 weeks,
neuron-like cells with axons and dendrites were observed,
whereas some cells remained at earlier stages with the
appearance of a growth cone. In these cells, the cel-
lular body demonstrated a spherical shape (Figure 6).
In the differentiated neuron-like cell, a neurofilament
was detected, which represents a neural specific protein
(Figure 6). By contrast, neither MSCs transfected with
the pcDNA6.2/C-EmGFP-CAT plasmid, nor MSCs treated
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Figure 6. Neuron-like cell differentiation of MSCs transfected with pcDNA6.2/C-EmGFP-Math1 plasmid plus treatment with 10 ng/ml
BDNF and 10 ng/ml GDNF for 2 weeks, shown by confocal microscopy. (A) Bright field image of (B). (B) Neuron-like cells stained
with neurofilament 200 (B). (C) MSCs treated with 10 ng/ml BDNF and 10 ng/ml GDNF alone for 2 weeks. No neurofilament
200-positive cells were detected. (D) MSCs were transfected with pcDNA6.2/C-EmGFP-CAT plasmid plus treatment with 10 ng/ml
BDNF and 10 ng/ml GDNF for 2 weeks. No neurofilament 200-positive cells were detected. Arrow heads: unipolar cell indicates
neuron-orientated differentiation; arrow: bipolar shape of the neuron-like cell; red: neurofilament. Scale bar = 25 µm
with BDNF and GDNF alone differented into neuron-like
cells.
Math1 expression in defined cell types
is mediated by liposome nanoparticles
After 24 h of incubation, internalization of TRITC-
tagged liposome nanoparticles LPX-PEG and LPX in
NIH 3T3 cells was identified by the appearance of
red vesicles in the cytoplasm. Quantification of the
fluorescent intensity showed a concentration dependent
internalization among both PEGylated lipoplexes and
unPEGylated lipoplexes (p < 0.05) (Figure 7). However,
no significant difference was observed between pegylated
lipoplexes and unPEGylated lipoplexes when cells
were treated with the same concentration (p > 0.05)
(Figure 7).
The EmGFP-Math1 fusion protein was expressed in
NIH 3T3 cells, SH-SY5Y cells and primary cochlear cells
24 h after transfection (Figure 8). When the pcDNA6.2/C-
EmGFP-Math1 plasmid was delivered with LPX-PEG
(PEGylated) and LPX-DOPE (1.2:1) (lipid/plasmid molar
charge ratio of 1.2:1) in NIH 3T3 cells, the transfection
efficiency was 0.7% and 0.8%, respectively (Figures 9B
and 9D). The other two lipoplexes LPX (unPEGylated)
and LPX-DOPE (2:1) (lipid/plasmid molar charge ratio
of 2:1) showed higher transfection efficiencies of
3.8% and 3.6%, respectively (Figures 9A and 9C). The
transfection efficiency of LPX was higher than that of
LPX-PEG (Figures 9C and 9D). LPX-DOPE (2:1) showed
a higher transfection efficiency than LPX-DOPE (1.2:1)
Figure 7. Impact of PEGylation and concentration on lipoplex
internalization in NIH 3T3 cells. A higher concentration
(0.2 mM) of TRITC-labeled LPX and LPX-PEG induced sig-
nificantly higher internalization than a lower concentration
(0.02 mM) (p < 0.05; Bonferroni test). No significant difference
in internalization was observed between LPX and LPX-PEG at
the same concentration (p > 0.05; Bonferroni test). LPX, unPE-
Gylated lipoplex; LPX-PEG, PEGylated lipoplex
(Figures 9A and 9B). However, all nanoparticles showed
lower transfection efficiencies compared to Lipofectamine
2000.
The subcellular location of the EmGFP-Math1 fusion
protein in cells transfected by lipoplexes was similar to
that in cells transfected by Lipofectamine 2000, which was
mainly distributed in the nuclei, whereas it was sparsely
retained within the cytoplasm. Vesicles with variable sizes,
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Figure 8. Liposome nanoparticles mediated transfection of the pcDNA6.2/C-EmGFP-Math1 plasmid in different cell types shown
by confocal microscopy. (A–E) Transfection with unPEGylated LPX in NIH 3T3 cells. (F) Transfection with unPEGylated LPX in
SH-SY5Y cells. (G) Transfection with unPEGylated LPX in mixed primary cochlear cells. (H) Transfection with PEGylated LPX-PEG
in NIH 3T3 cells. Vesicles composed of EmGFP-Math1 fusion protein with variable sizes, with a diameter in the range 0.4–3 µm,
were observed in NIH 3T3 cells (C, D, E). The vesicles are located either solely in the nucleus (C, E) or simultaneously in nucleus
and cytoplasm (D). Additional homogeneous fluorescent signals beside the vesicles suggested the release of EmGFP-Math1 fusion
proteins from the vesicles (C). Green: EmGFP-Math1 fusion protein; blue: contrast staining of nuclei with DAPI; red in (A): F-actin
stained by TRITC-conjugated phalloidin; red in (B–H), TRITC-tagged liposome nanoparticles. Scale bar = 7.5 µm
Figure 9. Impact of surface charge and pegylation on transfection efficiency in NIH 3T3 cells treated with 0.02 mM liposome
nanoparticles shown by confocal microscopy. (A) NIH 3T3 cells were transfected with LPX-DOPE (2:1), which bears a higher
cationic charge. (B) NIH 3T3 cells were transfected with LPX-DOPE (1.2:1), which bears a lower cationic charge. (C) NIH 3T3
cells were transfected with TRITC-labeled LPX. (D) NIH 3T3 cells were transfected with LPX-PEG. LPX-DOPE (2:1) has a higher
transfection efficiency (3.6%) than LPX-DOPE (1.2:1) (0.8%). LPX has a higher transfection efficiency (3.8%) than LPX-PEG (0.7%).
Green: EmGFP-Math1 fusion protein; blue: contrast staining of nuclei with DAPI; red: liposome nanoparticles. LPX, unPEGylated
lipoplex; LPX-PEG, PEGylated lipoplex. Scale bar = 100 µm
with diameter in the range 0.4–3 µm, appeared in these
cells (Figures 8C, 8D and 8E), with several demonstrating
fusion (Figure 8C). Vesicles were also observed in both
the nucleus and cytoplasm (Figure 8D).
Discussion
PCR amplification, gene sequencing and western
blot analysis confirmed the structure, integrity and
Copyright  2011 John Wiley & Sons, Ltd. J Gene Med 2011; 13: 134–144.
DOI: 10.1002/jgm
142 W. Zhang et al.
gene expression capability of the newly-constructed
plasmid, pcDNA6.2/C-EmGFP-Math1 (Figure 1). Using
lipofectamine, this novel pcDNA6.2/C-EmGFP-Math1
plasmid induced significantly higher transfection efficien-
cies than the pCLIG-Math1 plasmid, which was developed
using the Moloney murine leukemia virus. An additional
advantage of pcDNA6.2/C-EmGFP-Math1 is that EmGFP
is fused to Math1 protein, thus making it possible to
observe the subcellular localization of the EmGFP-tagged
Math1 protein. Furthermore, mutations have been intro-
duced into GFP that further enhance and shift the spectral
properties of GFP such that these proteins emit vivid
emerald fluorescence, making it easier to visualize.
Several cell types including NIH 3T3, MSCs and pri-
mary cochlear cells showed efficient transfection of
the pcDNA6.2/C-EmGFP-Math1 plasmid using lipofec-
tamine. In addition, NIH 3T3 cells, SH-SY5Y cells and
primary cochlear cells were successfully transfected by
the pcDNA6.2/C-EmGFP-Math1 plasmid using liposome
nanoparticles. This result confirmed that the new Math1
plasmid is valuable for nonviral-vector-mediated Math1
gene delivery. NIH 3T3 cells demonstrated the high-
est transfection efficiency among all cell types tested,
using either lipofectamine or liposome nanoparticles
(Figures 2A, 9A and 9C). There is important significance
in using autologous fibroblasts in the cell replacement
treatment of deafness mediated by Oct3/4, Sox2, c-Myc,
Klf4 and Math1 [21,22]. Poor transfection efficiencies in
the primary cochlear cells compared to other cell types
(Figure 4A) can be explained by cell cycle correlated
gene transfection efficiency, where the more differenti-
ated state of the cell, the worse the transfection efficiency
is in gene delivery. Usually, nondividing cells are more
difficult to transfect than dividing cells, which can be
attributed to the absence of mitotic activity in nondivid-
ing cells. In dividing cells, DNA is passively transported
into the nucleus during the M-phase of cell division when
the nuclear membrane temporarily disintegrates [28].
For nondividing cells, the presence of an intact nuclear
membrane limits the entry of plasmid DNA (pDNA) into
the nucleus. The mechanism of pDNA cyto-nucleoplasmic
transport in nondividing cells is likely to be a process
mediated by the interaction of soluble cytoplasmic factors
with the minimal nuclear transport machinery [29].
A unique subcellular localization of EmGFP-fused
Math1 was observed in the transfected cells. In some cells,
EmGFP-Math1 fusion proteins were detected in both the
nuclei and cytoplasm (Figures 3B, 3D, 4C, 5E and 8D).
The multiple locations within a single cell suggest that
Math1 proteins are transported from the cytoplasm to
the nucleus. In the majority of the cells, EmGFP-Math1
fusion proteins appeared in the nucleus, suggesting that
this cytoplasmic-nuclear transport event is rapid. This
observation strongly supports the idea that fusion of
EmGFP onto Math1 did not disrupt the intracellular
trafficking of Math1. Encapsulation of EmGFP-Math1
fusion proteins into vesicles (Figures 3C, 3E, 3G, 4B and
8C to 8E) was in accordance with the nuclear transport
mechanism of vesicle fusion events [30]. Simultaneous
appearance of vesiculated and homogeneous EmGFP-
Math1 fusion protein in the same nuclei (Figures 3E
and 8C) demonstrated the process of vesicle fusion events.
Therefore, promoting the fusion of vesicles may be
important to realize the function of each Math1 molecule.
Possibly, Ca2+ and inositol 1,4,5-trisphosphate receptors
will contribute to this effort [31].
It has been reported that the Math1 fused GFP
induces the development of hindbrain neurons in mice
[32]. EmGFP fused to the C-terminal end of Math1
should not disrupt the interaction between Math1 and
chromosomal E-box, which occurs at the N-terminal end
of Math1. We were unable to evaluate the binding efficacy
of Math1 protein to the chromosomal E-box directly,
although it is a critical step for the Math1 transcription.
Our observation that MSCs differentiated into neural
progenitor cells and sequentially to neuron-like cells after
treatment with BDNF and GDNF further supported the
preserved transcription function of EmGFP-fused Math1.
It has been reported that the role of Math1 protein in
these sequential events is to direct neural progenitor
differentiation [33]. Maturation of the differentiated
neural progenitor is maintained by BDNF and GDNF
treatment, which induces the growth cone of the neuron
[34]. Although neural-orientated differentiation of MSCs
without Math1 stimulation has been reported, agents
other than BDNF and/or GDNF (such as retinoid acid,
β-mercaptoethanol, etc.) were added to the cell culture
medium [25]. This did not mean that BDNF and GDNF
alone induced the differentiation of MSCs and ruled out
the role of Math1 in the present study. MSCs are reported
a source of progenitors for inner ear hair cells in the cell
replacement treatment [35]. Modification of MSCs with
Math1, BDNF and GDNF using a nonviral gene delivery
technique can potentially be applied in future therapies
for treating deafness.
Liposome nanoparticles represent a beneficial applica-
tion of in vivo gene therapy. However, the transfection
efficiency of pcDNA6.2/C-EmGFP-Math1 plasmid medi-
ated by liposome nanoparticles was lower than that
mediated by commercial Lipofectamine 2000, even in
the NIH 3T3 cells, which showed the highest transfection
efficiency among the tested cell types (Figures 2A, 9A
and 9C). There are four aspects that should be con-
sidered: ‘endosomal escaping’, nanoparticle size, surface
charge of the nanoparticles and the PEGylation effect in
the medium. Endocytosis was reported to be the major
pathway of internalization for lipoplexes [36,37]. The
tested lipoplexes probably lack ‘endosomal escaping’ abil-
ity. If the pcDNA6.2/C-EmGFP-Math1 plasmid cannot be
released into the cytoplasm by breaking the membrane
of the endosome, it may become destined to lysosomes
where DNA is destroyed before executing its function.
Lipoplex size was reported to be a major factor influencing
in vitro lipofection efficiency [38,39]. Lipoplex size plays
a key role for gene transfer to actively endocytosing cells
[37,38]. The results obtained in the present showed that
lipoplex with 255 nm gained higher transfection efficiency
than others (Table 1). This is consistent with previous
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studies showing that optimal transfection efficiencies are
obtained with lipoplexes of 200–400 nm in size in vitro
[40,41]. The mechanism by which lipoplexes of a rela-
tively large size induced higher transfection efficiencies
involves the larger size facilitating membrane contact and
fusion [42]. Furthermore, larger lipoplexes may delay the
dissociation of DNA with lipid, thereby enhancing DNA
transfection efficiency [43].
The surface charge of the lipoplexes is also an impor-
tant parameter that can influence transfection efficiencies
[41]. It was reported that, by increasing the lipid/DNA
charge ratio, the size of the lipoplex decreases and the
lipoplex becomes more stable [44]. The size and stability
of the lipoplexes depend on the cationic lipid/DNA charge
ratio used for lipoplex preparation [45–47]. Impact on
the transfection efficiency of lipoplexes by the lipid/DNA
ratio is realized mainly through influences on lipoplex
size and lipoplex stability. In Table 1, LPX-DOPE (2:1)
has a higher lipid/DNA molar charge ratio than LPX-
DOPE (1.2:1), whereas the former has a smaller size. In
the present study, the transfection efficiency of LPX-DOPE
(2:1) is higher than LPX-DOPE (1.2:1) (Table 1). This
result indicates that a lipid/DNA molar charge ratio of
2:1 is favourable for endocytosis, and is more stable to
protect the plasmid DNA against degradation by cellular
nucleases.
PEGylation of liposome nanoparticles can not only pro-
tect DNA against degradation by serum, but also inhibits
the transfection capacity [48]. In the present study, unP-
EGylated LPX showed a higher transfection efficiency
than PEGylated LPX-PEG, which was inconsistent with a
previous study [49]. The mechanism by which PEGyla-
tion affects the transfection efficiency is that PEGylation
adversely interacts with the intracellular trafficking of
nanoparticles [49,50]. However, a recent report showed
that PEGylation of lipoplexes did not hamper internaliza-
tion but interfered with the intracellular release of DNA
from lipoplexes [51]. No difference in internalization was
observed between PEGylated and unPEGylated lipoplexes
in the present study, supporting the second hypothesis
(Figure 7). The results obtained in the present study indi-
cated that PEGylation affects the release of DNA but not
the internalization of nanoparticles.
In summary, the present study provides evidence
that the newly-constructed plasmid pcDNA6.2/C-EmGFP-
Math1 is suitable for the nonviral gene delivery of Math1.
Unique intracellular trafficking of Math1 was demon-
strated by the novel plasmid. Modification of MSCs by
Math1 gene delivery together with BDNF and GDNF
treatment can potentially be applied to cell replacement
treatment of the cochlear spiral ganglion cell loss in
deafness.
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Abstract
Objectives: To investigate the targetability of TrkB ligand-functionalized liposome nanoparticles for 
gene delivery to spiral ganglion cells. Materials and methods: A TrkB affinity peptide was synthesized 
and coupled to liposome nanoparticles carrying the plasmid pGeneClipTM hMGfp encoding shrnA to 
transiently silence inhibitor of differentiation and dnA binding-2 (id2� along with the reporter gene 
EGfp. internalization and targetability were analyzed in primary cochlear cell culture, cochlear explants, 
and live rats. Gene transduction was evaluated in rat cochlear explants. immunofluorescent staining in 
combination with confocal microscopy was used for observation. Results: Efficient internalization was 
observed in primary cochlear cell culture for both peptide-functionalized liposome nanoparticles and blank 
liposome nanoparticles in a concentration-dependant manner. Both particles showed uptake in spiral 
ganglion cells and adjacent nerve fibers. potential targetability with TrkB affinity peptide-functionalized 
liposome nanoparticles was observed in the adult rat cochlea. More efficient gene expression was seen for 
the peptide-functionalized liposome nanoparticles, and the function of the shrnA was demonstrated in 
cochlear explants and adult rat cochleae. 
Conclusions: potential targetability of A371-functionalized liposome nanoparticles was observed in the 
adult rat cochlea. functionalization of liposome nanoparticles with TrkB ligand did not change cellular 
internalization, but it did enhance gene expression.
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Afu, adaptive focused ultrasound; Bdnf: brain derived neurotrophic factor; BSA: bovine serum albumin; dLS, dynamic light 
scattering; dSpE-pEG-2000, 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy(polyethylene glycol�-2000] 
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Introduction
Targeted drug delivery is an efficient 
means of therapy due to improved biodis-
tribution and minimized side effects. Lipo-
some nanoparticles functionalized with 
different ligands or antibodies have been 
broadly applied for targeted treatment of 
cancer, inflammation, and cardiovascular 
diseases, among others. (1-7� deafness 
is a major disease causing disability and 
lacks a curative treatment using conven-
tional drugs. Cochlear implants effective-
ly replace the mechanosensory transduc-
tion function of lost hair cells and furnish 
the user with a substantial hearing bene-
fit by exerting direct electrical stimulation 
on spiral ganglion cells or their dendrites 
(peripheral processes�. Although there 
are controversial clinical reports on the 
contribution of spiral ganglion cells to the 
efficacy of cochlear implants, at least 10% 
survival of spiral ganglion cells is needed 
for current cochlear implants to succeed 
in helping patients communicate. in or-
der to broaden the application of cochlear 
implants, strategies aimed at preserving 
or regenerating deafferented spiral gan-
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glion cells in combination with cochlear 
implants are key for further advances in 
cochlear implant technology. Targeted 
delivery of agents to spiral ganglion cells 
using functionalized liposome nanoparti-
cles will be the most efficient way to fulfill 
this goal.
The neurotrophin receptor tropomyosin-
related kinase (Trk� receptor tyrosine ki-
nase, especially TrkB, is expressed in spi-
ral ganglion cells. (8� peptides that bind 
TrkB have been developed using either 
phage display or molecular modeling with 
the aim of mimicking the biological func-
tions of brain derived neurotrophic factor 
(Bdnf� and nerve growth factor (nGf�. 
(9-11� The sequence CTfVKALTMdG-
KQAAWr, denoted in our work as A371, is 
derived from the peptide hngf_EE, which 
has been shown to bind the TrkB receptor 
and is in turn a modification of the natural 
sequence of amino acids 84-100 of nGf. 
(11� The sequence was extended with an 
n-terminal cysteine for coupling to lipo-
some nanoparticles. Liposome nanopar-
ticles with a payload of plasmid dnA 
were pegylated (dSpE-pEG-2000� and 
conjugated to A371 peptide. This study 
was aimed at evaluating the impact of 
target peptide functionalization on inter-
nalization of nanoparticles in cochlear cell 
populations. observations were made in 
primary cochlear cell culture, cochlear ex-
plants, and in vivo.
Materials and methods
Materials for liposome nanoparticle 
manufacturing
Sph, EggpC, dSpE-pEG-2000, and dSpE-
pEG (2000� maleimide were from Avanti 
polar lipids (Alabaster, AL�. HpLC-grade 
trifluoroacetic acid (TfA� was from fluka 
(Buchs, Switzerland�, and acetonitrile was 
from rathburn (Walker Burn, Scotland, 
uK�. The purity of the lipids was checked 
by thin layer chromatography on silicic 
acid-coated plates (Merck, darmstadt, 
Germany� developed with a chloroform�
methanol�water mixture (5:25:4, v�v�
v�, with examination of the plates after 
iodine staining and, when appropriate, 
with uV illumination revealing no impuri-
ties. Lipid concentration was determined 
gravimetrically with a high precision elec-
trobalance (Cahn, Cerritos, CA�. Hepes 
and EdTA were from Sigma-Aldrich, and 
Tritc-dHpE was from Molecular probes 
(Eugene, or�. The concentration of the 
fluorescent lipid analogue Tritc-dHpE was 
determined spectrophotometrically using 
molar absorptivity ε
45
 = 19000 M-1cm-1	(in	
C2H5oH�. The other chemicals were of an-
alytical grade and from standard sources. 
All experiments were conducted in 5 mM 
Hepes and 0.1 mM EdTA, pH 7.0, unless 
otherwise indicated.
Peptide manufacturing
peptides were synthesized by fMoC 
technology (in Storkbio former inbiolabs, 
Tallin, Estonia� and purified by HpLC to 
90% purity, and the sequences were con-
firmed by mass spectrometry. Some of 
the synthesized peptides were n-termi-
nally conjugated to fiTC and used for de-
termination of affinity and specificity. for 
conjugation to nanoparticles, only native 
peptides were used. in order to test speci-
ficity and affinity, two cell lines were se-
lected: rAW 24 heterologously express-
ing the TrkB receptor and the K52 line 
shown to be TrkB-negative but positive 
for the closely related TrkA receptor. (12, 
13� fiTC-conjugated peptides were added 
to a suspension of rAW 24 and K52 
cells at a concentration of 0.1 µg per 10	
cells, incubated for 20 min at room tem-
perature, washed four times with pBS, 
and fixed in 4% paraformaldehyde in pBS. 
fixed cells were measured using a fAC-
SAria (Becton dickenson� flow cytometer. 
The analysis showed that the sequence 
CrAniGGTHA had the strongest reactivi-
ty, while CTfVKALTMdGKQAAWr (A371� 
had higher selectivity for TrkB relative to 
TrkA (Tab. 1�.
Plasmid DNA preparation
plasmid pGeneClipTM hMGfp, encoding 
an shrnA to transiently silence inhibi-
tor of differentiation and dnA binding-2 
(id2� and the reporter gene EGfp (Super-
Array, Bioscience Corp., frederick, Md, 
uSA�, was propagated in oneShot Top10 
Competent Cells (invitrogen, Carlsbad, 
CA, uSA� and then extracted using the 
pureLinkTM plasmid dnA Megaprep kit 
(invitrogen, Carlsbad, CA, uSA� according 
to the manufacturer’s instructions. The 
Sequence Signal from rAW24
	
cells (mean ± CV�
Signal from K52 
cells	(mean ± CV�
Signal ratio
CSMAHpYfAr (3� A3 34.04 ± 109.55 2187.1 ± 25.43 3.03
CrAniGGTHA (3� A38 8543.85 ± 72.3 2959.14 ± 93.81 2.89
CSpGSiHTLV (3� A370 5708.78 ± 128.13 2302.21 ± 300.7 2.48
CTfVKALTMdGKQAAWr (4� A371 418.2 ± 105.09 1417.59 ± 188.35 3.2
Table 1. flow cytometry showing binding of peptide candidates to TrkB positive (rAW24� 
and TrkB negative (K52� cell line.
note: Every peptide binds to both TrkB and TrkA, however A371 had higher selectivity for TrkB                
relative to TrkA according to signal ratio.    
purity and concentration of pdnA id2.3 
were determined by measuring the ra-
tio of absorbance at 20 nm�280 nm (ε = 
00 l�mol x cm�.
Coupling of peptide A371 to DSPE-PEG 
(2000) maleimide
dSpE-pEG (2000� maleimide and A371 
peptides were incubated at a 1:1.3 molar 
ratio in a reaction mixture with 100 mM 
hepes and methanol in a 1:1.11 molar 
ratio, pH 7.0, for 3 hours at room tem-
perature under constant stirring. Lipid-
peptide conjugate was purified by HpLC 
on a reverse phase column (Jupiter 5µm 
C4 300A ST 4.�150, Amersham Biosci-
ences, uppsala, Sweden� and eluted with 
a linear gradient from 0 to 100% aceto-
nitrile in water with 0.1% TfA at a flow 
rate of 1 mL�min. Samples were moni-
tored at a uV absorbance of 20 nm and 
280 nm. fractions corresponding to pure 
lipid-peptide conjugate were collected 
and lyophilized. The concentration of 
lipid-peptide conjugate was determined 
spectrophotometrically by measuring 
tryptophan fluorescence. Lipid-peptide 
conjugate was dissolved in methanol pri-
or to the experiments. 
Dynamic light scattering 
The apparent hydrodynamic particle di-
ameter (Z
av
� and polydispersity index 
(pdi� of lipid vesicles were determined by 
dynamic light scattering at 25°C (Zeta-
sizer nano ZS, Malvern instruments Ltd., 
uK�. The instrument uses photon corre-
lation spectroscopy at a scattering angle 
of 173° to evaluate Z
av
 from the diffusion 
coefficient (d� using the Stokes-Einstein 
equation, d
Z
 = kT�3πηd, where k is the 
Boltzmann constant, T is the absolute 
temperature, and η is the viscosity of the 
solvent. The Z
av
 analysis gives two values, 
a mean value for the size and a width 
parameter known as the polydispersity 
index. Z
av
 is also known as the cumulants 
mean. The cumulants analysis is the fit of 
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a polynomial to the log of the G1 correla-
tion function
Ln[G1] = a + bt + ct2 + dt3 + et4 + ……………
The coefficient of the squared term, c, 
when scaled as 2c�b2, represents the poly-
dispersity index.
Preparation of liposome nanoparticle
The appropriate amounts of the lipid 
stock solutions in chloroform and the lipid 
peptide conjugate were mixed in organic 
solvent to obtain the desired liposome 
compositions. in brief, lipid film was pre-
pared from Sph, eggpC, dSpE-pEG-2000, 
lipid-peptide conjugate and Tritc-dHpE 
(0.5:0.44:0.02: 0.01, 0.03 molar ratios�. 
Solvents were removed under a stream 
of nitrogen, and the lipid residues were 
subsequently maintained under reduced 
pressure for at least 2 h. The dry lipid film 
was then hydrated at 0°C for one hour in 
5 mM Hepes, 0.1 mM EdTA, pH 7.0. The 
lipid mixture at final concentration of 0.1 
mM was subjected to focused ultrasound 
(Covaris, KBiosciences, uK�. An average 
particle diameter (Z
av
� of 182 and 89 nm 
for particles with and without targeting 
peptide (A371�, respectively, was deter-
mined by dynamic light scattering (Zeta-
sizer, nano ZS, Malvern instruments Ltd., 
uK�. 
Preparation of lipoplexes
After being subjected to focused ultra-
sound, liposome nanoparticles were 
mixed with plasmid dnA at a lipid�dnA 
charge ratio (+�-� of 1.2:1 to obtain na-
noscale particles, also termed as lipo-
plexes. After the addition of pdnA, a Z
av
	
of 108 and 112 nm was obtained for lipo-
plexes with and without targeting pep-
tide A371, respectively three batches of 
liposome nanoparticles with and without 
A371 peptide conjugation, with and with-
out plasmid dnA encapsulation were 
manufactured.
Primary cochlear cell culture
five p1-p5 pups were decapitated after 
deep anesthetization and sterilized with 
70% ethanol. The cochleae were isolated 
and cut into small pieces, then dissociat-
ed with a pBS-based solution containing 
elastase (1 mg�ml, Sigma Aldrich, uSA�, 
collagenase type i (1 mg�ml, Sigma Al-
drich, uSA�, and trypsin (0.5 mg�ml, Sig-
ma Aldrich, uSA� for 35 min at 37°C, fol-
lowed by trituration (every four cochleae 
were dissociated in 0. ml of solution�. 
The digestion was terminated by adding 1 
ml dMEM-f12 (Sigma Aldrich, uSA�, con-
taining 10% fetal bovine serum (Sigma 
Aldrich, uSA�. After centrifugation for 5 
min at 250 x g, the cell pellets were resus-
pended in 1 ml defined medium (dMEM-
f12 with B27 supplement, 1 mM n-acetyl-
L-cysteine, penicillin–streptomycin, and 
20 ng�ml EGf (Sigma Aldrich, uSA�� and 
plated on the 4-well Lab-Tek®ii Cham-
ber SlideTM System (nalge nunc interna-
tional, naperville, uSA� containing 1.0 
ml defined medium�well. The cells were 
cultured at 37ºC in the Co2 incubator 
overnight, then treated with lipoplexes. 
A371-functionalized liposome nanopar-
ticles (final concentrations: 10 μM, 1.0 μM, 
and 0.1 μM� and blank liposome nanopar-
ticles (final concentrations: 10 μM, 1.0 
μM, 0.1 μM, and 0.01 μM� without plas-
mid dnA encapsulation were prepared 
with defined medium, and 1.0 ml of each 
was applied to the cells for 2 hours and 24 
hours under the same incubation condi-
tions. After washing with pBS for 3x1 min, 
cells were fixed with 4% paraformalde-
hyde for 30 minutes. The cell cytoplasm 
was counter-stained with 50 μg�ml fiTC-
labeled phalloidin (Sigma Aldrich, uSA� 
for 30 min, and nuclei were stained with 
4’,-diamidino-2-phenylindole (dApi� (10 
ng�ml, Sigma-Aldrich, uSA� for 10 min. 
Cells were then mounted with fluoro-
mount for confocal microscopy (3x5 min 
pBS washes were applied between each 
staining step�.
Cochlear explants study
five p1-p pups were decapitated after 
deep anesthetization and sterilized with 
70% ethanol. Each cochlea was isolated, 
cut into 3-4 pieces, and plated on the 4-
well Lab-Tek®ii Chamber SlideTM System 
(nalge nunc international, naperville, 
uSA� containing 1.0 ml defined medium�
well, just as for the primary cochlear cell 
cultures. The explants were cultured at 
37ºC in the Co2 incubator overnight and 
then treated with liposome nanoparticles 
carrying plasmid pGeneClipTM hMGfp 
dnA at concentrations of 1 μM and 0.2 
μM for different time points (15 min, 30 
min, 0 min, and 120 min, 2 d, and 4 d�. 
At the end of incubation, explants were 
washed with pBS 3x3 min and fixed in 4% 
paraformaldehyde for 30 minutes. After 
washing with pBS, samples at the 2 d and 
4 d time points were counter-stained with 
dApi (10 ng�ml� for 10 min and mounted 
with fluoromount for confocal micros-
copy. other samples were used for neuro-
filament staining. After washing with pBS, 
explants were incubated with 0.1% Triton 
X-100 for 15 min. After washing with pBS, 
explants were then incubated with pre-in-
oculated goat serum (1:20� for 30 min, fol-
lowed by rabbit anti-neurofilament 200 
antibody (diluted at 1:100 with pBS con-
taining 0.1% bovine serum albumin (BSA�, 
Sigma Aldrich, uSA� overnight. Explants 
were washed with pBS-tween-20 (pBS-
T� for 3x2 min, incubated with fiTC-con-
jugated goat anti-rabbit igG (diluted at 
1:400 with 0.1% BSA-pBS, Sigma Aldrich, 
uSA� for 0 min, incubated with dApi (10 
ng�ml� for 10 min, washed with pBS-T for 
3x2 min, and mounted with fluoromount 
for confocal microscopy. for a negative 
control, the primary antibody was re-
placed with 0.1% BSA-pBS.
In vivo observation
five male Sprague-dawley rats, 3-10 
month old, weighing for 400-750 g, with 
normal pryer’s reflex (supplied by the 
experimental animal unit, university of 
Tampere�, were used in the study in accor-
dance with the standards of the local eth-
ics committee of the university of Tam-
pere (permission no: 985�2003�. All animal 
experiments were approved by the Ethical 
Committee of the university of Tampere. 
Animal care and experimental procedures 
were conducted in accordance with Euro-
pean legislation. for round window ad-
ministration of lipoplexes, animals were 
under general anesthesia with domitor 
(0.5 mg�kg medetomidine hydrochloride, 
orion pharma, finland� and Ketalar (75 
mg�kg ketamine, pfiZEr AB, finland� giv-
en intraperitoneally. The operation was 
performed under sterile conditions. After 
local analgesia with lidocaine, a retro-au-
ricular incision was used to expose the left 
bulla. A hole was drilled on the bulla with a 
2 mm diameter burr. After visualizing the 
stapes artery, the round window mem-
brane was identified above the artery. A 
small piece of gelfoam (around 8 mm3� 
was saturated with liposome nanopar-
ticles at a concentration of 100 μM and 
placed on the round window membrane 
for 24 hours. Atipamezole hydrochloride 
(2 mg�kg� was injected i.p. immediately 
after the operation to accelerate recovery 
from anesthesia. Saline (2 ml� was admin-
istered through subcutaneous injection 
in the neck. L-polamivet (0.4 ml�kg� was 
injected b.i.d. to relieve pain.
following i.p. injection of pentobarbital 
(0 mg�kg�, cochleae were fixed using 
cardiac perfusion with 4% paraformal-
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dehyde, and bulla were removed and 
further fixed for 1 h. The cochleae were 
thoroughly washed with tap water for 30 
seconds, then opened by breaking the 
bony wall under a stereomicroscope and 
washed again with pBS for 2x5 min. The 
bulla were counter-stained with fiTC-la-
beled phalloidin (50 µg�ml, Sigma Aldrich, 
uSA� for 40 min and then with dApi (10 
µg�ml� for 10 min. After washing with pBS 
for 3x5 min, the round window membrane, 
lateral wall and modiolus together with 
basilar membrane were taken under a 
stereomicroscope, placed on glass slides, 
and mounted with fluoromount for con-
focal microscopy.
Confocal microscopy
The samples were observed under an 
olympus iX70 microscope with Andor 
iQ installed. The excitation filters were 
488 nm (blue excitation� and 58 nm 
(green excitation�, using an Ar-Kr laser as 
the excitation source. The corresponding 
emission filters were 525�50 (fiTC� and 
07�45 (TriTC�. dApi was excited with 
a 340-380 nm filter and detected using 
a 500 Lp filter. Signal intensity was ana-
lyzed with imageJ 1.32j software.
Statistical analysis
The signal intensity was corrected by the 
intensity of a randomly selected back-
ground region. The corrected mean val-
ues were analyzed with the SpSS 11.5 
program. differences in the levels of sig-
nal intensity among concentrations and 
cell populations were analyzed by Ano-
VA (p<0.05 was accepted as an indication 
of statistical significance�. differences in 
levels of signal intensity between A371-
functionalized liposome nanoparticles 
and blank liposome nanoparticles were 
analyzed using a t-test (p<0.05 was ac-
cepted as an indication of statistical sig-
nificance�.
Results
internalization of liposome nanoparticles 
in primary cochlear cells
Two batches of liposome nanoparticles 
without plasmid dnA encapsulation 
were tested in primary cochlear cell cul-
tures. one batch showed aggregation of 
nps but no cellular internalization. The 
other batch showed efficient internaliza-
tion of both peptide functionalized lipo-
some nanoparticles and blank liposome 
nanoparticles, which were observed in 
the primary cochlear cells, including spiral 
ganglion cells, fibrocytes, and intermedi-
ate cells of the stria vascularis. Cytosolic 
localization, perinuclear localization, and 
nuclear localization of liposome nanopar-
ticles were seen in different cell types. The 
nanoplex signal intensity was significant-
ly dependent on the nanoplex concentra-
tion in the medium (p<0.01�. no statisti-
cally significant difference was observed, 
however, between A371-functionalized 
liposome nanoparticles and blank lipo-
some nanoparticles (p>0.5� (fig. 1�. 
Figure 1. Confocal microscopy showing the in-
ternalization of liposome nanoparticles in pri-
mary rat cochlear cell cultures. for A371-func-
tionalized liposome nanoparticles without 
plasmid dnA, efficient uptake was observed 
in the cytoplasmic and perinuclear regions of 
type i (A� and type ii (B� spiral ganglion cells 
and stria intermediate cells (C� at a concen-
tration of 1.0 μM. Sparse uptake was also de-
tected in fibrocytes at a concentration of 0.1 
μM (d�. for the blank liposome nanoparticles 
without plasmid dnA, efficient internalization 
occurred in spiral ganglion cells (E� and fibro-
cytes (f� at a concentration of 1.0 μM. Sparse 
internalization was observed in fibrocytes at 
a concentration of 0.1 μM (G�, but no uptake 
was detected in spiral ganglion cells at a con-
centration of 0.01 μM (H�. Concentration-de-
pendant internalization was observed in both 
A371-functionalized liposome nanoparticles (i� 
and blank liposome nanoparticles (J�. red: li-
posome nanoparticles; green: f-actin stained 
with fiTC-conjugated phalloidin; blue: nuclei 
stained with dApi. A371-np: A371-functiona-
lized liposome nanoparticles. 
Scale bar=10 μm. 
Nanoplex internalization and possible 
EGFP expression in cochlear explants
Liposome nanoparticles carrying plasmid 
pGeneClipTM hMGfp dnA was tested in 
cochlear explants. dynamic uptake of 
liposome nanoparticles in both neuro-
filaments and spiral ganglion cells was 
observed, with liposome nanoparticles 
accumulating in the spiral ganglion satel-
lite cells and gradually appearing on the 
neurofilaments and in the spiral ganglion 
cells. Abundant distribution of liposome 
nanoparticles with and without functional 
peptides was seen in the neurofilaments 
(fig. 2�. 
figure 2. Confocal microscopy showing the 
internalization of liposome nanoparticles in 
rat cochlear explants. A371-functionalized 
liposome nanoparticles carrying plasmid 
pGeneClipTM hMGfp dnA appeared adjacent 
to neurofilaments at 1 h post-treatment (A�, 
abundantly attached to neurofilaments at 2 
h post treatment (B�, and distributed in the 
cytoplasm and nucleus of type i spiral ganglion 
cells at 2 h post-treatment (C�. Blank liposome 
nanoparticles carrying plasmid pGeneClipTM	
hMGfp dnA were detected in spiral ganglion 
satellite cells adjacent to neurofilaments 
(d�, attached to neurofilaments (E� at 1 h 
post treatment, greatly accumulated on 
neurofilament (f�, and within spiral ganglion 
cells (G� at 2 h post treatment. red: liposome 
nanoparticles; green: neurofilaments; blue: 
nuclei stained with dApi. A371-np: A371-
functionalized liposome nanoparticles. Scale 
bar=10 μm.
Potentially aggregated EGfp expression 
was seen in the explants on day 2 post-
treatment with A371-functionalized lipo-
some nanoparticles carrying pGeneClipTM	
hMGfp plasmid dnA encoding shrnA 
to transiently silence id2. More EGfp 
expression was detected on day 4 post-
treatment. only sparse EGfp expres-
sion was detected in the explants on day 
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4 post-treatment with blank liposome 
nanoparticles carrying the same plasmid 
dnA as the A371-functionalized liposome 
nanoparticles. in general, EGfp expres-
sion was inefficient (fig. 3�.
Figure 3. Confocal microscopy showing 
EGfp expression in rat cochlear explants. 
Two days post-gene delivery with A371-
functionalized liposome nanoparticles 
carrying plasmid pGeneClipTM hMGfp dnA, 
dot-like EGfp expression was detected in 
the cell (B�, while nanoparticles started to 
disassemble (A� (C: merged image of A and B�. 
faint EGfp expression was observed in cells 
transduced with blank liposome nanoparticles 
carrying plasmid pGeneClipTM hMGfp dnA 
(E�, although the nanoparticles showed 
disassembly (d� (f: merged image of d and 
E�. four days after gene delivery with A371-
functionalized liposome nanoparticles, greater 
dot-like EGfp expression was seen in cells (H�, 
while the nanoparticles were disassembling 
(G� (i: nuclear staining with dApi; J: merged 
image of G, H, and i�. EGfp expression was still 
sparse (L�, although abundant blank liposome 
nanoparticles were internalized by the cells (K, 
M, and n� at 4 days post-treatment. A371-np: 
A371-functionalized liposome nanoparticles; 
Scale bar=10 μm.
Nanoplex distribution and possible 
EGFP expression in cochlear cell popu-
lations after round window membrane 
permeation
in the adult rat cochleae receiving round 
window membrane permeation with 
A371-functionalized liposome nanopar-
ticles, greater particle distribution was 
observed in the spiral ganglion region 
than in the cochleae treated with blank 
liposome nanoparticles. This difference 
was not statistically significant, however, 
possibly due to the small sample size 
(p>0.05�. dot-like EGfp expression was 
detected sparsely in the spiral ganglion 
cells and spiral ganglion satellite cells 
with nanoplex internalization (figs. 4 and 
7�. in the inner hair cell region, there was 
significantly greater uptake of functional-
ized liposome nanoparticles than blank 
liposome nanoparticles (p<0.05� (figs. 5 
and 7�. nanoplex uptake was also ob-
served in the lateral wall, including the 
spiral ligament and stria vascularis, but 
was not significantly different between 
the functionalized and blank liposome 
nanoparticles (p>0.05� (figs.  and 7�. no 
uptake was detected in the outer hair cell 
region in cochleae treated with either 
A371-functionalized liposome nanopar-
ticles or blank liposome nanoparticles 
(fig. 5�.
Figure 4. Confocal microscopy showing the 
distribution of liposome nanoparticles in the 
spiral ganglion region of the rat cochlea at 24 
h post-round window membrane permeation. 
Abundant A371-functionalized liposome 
nanoparticles carrying plasmid pGeneClipTM	
hMGfp dnA (A� and blank liposome 
nanoparticles carrying plasmid pGeneClipTM	
hMGfp dnA (B� appeared in the spiral ganglion 
cells. Bright dot-like green fluorescence 
appeared in SGCs, showing uptake of A371-
functionlizaed liposome nanoparticles (arrow 
in A�, and weaker dot-like green fluorescence 
appeared in the spiral satellite cells that was 
suspected to be EGfp expression, showing 
internalization of blank liposome nanoparticles 
(arrow in B�. red autofluorescence was also 
detected in SGCs of untreated cochleae (C�. 
red: liposome nanoparticles; green: f-actin 
stained with fiTC-conjugated phalloidin; 
blue: nuclei stained with dApi. A371-np: 
A371-functionalized liposome nanoparticles; 
nC: untreated control; SC: satellite cell; SGC: 
spiral ganglion cell. Scale bar=10 μm.
Figure 5. Confocal microscopy showing the 
distribution of liposome nanoparticles in 
the hair cell region of the rat cochlea at 24 h 
post-round window membrane permeation. 
After treatment with A371-functionalized 
liposome nanoparticles carrying plasmid 
pGeneClipTM hMGfp dnA, abundant liposome 
nanoparticles were detected in the inner hair 
cells and adjacent supporting cells (A, B�, while 
few liposome nanoparticles were found in the 
pillar cells (A� and outer hair cells (C�. After 
treatment with blank liposome nanoparticles 
carrying plasmid pGeneClipTM hMGfp dnA, 
fewer liposome nanoparticles appeared in the 
outer hair cells, pillar cells (d�, and inner hair 
cells (E�. in the untreated controls, faint red 
autofluorescence was found in the inner hair 
cells (f�. red: liposome nanoparticles; green: f-
actin stained with fiTC-conjugated phalloidin; 
blue: nuclei stained with dApi. A371-np: A371-
functionalized liposome nanoparticles; BC: 
border cells; iHC: inner hair cell; oHC: outer 
hair cell; pC: pillar cell. Scale bar=10 μm.
Figure 6. Confocal microscopy showing the 
distribution of liposome nanoparticles in the 
lateral wall of the rat cochlea at 24 h post-
round window membrane permeation. After 
treatment with A371-functionalized liposome 
nanoparticles carrying plasmid pGeneClipTM 
hMGfp dnA, aggregated liposome nanopar-
ticles were detected in spiral ligament fibro-
cytes (A� and stria vascularis (B�. After treat-
ment with blank liposome nanoparticles carry-
ing plasmid pGeneClipTM hMGfp dnA, small-
er dots of liposome nanoparticles appeared in 
the spiral ligament fibrocytes (C�. red: lipo-
some nanoparticles; green: f-actin stained 
with fiTC-conjugated phalloidin; blue: nuclei 
stained with dApi. A371-np: A371-function-
alized liposome nanoparticles; SL: spiral liga-
ment; StrV: stria vascularis. Scale bar=10 μm.
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in primary cochlear cell culture and ex-
plants, no cell type specific internalization 
of A371-functionalized liposome nanopar-
ticles was observed. The uptake of blank 
liposome nanoparticles in the cochlear 
cells was as efficient as that of function-
alized liposome nanoparticles. This indi-
cates that the TrkB receptor pathway is 
not involved in the internalization of lipo-
some nanoparticles in spiral ganglion cells, 
although TrkB internalization occurs upon 
binding to Bdnf. There are two possible 
explanations for the different behavior 
of A371 peptide-functionalized liposome 
nanoparticles and Bdnf in spiral ganglion 
cells. first, as a modification of the natural 
sequence of amino acids 84-100 from the 
structure of nGf, A371 does not have the 
full functionality of nGf or Bdnf 11. Sec-
ond, coupling of the peptide to liposome 
nanoparticles significantly increases the 
size of A371, making it much larger than 
Bdnf and nGf. The large size of the A371-
coupled liposome nanoparticles may 
prevent the internalization of TrkB upon 
binding. Since they were equally exposed 
to the liposome nanoparticles, every cell 
population displayed the same amount of 
internalization.
Figure 7.	Quantification of the nanoplex dis-
tribution in different cell populations of adult 
rat cochleae at 24 h post-round window mem-
brane permeation. There was a significantly 
greater distribution of A371-functionalized li-
posome nanoparticles compared to blank li-
posome nanoparticles in the inner hair cells. 
There was also a tendency toward enhanced 
distribution of A371-functionalized liposome 
nanoparticles compared to blank liposome 
nanoparticles in the spiral ganglion cells. There 
was no difference in the nanoplex distribution 
in the spiral ligament of the lateral wall. iHC: 
inner hair cell; SGC: spiral ganglion cell; SL: 
spiral ligament.
for the in vivo study, the relatively accu-
mulation of A371-functionalized liposome 
nanoparticles in the spiral ganglion re-
gion and inner hair cell region was a result 
of targeting. our previous study on round 
window membrane permeation of lipid 
nanocapsules pegylated with dSpE-pEG-
2000, the same coating material used for 
liposome nanoparticles in the present ex-
periment, showed that the nanocapsules 
mainly appeared in the spiral ganglion 
region, correlated nerve fibers, inner hair 
cell region, and spiral ligament of the lat-
eral wall. (14� This means that there is a 
greater chance for the cells and tissues in 
these regions to be exposed to nanopar-
ticles upon round window membrane 
permeation. in the case of A371-function-
alized liposome nanoparticles, the affinity 
for TrkB on the surface of the spiral gan-
glion cells and peripheral processes of the 
neurons enhanced the distribution of lipo-
some nanoparticles in the spiral ganglion 
and inner hair cell regions. (15� We pro-
pose the following mechanism for nano-
plex distribution: after permeating the 
porous modiolar wall of the scala tympani, 
A371-functionalized liposome nanopar-
ticles bind to TrkB on the non-myelinated 
type ii spiral ganglion cells and peripheral 
processes, and the amount of liposome 
nanoparticles along the nerve pathway 
is enhanced. (14, 1� This provides more 
liposome nanoparticles to the inner hair 
cell region. (14� The movement of lipo-
some nanoparticles along nerve fibers 
was shown in the cochlear explant study, 
which showed an abundance of liposome 
nanoparticles attached to neurofilaments 
(fig. 2�. The access of nanoparticles to the 
lateral cochlear wall was directly related 
to the round window membrane and peri-
lymph and not limited by the nerve path-
way. (14� furthermore, internalization in 
the spiral ligament fibrocytes and inter-
mediate cells of blank-liposome nanopar-
ticles was as efficient as that of A371-func-
tionalized liposome nanoparticles (fig. 1�.
The mechanism of more efficient gene 
expression mediated by A371-function-
alized liposome nanoparticles than by 
blank liposome nanoparticles is unknown. 
The A371 peptide might also bind to epi-
dermal growth factor protein tyrosine ki-
nase (EGfr-pTK� without activation, sim-
ilar to the TrkB receptor binding observed 
in the spiral ganglion cells. This binding 
blocks EGfr-pTK signaling and improves 
the efficiency of intracellular traffick-
ing and transduction. (17, 18� The unique 
dot-like expression pattern of EGfp in 
the cochlear explants, which possible 
represents protein aggregation, might 
be caused by oxidative stress, nitrative 
insult, or proteasomal impairment. (19, 
22� in the cells successfully transfected 
by liposome nanoparticles, pGeneClipTM 
hMGfp plasmid dnA encoding shrnA 
transiently silenced id2 in the host cells. 
id2 (E47 protein� is reportedly involved in 
cell survival, cell cycle progression, lipid 
metabolism, stress response, and lym-
phoid maturation. (23�
in conclusion, potential targetability of 
A371-functionalized liposome nanopar-
ticles was observed in rat cochleae but 
not in primary cochlear cell culture or co-
chlear explants. functionalization of lipo-
some nanoparticles with TrkB ligand did 
not change cellular internalization, but 
it enhanced gene expression. in general, 
the gene transduction efficacy was poor 
for liposome nanoparticles; this might be 
resolved by using nuclear localization sig-
nal peptides.
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